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Chapter 1
General Introduetion
8Introduetion
General Introduetion
Most people associate histamine with allergies, like rashes, hayfever or asthma.
Although histamine is not the only mediator in these hypersensitive reactions of the
body, "anti-histaminics" have been prescribed successfully in the treatment of many
allergie disorders.
The physiologieal effects of histamine, like smooth muscle contraction, increased
capillary permeability and stimulation of gastric acid secretion, were first described
by Sir Henry Dale and his colleagues in 1910,1 reporting the effect of histamine
injections, similar to the effects observed in many allergie conditions. The following
search for compounds antagonising this harmful action of histamine, led to the
discovery of the first "anti-histaminies".2,3 and many more potent antagonists have
been synthesized since.
The observation that certain physiologieal effects of histamine, like gastric acid
secretion and cardiac chronotropism, could not be blocked by any of the available
"anti-histaminics", prompted Ash and Schild to postulate histamine receptor diver-
sity. They defined the histamine receptors, whieh can be blocked by the "anti-
histaminies" as Hl receptors. The other histamine receptor subtype, evoking gastric
acid secretion and cardiac chronotropism was defined as the H2 receptor in 1972 by
Black and Co-workers with the development of the selective antagonist burim-
amide,"
The existence of a third histamine receptor subtype, inhibiting the synthesis and
release of histamine, located presynaptically in histaminergic nerve endings in rat
cerebral cortex, was suggested in 1983 by Arrang et al.5 Confirmation of the exis-
tence of this new histamine receptor subtype was provided by the development of
the H3 selective agonist (R)-a-methylhistamine and the H3 selective antagonist thio-
peramide.? The H3 receptor has since been shown to play an important regulatory
role in the release of other neurotransmitters in the central nervous system7-lOand in
peripheral organs. ll-l6
For the histamine Hl- and H2 receptors, many potent and selective ligands have
been prepared. Whereas Hl agonists are only desired for fundamental pharmacolo-
gieal research, Hl antagonists are applied therapeutically in allergie conditions. The
H2 antagonists have become important, mainly in the treatment of peptic ulcers and
H2 agonists have been suggested as cardiac stimulants.
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The role of histamine H3 ligands as potential therapeutical agents, is under investi-
gation, but more potent, selective and less toxic H3 ligands than currently available,
are still needed.V
Scope of this Thesis
The aim of the research, described in this thesis, was the synthesis of new histamine
H3 ligands, especially meant for SAR- and molecular pharmacology studies on the
histamine H3 receptor. This was mainly achieved by the preparation of derivatives of
the endogenous H3 agonist histamine and the H3 antagonists burimamide and thio-
peramide. These compounds can be useful in the further characterisation of this
receptor and its role in physiology.
The structural requirements for H3 agonists or H3 antagonists are discussed in chap-
ter 2. In this chapter, an overview is presented of the most important compounds
with histamine H3 activity, that have been reported in literature so faro Several new
compounds that have been synthesized recently in our own laboratories and which
will be discussed in detail in subsequent chapters, have been included, in order to
provide an overview, as complete as possible.
For the determination of the H3 activity of the derivatives that we have prepared, an
in vitro assay was developed. This functional test system is based on the inhibitory
effect of H3 agonists on the electrically evoked cholinergic contractions of a guinea
pig intestine preparation. This simple test system was used for the rapid screening of
all our newly synthesized compounds and is described, together with an overview
of other possible H3 in vitro assays, in chapter 3.
A suitable route for the synthesis of 4(5)-substituted imidazole derivatives was
developed, since our target compounds all comprehended such a moiety. Potential
synthesis routes, and the route of our choice, are discussed in chapter 4.
In chapter 5, the synthesis of 4(5)-(ro-aminoalkyl)-imidazoles is discussed, using a
new route, based on the addition of a suitable bifunctional electrophile to a 5-lithi-
ated, 1,2-diprotected imidazole. These derivatives can be regarded as homologues of
histamine, b.ut can also function as precursors for many other histaminergics. With
this route other functionalized 4(5)-alkylimidazoles can be prepared as well.
The synthesis and identification of a new, potent and selective agonist for the H3
receptor is presented in chapter 6. This compound, immepip, can be useful as a phar-
macological tool, but also, because of its distinctive structure, for SAR- and
Molecular Modelling studies.
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The influence of alkyl chain length variation on the histamine H3 receptor activity of
homologues.of histamine is described in chapter 7. A series of histamine homologues
was prepared with an alkyl chain length varying from one methylene group to ten
inethylene groups. Elongation of the alkyl chain to a pentylene chain, led to a
remarkable new potent and selective H3 antagonist, impentamine.
Another class of selective H3 antagonists was obtained by the synthesis of a large
series of burimamide analogues, as weIl.This series is discussed in chapter 8.
Analogues of immepip and thioperamide have also been prepared. The synthesis
routes, employing different electrophiles are discussed in chapter 9. These
compounds were mostly much less active than there corresponding parent
compounds, stressing the specific structural demands of H3 ligands.
For the development of a theoretical model, using molecular modelling studies, an H3
agonist with a small, rigid structure is required. A suitable compound for this purpose
seems to be cyclopropylhistamine (4(5)-(2-aminocyclopropyl)-lH-imidazole).This
compound has been described to be a potent H3 agonist in a Patent Application.l''
Since the H3 receptor proved to be stereoselective and it is unknown, which of the
four possible diastereoisomers of cyclopropylhistamine is most active, part of the
research was focused on the preparation of these isomers. The possible use of
cyclopropylhistamine as a template for an H3 receptor activation model, will be
discussed in chapter 10, together with the synthesis of trans-cyclopropylhistamine
and the attempts of preparing its cis-isomer.
Chapter 2
Structural Requirements for Histamine H3
Receptor Ligands: an Overview
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Introduetion
The presence of histamine in the brain was already reported in 191919 and in 1959 it
was demonstrated that histamine was synthesized their locally.2D However, it lasted
until 1975 before the role of histamine as a neurotransmitter was first described.è!
With the help of the available selective H1- and H2 ligands, the occurrence of H1-
and H2 receptors in the brain was soon reported.22,23
In 1983 it was observed that histamine inhibited its own K+-stimulated release in rat
cortical brain slices.ê Since this effect could not be blocked by the available Hl
antagonists and only by some H2 antagonists (but with a different potency than
found in reference H2 receptor mediated responses), it was suggested that these
actions of histamine were mediated by a third histamine receptor subtype. This
receptor was described to be located presynaptically on histaminergic nerve
endings, regulating the release of histamine, by a negative feedback (autoreceptor).
Confirmation of the existence of this new histamine receptor subtype was provided
by the development of the H3 selective agonist (Rj-u-methylhistamine and the H3
selective antagonist thioperamide.P The histamine H3receptor has since been shown,
not only to inhibit the synthesis and release of histamine, but to play an important
regulatory role in the release of other neurotransmitters (e.g. serotonin, acetyl-
choline, noradrenaline) in the central nervous system7-10 and in the peripheryll-16 as
wen (heteroreceptor).
Many potent and selective ligands have been prepared for the histamine H3 recep-
tor, since its discovery. In this chapter, an overview is presented of the most impor-
tant compounds displaying histamine H3 activity, that have been reported in litera-
ture up to now. Several new compounds that have been synthesized recently in our
own laboratories and which will be discussed in the following chapters of this thesis,
have been included, in order to provide an overview, as complete as possible. The
activities of the compounds, are all represented by their corresponding pD2 cq pA2
value, for easy comparison. However, since the H3 activity of the compounds have
been tested on different assays, it is not always possible to compare the biological
activity directly (see chapter 3, where different H3 test systems are discussed).
Therefore each activity is represented with a reference to the test system that was
used.
Chapter 2
Histamine H3 Agonists
Derivatives ofhistamine as H3 agonists
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Since histamine (1) itself is already remarkably active on the histamine H3 receptor at
very low concentrations, it is not surprising that most potent H3 agonists, have been
derived from it's structure.
1, histamine
The 4(5)-alkyl-imidazole moiety in the structure of histamine (1), has proven to be
essential for H3 agonism. Replacement of the imidazole ring by other heterocycles,
resulted in compounds without agonistic activity on the histamine H3 receptor,
although the Hz agonist amthamine (2) has been described to be a very weak, but
full H3 agonist (see Table 1).
If the 2-aminoethylene chain of histamine is connected to the 2-position of the imi-
dazole ring instead of the 4(5)-position, all activity is lost (see table 2).
Substituents on the imidazole ring are not allowed for agonistic activity. From Table
3 it is obvious that alkylation of the imidazole ring of histamine in any position, leads
to a strong decrease in agonistic activity. This emphasizes the distinct structural
demands of this particular histamine receptor, since methylation of the 2-position of
histamine (2-methylhistamine, 13) leads to a rather selective Hl agonist and 4(5)-
methylhistamine (18) is an Hz agonist.
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Table 1. Histamine H3 Receptor activity of some histamine analogues, in which the
imidazole ring is replaced by other heterocycles.
»<: _NH2Her.... <;»:
No. Compound Het pD2 value" Ref.
1 histamine r=<HN~N
2 amthamine
H3C)=('
NyS
NH2
3 2-(2-aminoethyl)-thiazole S~~N
4 3(5)-(2-aminoethyl)-pyrazole n,N
N
H
5 3-(2-aminoethyl)-isoxazole n,N
0
6 2-(2-aminoethyl)-pyridine ©(
<3.0 5
< 4.0 26
< 4.0 26
<4.0 26
a Determined by evaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
b Same pD2 value, determined byevaluation of the influence of the compound on
electrically-stimulated [3H]-histamine release on rat cortex, as described by Van
der Werf et al.27
C Determined by evaluation of the influence of the compound on electrically
evoked, NANC conctractions of guinea pig intestine preparations, as described
by Menkveld et al.13
d Determined by evaluation of the influence of the compound on electrically
evoked, cholinergic conctractions of guinea pig intestine preparations, as
described by Vollinga et al.l 5
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Table 2. Histamine H3 activity of some 2-substituted ro-aminoalkyl imidazoles.
15
N=('(CH2)ilNH2
~N-R
No. Compound n R pD2 value'' Ref.
7 2-(2-aminoethyl)imidazole 2 H <4.0 26
8 2-(3-aminopropyl)imidazole 3 H <4.0 26
9 2-(4-aminobutyl)imidazole 4 H <4.0 26
10 l-methyl-2-(2-aminoethyl)imidazole 2 CH3 <4.0 26
11 l-methyl-2-(3-aminopropyl)llrüdazole 3 CH3 <4.0 26
a Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.s
Table 3. Histamine H3 Receptor activity of several ring substituted histamine ana-
logues.
~~NH2
RIN9NR3 Rs
R2
pD2
No. Compound Rl R2 R3 ~ Rs value" Ref.
12 Nt-methylhistamine CH3 H H H H < 6.0 s
13 2-methylhistamine H CH3 H H H <4.3 s
14 2-ethylhistamine H C2Hs H H H <4.0 26
15 2-n-propylhistamine H C3H7 H H H <4.0 26
16 2-phenylhistamine H C6Hs H H H <4.0 26
17 W-me~ylhistamine H H CH3 H H < 6.0 s
18 4(5)-methylhistamine H H H CH3 H <3.0 s
19 (Rj-u.Nî-methyfhistamine CH3 H H H (R)-CH3 4.3 26
20 (±)-5(4),a-dimethylhistamine H H H CH3 CH3 <4.0 26
a Determined by evaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.s
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Whereas the imidazole ring may not be replaced or substituted for agonistic activity
on the H3 receptor, modifications of the side chain of histamine have resulted in
some very potent and selective H3 agonists (Table 4 and Table 5). Especially the
introduetion of a methyl group on the ethylene chain of histamine resulted in
compounds that are more potent on the H3 receptor. Upon methylation, the stereo-
selective character of the H3 receptor becomes apparent, since the (R)-enantiomer of
a-methylhistamine 21 is about 100 times more potent than its (S)-enantiomer 22 on
the rat cortex. Because of its potency and selectivity (about 20,000 times more
potent on the H3 receptor than on the HI- and H2 receptorsj.î (R)-a-methylhistamine
is most often used as the standard agonist for pharmacological assays related to
histamine H3 receptors.
Replacement of the methyl group by a chloromethyl- or a hydroxymethyl group
leads to a reduction of activity, which might be the result of steric hindrance (23-
26). However, also these compounds display a large difference in activity between
the (R)- and the (S)-enantiomer (compare 23 and 25 with 24 respectively 26). The
eutomer (most active enantiomer) has the same absolute configuration as (R)-n-
methylhistamine (21).
The reported weak antagonistic activity of (±)-a-aminomethylhistamine (30) may be
explained differently, since this compound can also be regarded as an analogue of
the H3 antagonist homohistamine (109) (see histamine H3 antagonists, table 14).
The introduetion of a methyl group on the ~-position of the ethylene chain of
histamine results in a potent H3 agonist as weIl «±)-~-methylhistamine, 31) and also
here an increase of the van der Waals volume leads to a decrease of activity, since
(±)-~-ethylhistamine (32) is a very weak agonist.
Whereas large substituents on the ethylene chain of histamine are not allowed (see
also the cyclohexylhistamines 39 and 40), the histamine derivative with two methyl
groups on the e-position 33 is still a good agonist. ~,~-Dimethylhistamine (37)
however, results in a very weak agonist, suggesting that there is not enough space
in the 'active site' of the receptor, to accommodate two methyl groups on the ~­
position.
If both the a- and the ~-position are methylated, (R)a,(S)~-dimethylhistamine (27) is
the active diastereoisomer. This compound is equipotent as (R)-a-methylhistamine
(21) on the rat cortex and (S)a,(R)~-dimethylhistamine (28) is equipotent as (S)-a-
methylhistamine (22), indicating that the stereochemistry of the a-methyl group
largely determines the activation of the receptor. In addition to its high potency,
(R)a,(S)~-dimethylhistamine (27) is also highly selective, displaying an activity
profile that is about 1oo,000-fold more active at the H3 receptor than at the HI- and
H2 receptors.28
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Table 4. Agonistic activity of several optically pure substituted histamine ana-
logues at the H3 receptor.
R3.R4
r==CY NH2HN~N R2 'R1
Compound
No. (HA=histamine) Rl R2 R3 R4 pD2 value" Ref.
21 (R)-a.-methylHA CH3 H H H 8.4,7.8b 6,15
22 (S)-a.-methylHA H CH3 H H 6.3 6
23 (S)-a.-chloromethylHA CHzCI H H H 5.9 26
24 (R)-a.-chloromethylHA H CHzCI H H 4.7 26
25 (S)-a.-hydroxymethylHA CHzOH H H H 5.7 26
26 (R)-n-hydroxymethylHA H CHzOH H H 4.2 26
27 (R)a.,(S)f3-dimethylHA CH3 H CH3 H 8.5 29
28 (S)a.,(R)f3-dimethylHA H CH3 H CH3 6.5 29
a Determined by evaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et a/.5
b Determined byevaluation of the influence of the compound on electrically
evoked, cholinergic conctractions .of guinea pig intestine preparations, as
described by Vollinga et al.15
18 StructuraZ Requirements jor Histamine H3 Receptor Ligands
Table 5. Agonistic activity of several substituted histamine analogues at the H3
receptor (unresolved mixture of enantiomers).
R3 R4
r=<?!xNH2(±)
HN~N R2 'Rl
Compound pD2
No. (HA=histamine) Rl R2 R3 R4 value" Ref.
29 (±)-a-ethylHA C2HS H H H 5.0 29
30 (±)-a.-aminomethylHA CH2NH2 H H H pA2=5.3 26
31 (±)-~-methylHA H H CH3 H 7.7 29
32 (±)-~-ethyIHA H H C2HS H 5.0 29
33 a,a-dimethylHA CH3 CH3 H H 7.6 29
34 (±)-a-methylhistidine CH3 C02H H H 5.8 26
35 erythro-u.û-dimethyllfá CH3 H CH3 H 8.2 28,29
36 threo-c.ê-dimethyllfà H CH3 CH3 H 6.7 28,29
37 ~,f3-dimethylHA H H CH3 CH3 5.8 30
38 (±)-eyclopropylHA ~NH2 8.0 18
HN~N
39 (±)-trans-a-methyl- r=P_ NH2 (±) pKi < 5.7b 31
cyclohexylHA - N CH3HN~
40 (±)-cis-a-methyl- r=P-CHJ (±) pKi < 5.7b 31
cyclohexylHA - NH2HN~N
a Determined by evaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et aZ. 5
b Determined on guinea pig brain tissue, measuring the displacement of [3H] Nll_
methylhistamine. as described by Korte et al.32
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Another interesting reportedhistamine analogue with good H3 agonistic activity is
cyclopropylhistamine (4(5)-(2-aminocyclopropyl)-lH-imidazole) (38).33 This mole-
cule has been reported as a full H3 agonist in a Patent Application18 and might be
very useful for structure-activity relationshipand molecular modelling studies,
because of its small and rigid structure. Unfortunately nothing more has been
reported in literature about this compound. It is likely that the sample as described in
the Patent Application, consisted of a mixture of all four possible stereoisomers of
cyclopropylhistamine (38), because a non-stereoselective synthesis route was used
for its preparation. For the use of cyclopropylhistamine (38) in further SAR or
molecular modelling studies, the determination of the eutomer of cyclopropylhis-
tamine is obligatory (see also Chapter 10).
In addition to alkylations on the side chain of histamine that have been performed,
resulting in potent and selective agonists, the amino group has also been alkylated
(see table 6). The introduetion of one methyl group on the amino group results in a
potent H3 agonist and even two methyl groups are tolerated for activity (although
there is a large difference in activity between Ncx-methylhistamine (41) and Ncx,Ncx_
dimethylhistamine (42) on the electrically stimulated [3H]-histamine release assay).
The introduetion of larger substituents on the amino group leads to a decrease in
activity. Whereas Ncx-ethylhistamine (43) is still a full agonist, the incorporation of
the amino group in a pyrrolidine ring results in a partial agonist (compound, 44) and
introduetion of a propyl group leads to a complete loss of activity (NCX-propylhis-
tamine, 45).
Intriguing is the observation that (R)-a-methylhistamine (21) and Ncx-methylhis-
tamine (41) are both potent H3 agonists, but that (R)a,Ncx-dimethylhistamine (46) is a
weak agonist. This could mean that there is not enough space inthe receptor, to
tolerate substituents on both the a-position and the amino group. Another possible
explanation may be that (R)-a-methylhistamine (21) and Ncx-methylhistamine (41)
are in a different conformation when binding to the receptor or that (R)a,NCX-
dimethylhistamine (46) is in a different conformation than (R)-a-methylhistamine
(21) and Ncx-methylhistamine (41). However it must be noted that the trend of a
decrease in activity, going from (Rj-c-methylhistamine (21) to its (S)-enantiomer 22,
can also be observed between the enantiomers of a,Ncx-dimethylhistamine (46 and
47), as weIl as between the enantiomers of a-chloromethyl-Ncx-methylhistamine (48
and 49). Introduetion of the more hydrophilic a-hydroxymethyl group to NCX _
methylhistamine is clearly not tolerated and both enantiomers (50 and 51) are in-
active.
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Table 6. H3 Agonistic activity of severa1Na.-alkyl substituted histamine ana1ogues.
pD2
No. Compound RI R2 R3 R4 value" Ref.
41 Na.-methylhistamine H H CH3 H 7.8b (8.7C) 5,15,24
42 Na.,Na._ H H CH3 CH3 7.6 (7.3C) 5,24
dimethylhistamine
43 Na.-ethylhistamine H H C2HS H 7.1 34
44 4(5)-(2-pyrrolidin- H H -(CH2) 4- 6.0d 6
ethyl)imidazole
45 Na.-propylhistamine H H C3H7 H <5.2 34
46 (R)a,Na.-dimethyl- CH3 H CH3 H 5.8 35
histamine
47 (S)a,Na.-dimethyl- H CH3 CH3 H 4.3 35
histamine
48 (Sju-chloromethyl-Nê- CH2Cl H CH3 H 5.3 35
methylhistamine
49 (R)a-chloromethyl-Na._ H CH2Cl CH3 H 3.0 35
methylhistamine
50 (S)a-hydroxymethyl-Na._ CH20H H CH3 H 3.2 26
methylhistamine
51 (R)a-hydroxymethyl- H CH20H CH3 H 3.0 26
Na.-methylhistamine
a Determined by eva1uation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
b Same pD2 va1ue, determined by eva1uation of the influence of the compound on
electrica1ly evoked, cholinergic conctractions of guinea pig intestine preparations,
as described by Vollinga et al.15
Determined by eva1uation of the influence of the compound on electrica1ly-stimu-
lated [3H]-histamine release on rat cortex, as described by Van der Werf et al.27
d Partia1 agonist (a =0.6).
Chapter 2 21
Recently a new series of histamine analogues has been described, in which the
structure of histamine is partly incorporated in a ring structure (see table 7 and table
8). In this series, variations in ring size and substituents were performed. SCH 49648
(52), which can be regarded as a rigid analogue of (Rj-u-methylhistamine (21) is still
reasonably active, although less potent as (Rj-u-methylhistamine itself. Moreover it
has been reported, that SCH 49648 (52) and SeH 50971 (54) were both as effective
as (Rj-cc-methylhistamine (21) in vivo in the inhibition of an electrically induced
CNS hypertensive response.é!
Table 7. Histamine H3 activity of some optically pure ring-closed histamine ana-
logues.
No. Compound Structure pD2 value" pKi value" Ref.
52 SCH 49648 r=/;NH (+)-[2R,38] 7.1 8.5 31
HN'-7 N CH3
53 SCH 49647 ...,'ÇNH (-)-[28,3R] 7.5 311 \
HN'-7 N CH3
54 SCH 50971
H3:/:'NH (+)-[3R,4R] 7.5 8.6 31
1 \
HN'-7 N
H3C.
55 SCH 50972 ~NH (-)-[38,48] 7.5 31
HN'-7 N
a Determined byevaluation of the influence of the compound on electrically
evoked, cholinergic conctractions of guinea pig intestine preparations, as
described by VoIlinga et al.15
b Determined on guinea pig brain tissue, measuring the displacement of PH] Na_
methylhistamine, as described by Korte et al.32
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Table 8. Histamine H3 activity of some ring-closed histamine analogues
(enantiomers unresolved).
Rsit?-~R3--- ,NH (±)
HN N 'V Rz Rl
No. Rl Rz R3 R4 Rs R() pKi value" Ref.
56 H H H H H H 8.5; 8.7 31,36
57 CH3 H H H H H 8.2;8.5 31,36
58 CH2C6HS H H H H H < 5.8 31,36
59 H CH3 H H H H 6.8 31,36
60 H (CH2)zC6HS H H H H 6.2 36
61 H H CH3 H H H 6.8 31,36
62 H H H CH3 H H 8.1;8.3 31,36
63 H H H C2HS H H 6.8; 6.4 31,36
64 H H H CsHll H H 6.3 31,36
65 H H H H CH3 H 8.5 31
66 H H H H CsHl1 H 7.1 31,36
67 H H H H H CH3 7.2;7.1 31,36
68 CH3 CH3 H H H H 7.2;6.2 31,36
69 CH3 H H CH3 H H < 5.7 31
70 CH3 H H H CH3 H 6.7 31
71 H H H CH3 CH3 H 7.0 31
72 ~NH 8.2 31,36(±)
HN~N I
CH3
73 ~NH(±) < 5.7 31
HN~N :
CH3
Table 8. (Continued).
No.
Chapter 2
Structure
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pKi value" Ref.
74 6.4 31
a Determined on guinea pig brain tissue, measuring the displacement of [3H] Nll_
methylhistamine, as described by Korte et al.32
When comparing affinities, SCH 49648 (52) (same absolute configuration as (R)-c-
methylhistamine (21)) can be regarded as the eutomer and SCH 49647 (53) as the
distomer.
Whereas large substituents on the ~-position of the ethylene chain of histamine
were not tolerated (see Table 5), it is remarkable that SCH 50971 (54), which can
also be regarded as an analogue of ~-ethylhistamine (32) is even slightly more active
than SCH 49648 (52). This means that large substituents on the ~-position are tole-
rated, but that the stereochemistry on this position is very critical for H3 agonism.
Another intrlguing observation is that the absolute configurations of the 3-position
of the pyrrolidine ring of SCH 49648 (52) and SCH 50971 (54) are different, but the
affinities of both compounds for the H3 receptor are comparable. This would indi-
cate totally different orientations of both compounds when binding to the receptor.
When comparing the affinities of the unresolved (mixture of enantiomers) ring-
closed histamine analogues (Table 8), an increase of the ring size from a five mem-
bered ring to a six membered ring (73,74) results in a large decrease in affinity
(compare 57 with 73). A decrease of ring size to a four membered ring (72) leads to a
compound with a high affinity for the H3 receptor, but less selectivity, since Hl acti-
vity has been reported for 72.31 Also for the large series of five membered rings, the
introduetion of methyl substituents seems to be essential for selectivity, since the
nor-methyl analogue (56) exhibits Hl activity as well.31
The introduetion of larger substituents on the pyrrolidine ring results in a strong
decrease in activity. The compounds with the highest affinities have a methyl group
on the 2-position (57) or at the 4-position (62), trans (not on the same site of the
pyrrolidine ring) to the imidazole ring. However the introduetion of two methyl
groups, one on the 2-position and the other at the 4-position, both trans-orientated,
relatively to the imidazole ring (compound, 69), is not tolerated, suggesting a differ-
24 Structural Requirements for Histamine H3 Receptor Ligands
ent binding orientation between the 2-methyl- (57) and the 4-methyl derivative
(62). The derivative with a cis orientated methyl group relatively to the imidazole
ring on the 4-position (65) has a high affinity as well, but has also been described to
display Hl activity.3l
Derivatives of imetit as H3 agonists
The replacement of the amino group of histamine by an isothiourea group has
resulted in the very potent and selective H3 agonist imetit (75).
Table 9. Histamine H3activities of some analogues of imetit.
r{'Rl
)l
p=('(CHÛi1X N-R2
_ H
HN~N
No. Compound n X Rl R2 pD2 value Ref.
75 imetit 2 S H H 8.1a,b (9.0C) 37-40
76 SKF91606 2 CH2 H H 9.0b 38
77 VUF83100 2 NH H H 6.3a (7.4d,e) 37,41
78 VUF8621 2 S CH3 H 7.3a (7.8C) 37,40
79 VUF8973 2 S CH3 CH3 pA2 = 6.6a (7.3C) 37,40
80 VUF8321 1 S H H 5.2a 37
81 VUF8328 3 S H H pA2= 8.0a 37
a Determined byevaluation of the influence of the compound on electrically
evoked, NANC conctractions of guinea pig intestine preparations, as described
by Menkveld et al.13
b Determined by evaluation of the influence of the compound on electrically
evoked, cholinergic conctractions of guinea pig intestine preparations, as
described by Vollinga et af.l s
C Determined by evaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.s
d Determined by evaluation of the influence of the compound on electrically-stimu-
lated [3H]-histamine release on rat cortex, as described by Van der Werf et al.27
e Partial agonist (a = 0.5).
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Several analogues of this compound have been prepared (see table 9). The sulphur
atom of the isothiourea group of imetit (75), is not involved in an interaction with
the H3 receptor, since SKF 91606 (76) is even more potent. SKF 91606 (76) is the
most potent H3 agonist sofar, but has only be reported once.38 Replacement of the
isothiourea group of imetit by a guanidine group (YUF 83100, 77) results in a drastic
decrease of activity.
The introduetion of substituents on the isothiourea group of imetit (75) is not very
weIl tolerated for agonism, since the monomethylated imetit derivative VUF 8621
(78) is less active and the introduetion of two methyl groups results in an antagonist
VUF 8973 (79). Variation in the length of the alkyl chain is also not allowed for H3
agonistic activity and VUF 8328 (81) is even a potent H3 antagonist. Apparently the
distance between the amidine system and the imidazole ring is very strict for H3
agonism. The introduetion of a methyl group on the 5-position of the imidazole ring
of imetit leads to a weak agonist (YUF 9032, 82) and a methyl group on the 2-posi-
tion results in a very weak antagonist (VUF 8974, 83). Replacement of the imidazole
ring with other heterocycles results in inactive compounds (see table 10). Only YUF
8863 (85) has been reported a very weak partial agonist. These results indicate
again the importance of the 4(5)-alkyl-imidazole moiety for H3 agonism and the
intolerance (probably sterical hindrance) for additional substituents on this ring.
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Table 10. Histamine H3 activities of analogues of imetit, in which the imidazole
has been replaced by other heterocycles.
~Xî(NH2Het
NH
No. Compound Het X pD2 value Ref.
82 VUF9032 H
3CT=f S 6.0 (a = 0.9)a 37
HN~N
83 VUF 8974 r=< S pA2 = 5.4a 37
HN'fN
CH3
84 VUF8844 H
3CT=f S inactive" 41
SVN
85 VUF 8863
86 VUF 8848
87 VUF8862
S
S
NH
6.0 (a =O.5)b
inactive''
inactive''
41
41
41
a Determined by evaluation of the influence of the compound on electrically
evoked, NANC conctractions of guinea pig intestine preparations, as described
by Menkveld et al.13
b Determined by evaluation of the influence of the compound on electrically-stimu-
lated [3H]-histamine release on rat cortex, as described by Van der Werf et al.27
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Recently a new potent and selective H3 agonist has been described, which is not an
ethylene analogue of histamine (see Chapter 6).42
~NH
HN~N
88,immepip
This compound, immepip (88) has a pD2 value of 8.0 on the guinea pig intestine and
is therefore equipotent as (R)-a-methylhistamine (21) and imetit (75) on the same
assay,15,42 but has a distinct structure.
The affinities of immepip (88) and some of its analogues as determined on guinea pig
brain tissue (see table 11), have also been reported independently, however in a
Patent Application only.43 From table 11 it can be seen that immepip (88) has a high
affinity for the H3 receptor. Methylation of the amino group leads to a slight
decrease in affinity (compound 91). Replacement of the piperidine ring of immepip
by a pyrrolidine ring however, results in a drastic reduction of affinity (compound
89). It must. be noted that this compound has not been resolved in its enantiomers.
Surprisingly, methylation of the amino group of this pyrrolidine derivative 89, results
in a compound with a strongly increased affinity (compound 90). The replacement
of the piperidine ring by the synthetically more convenient piperazine ring
(compound 92), results in a ten fold decrease of affinity and the introduetion of
methyl substituents on the piperazine ring leads to a drastic loss of affinity.
Because immepip (88) has the highest affinity, it seems likely that it is also the most
active H3 agonist from this series. However, in order to draw conclusions for struc-
ture-activity relationship studies it is necessary to determine the H3 activities of the
analogues represented in table 11.
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Table U. Affinities of some analogues of immepip, detennined on guinea pig brain
tissue (enantiomers unresolved).
No.
88b
89
90
91
92
93
94
Z n R
CH 2 H
CH 1 H
CH 1 CH3
CH 2 CH3
N 2 H
N 3 H
~N-CH3
HN~N
pKi value" Ref.
9.5 43
7.0 36
8.5 36
9.1 43
8.3 44
7.1 36
7.9 43
95
96
97
6.7
<5.2
<5.2
43
44
44
a Determined on guinea pig brain tissue, measuring the displacement of [3H] Nll_
methylhistamine, as described by Korte et al.32 Values from a Patent Application.
b Immepip; pD2 = 8.0 as determined byevaluation of the influence of the
compound on electrically evoked, cholinergic conctractions ofguinea pig intes-
tine preparations, as described by Vollinga et al.IS
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Obviously, the 4(5)-alkyl-imidazole moiety is essential for activation ofthe H3 recep-
tor, since this structural element is apparent in all potent H3 agonists known at this
time. The only non-imidazole derivatives known sofar, which have been reported to
be weakly and partially active at the H3 receptor are YUF 8863 (85) (see table 10)
and VUF 8430 (98) (see table 12). If an interaction of either the isothiourea group or
the guanidine group of YUF 8430 (98) is assumed, it is interesting to see that the
compound with two guanidine groups 100 is inactive and that the bis-isothiourea
derivative 99 is a weak antagonist. Apparently both functionality's are required for
(partial) activation of the H3 receptor by VUF 8430 (98). Based on these results it
might be speculated that the guanidine group is capable of activating the receptor
(although weakly), but that the isothiourea group of VUF 8430 (98) is required for
the binding to the receptor. This could also explain why the guanidine derivative of
imetit (VUF 83100, 77) is much less active (see table 9), since the guanidine group is
less capable of binding to the receptor.
Table 12. Histamine H3activity of some bifunctional amidine derivatives.
NH
HzNJlX~YyNHz
NH
No. Compound X Y H3 activity" Ref.
98 VUF8430 S NH pDz = 5.9 (0.=0.5) 41
99 VUF8332 S S pAz= 6.0 41
100 VUF8309 NH NH inactive 41
a Determined by evaluation of the infIuence of the compound on electrically-stimu-
lated [3H]-histamine release on rat cortex, as described by Van der Werf et alP
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Histamine H3 Antagonists
Derivatives ofhistamine with H3 antagonistic activity
From table 6 it is clear that large substituents on the amino group of histamine, dimi-
nish the H3 agonistic activity and in table 13 some other Na-substituted histamine
derivatives are presented, which have been reported as weak H3 antagonists. There
is not a large influence of the length of the alkyl chain, separating the phenyl ring
from the amino group. Apparently the position of this phenyl ring is not very impor-
tant for antagonistic activity. However a ten-fold increase in antagonistic activity is
observed if a 4-chloro group is introduced on the phenyl ring of 106, indicating that
lipophilicity plays a role in the binding of these compounds to the H3 receptor
(compound 107).
Table 13 Histamine H3 antagonistic activity of some Na substituted histamine ana-
logues.
~~-Z-o-R
HN~N
No. Z R pAz value" Ref.
101 (CH2)z H 5.5 45
"102 (CH2)3 H 6.2 45
103 (CH2)4 H 6.2 45
104 (CHÛ5 H 5.7 45
105 (CH2)zO H 6.4 45
106 (CH2)zS H 5.6 45
107 (CH2)zS Cl 6.6 45
a Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
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Elongation of the side chain of histamine (1) resulted in compounds with H3 anta-
gonistic properties (see tabIe 14), with impentamine (111) as the most potent and
selective H3 antagonist from this series (see Chapter 7 for more details).
'I'able 14 Histamine H3 antagonistic activity of some homologues of histamine, in
which the length of the ro-aminoalkyl chain is varied.
p{(CH2)n- NH2
HN~N
No. Compound n pA2 value" Ref.
108 VUF 8319 1 inactive 46
1 histamine 2 pD2 =7.3b 5
109 . homohistamine 3 5.9 46
110 VUF4701 4 7.7 46
111 impentamine 5 8.4 46
112 VUF4732 6 7.8 46
113 VUF4733 8 6.0 46
114 VUF4734 10 6.0 46
30 (±)-a-aminomethyl- r=CY NH2 5.3c 26
histamine
HN~N NH2
CH3
115 (±)-a-methyl- ~NH2 pD2< 4.0c 26
homohistamine HN~N
a Determined by evaluation of the influence of the compound on electrically
evoked, cholinergic conctractions of guinea pig intestine preparations, as
described- by Vollinga et al.15
b Determined byevaluation of the influence of the compound on electrically
evoked, NANC conctractions of guinea pig intestine preparations, as described
by Menkveld et al.13
Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
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The fact that homohistamine (109) is a weak antagonist, might explain why a-
aminomethylhistamine (30, already mentioned in table 5) is a weak antagonist, since
this compound can also be regarded as an analogue of homohistamine. For the same
reason, n-methylhomohistamine (U5), which has been reported to show no H3
agonistic activity, might be a weak antagonist as wen.
Table 15 Histamine H3 antagonistic activity of some analogues of histamine with
an aminopropylene chain, enclosed in a piperidine ring.
No. Structure
116 ~NH
HN~N
117 ~o~
HN~N
118 0~)lNH
H,C _ g
HN~N
119 0~
HN~N
pA2 value" Ref.
5.7 (6.2b) 26,47
7.2 48
6.3 48
7.4 48
a Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
b Determined byevaluation of the influence of the compound on electrically
evoked, cholinergic conctractions of guinea pig intestine preparations, as
described by Vollinga et al.15
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The rigid piperidine analogue of homohistamine, 116 is still a weak antagonist, but
coupling of a lipophilic moiety to the amino group leads to an increase of antago-
nistic activity (see table 15). Introduetion of a methyl group on the 5-position of the
imidazole ring, presumably results in a decrease of affinity, although compound 118
is slightly more potent than 116 on the rat cortex.
Derivatives of imetit with H3 antagonistic activity
Also derivatives of the potent H3 agonist imetit (75) resulted in some potent anta-
gonists (see table 16). Substitution of the isothiourea group with more than one
methyl group leads to moderately active H3 antagonists. The introduetion of a
phenyl group, separated from the isothiourea group by an alkyl chain leads to good
antagonists. The length of this alkyl spaeer does not seem to be very strict. The
introduetion of a methyl group on the isothiourea group of the phenylethyl deriva-
tive YUF 9029 (125), does not influence the activity (see YUF 9051 (126)).
Elongation of the ethylene chain of imetit (75) however, has a drastic effect on the
activity. YUF 8328 (81) is already a potent antagonist and the introduetion of a
phenyl group to the isothiourea group, separated by an alkyl spacer, leads to more
potent H3 antagonists. Replacement of a phenyl group by a non-aromatic cyclo-
hexyl group (VUF 9163, 132) has no effect on the H3 antagonistic activity, sug-
gesting that receptor binding by this part of the molecule is through a hydrophobic
interaction and not a 1t-1t interaction. This is verified by the introduetion of a chloro
group in the para position of the benzyl group, resulting in clobenpropit (131), the
most potent H3 antagonist reported sofar (pA2 value of 9.9 at guinea pig ileum). This
observation Ied to the development of the first selective radiolabelled H3 antagonist
[l25I]-iodophenpropit (134), which is currently used as a radioligand for histamine
H3 receptor binding studies.49-51
Methylation of the 2-position of the imidazole ring of imetit results in a very weak
antagonist (VUF 8974, 83), whereas 5-methylimetit (82, see table 10) is a weak
agonist.
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Table 16 Histamine H3 antagonistic activity of several substituted analogues of
irnetit.
NRI
.)l
Á(CHl)n-S N-X-Rl
- I
HN N R3~
No. Compound n Rl X Rl R3 pAl value" Ref.
120 2 H CH3 CH3 6.3b 40
79 VUF8973 2 CH3 CH3 H 6.6 (7.3b) 37,40
121 2 (CH2h--- H 6.6b 40
122 2 CH3 CH3 CH3 6.3b 40
123 VUF8397 2 H C6HS H 7.0 37
124 VUF9028 2 H CH2 C6HS H 7.8 37
125 VUF9029 2 H (CH2h C6HS H 8.0 37
126 VUF9051 2 CH3 (CH2)2 C6Hs H 7.8 37
127 VUF9030 2 H (CH2h C6Hs H 7.6 37
128 VUF9031 2 H (CH2)4 C6HS H 7.7 37
129 VUF8404 2 H (CH2hSCH2 C6Hs H 7.5 «5.3C) 24,37
81 VUF8328 3 H H H 8.0 37
130 VUF9107 3 H CH2 C6Hs H 8.8 37
131 clobenpropit 3 H CH2 C6Hs-4-CI H 9.9 37
132 VUF9163 3 H CH2 C-C6Hll H 8.8 37
133 VUF9151 3 H (CH2h C6HS H 8.8 37
134 iodophenpropit 3 H (CH2)2 C6Hs-4-I H 9.6 50
135 VUF9152 3 H (CH2h C6Hs H 8.3 37
136 VUF4571 3 H (CH2)4 C6HS H 8.5 37
137 VUF8414 3 H (CH2hSCH2 C6HS H 8.6 37
TabIe 16 (Continued).
No. Compound
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pA2 value" Ref.
83 YUF 8974
138
139
5.4 37
52
52
a Determined byevaluation of the influence of the compound on electrically
evoked, NANC conctractions of guinea pig intestine preparations, as described
by Menkveld et al.13
b Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5 Values from
patent application.
Determined byevaluation of the influence of the compound on electrically-stimu-
lated [3H]-histamine release on rat cortex, as described by Van der Werf et al.27
It is interesting to note that Compound 138 might also fit in this series of
compounds. Although the isothiourea group is "reversed", a pA2 value comparable
to the ro-phenylalkyl derivatives of imetit is reported in a patent application. The
same is true for compound 139, which may also be regarded as an analogue of imetit.
This could be an indication that binding of this series of compounds, depends on the
interaction of the nitrogen with the receptor and that the sulphur atom is not impor-
tant.
The isothiourea group of the imetit analogues has also been replaced by a guanidine
group. Although less active, a comparable pattern as with the substituted imetit
series (described above) can be observed (see table 17).
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Table 17 Histamine H3 antagonistic activity of some substituted guanidine ana-
logues of imetit.
N""R1
)l
Á(CHz)n-~ ~-Z-Rz
HNvN
No. Compound n Rl Z Rz pAz value Ref.
77 YUF 83100 2 R H pDz=6.3a (7.4)b,C 37,41
140 YUF 8845 2 N02 H inactive'' 41
141 YUF 9006 2 H phenyl 5.8a 37
142 YUF 9007- 2 H (CH2)2 phenyl 6.3a 37
143 VUF8411 2 H (CH2hSCH2 phenyl > 5.3b 24
144 SKF 91486 3 H H 7.1d 5
145 3 H CH2 cyclohexyl 9.2e (8.8f) 53
146 3 C02C(CH3h CH2 cyclohexyl 8.7e (7.4f) 53
147 YUF 8405 3 H (CH2hSCH2 phenyl 7.9a 37
148 impromi- 3 H (CH2hSCH2
'J=(CH3
7.2a 5
dine HN-...,::::.N
149 YUF 8413 3 H (CH2hSCH2 0 6.9a 41'UN(CH3)z
150 YUF 8407 3 H (CH2hSCH2 "(yNyNH
z
7.4a 41
S NH2
151 YUF 8406 3 CN (CH2hSCH2 "(yNyNH
z
> 5.3b 24
S NHz
152 4 C02C(CH3h cyclohexyl 7.3e (6.9f) 53
Table 17 (Continued).
No. Compound
153
154 mifentidine
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48
54
a Determined byevaluation of the influence of the compound on electrically
evoked, NANC conctractions of guinea pig intestine preparations, as described
by Menkveld et al.13
b Determined byevaluation of the influence of the compound on electrically-stimu-
lated [3H]-histamine release on rat cortex, as described by Van der Werf et al.27
c Partial agonist (a =0.5).
d Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
e Determined byevaluation of the influence of the compound on electrically stimu-
lated [3H]-noradrenaline release on mouse cortex, as described by Schlicker et
al.55
f Determined by evaluation of the influence of the compound on electrically
evoked, cholinergic conctractions of guinea pig intestine preparations, as
described by Vollinga et al.15
Elongation of the ethylene chain of VUF 83100 (77) leads to a reasonably active H3
antagonist SKF 91486 (144). A remarkable hundred-fold increase of H3 antagonistic
activity is observed if a cyclohexyl group, separated by a methylene group is intro-
duced to the guanidine group of SKF 91486 (144) (see compound 145).
Esterification of the guanidine group of 145 reduces the antagonistic activity
(compound 146). It is worth noting that this reduction is more drastic on the guinea
pig intestine assay than on the mouse cortex assay. The butylene derivative 152 is
less active than its propylene analogues, but the compound is still reasonably active.
This might explain the H3 antagonistic properties of mifentidine (154) (comparabie
distance between the imidazole ring and the amidine system).
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The propylene chain between the imidazole ring and the amidine system however is
optimal for antagonistic activity for this series of guanidine analogues, which was
also observed for the isothiourea analogues, described in table 16. Since both series
of analogues are likely to interact in a comparabie manner with the H3 receptor, it
seems that the nitrogen of the guanidine group, connected directly to the 4(5)-
alkylimidazole moiety, is not required for binding.
Derivatives ofimpromidine as H3 antagonists
The H3 antagonistic activity of the H2 agonist imprornidine (148)was described
already in the first paper on the H3 receptor.f
148, imprornidine
The replacement of the propylene chain which separates the unsubstituted irnida-
zole ring and the guanidine group, with an ethylene chain, results in a slight increase
of antagonistic activity (see table 18, compound 155). Methylation of the ethylene
chain in a comparabie marmer as for a-methylhistarnine, does not have much effect
on the antagonistic activity (enantiomers of soprornidine 156 and 157). Since no
stereoselectivity can be observed between these compounds, an interaction of the
unsubstituted irnidazole ring in the same manner as for agonists, must be ruled out.
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Table 18 Impromidine analogues
H H
~~NIîN,Ar I R2
N,
. Rl
pA2
No. Compound Ar Rl R2 value" Ref.
148 impromidine H3
Cl==('
H~ 7.2 5
HN~N No/NH
155 H
3Cl==('
H~ 7.7 26
HNvN No/NH
156 (S)- H3
Cl==('
H~ 7.4 35
sopromidine HN~N CH3No/NH
157 (R)- H3Cl==(' H YA 7.2 35
sopromidine HNvN CH3No/NH
147 VUF 8405 ©( H~ 7.9b 37No/NH
150 VUF8407 NH2 NJ H~ 7.4b 41À~~H2N S No/NH
0 ~149 VUF8413 (H3ChN~ H 6.9b 41
No/NH
158 cimetidine H3
Cl==('
CN CH3 4.5 5
HN~N
159 tiotidine NH2 NJ CN CH3 4.8 41À/~H2N s
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Table 18 Impromidine analogues
No. Compound Ar R2
pA2
value" Ref.
151 VUF8406 CN
159 ranitidine 4.3 41
3 Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
b Determined by evaluation of the influence of the compound on electrically
evoked, NANC conctractions of guinea pig intestine preparations, as described
by Menkveld et al.13
C Determined byevaluation of the influence of the compound on electrically-stimu-
lated [3H]-histaminerelease on rat cortex, as described by Van der Werf et al.27
Replacement of the 5-methyl-imidazole ring of impromidine (148) is allowed. For
instanee YUF 8405 (147), in which the 5-methyl-imidazole ring is replaced by a
phenyl group, is an even more potent H3 antagonist than impromidine (148). This
indicates that the 5-methyl-imidazole ring is not essential for the antagonistic activi-
ty of impromidine. This is confirmed by the observation that cimetidine (158), is
almost inactive. Although the introduetion of a cyano group to the guanidine, as
with cimetidine, might have a negative effect on the antagonistic activity of the
compound, it must be noted that VUF 8406 (151), with a 4(5)-propyl-imidazole
moiety, has been found to be more active. This means that the antagonistic activity
of impromidine depends on the unsubstituted imidazole ring and the guanidine
system, separated by an alkyl spaeer (as described in table 17) and not on the 5-
methyl-imidazole part on the other side of the guanidine group.
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Table 19 Histamine H3 antagonistic activity of several analogues of burimamide.
S
Jl
J=("(CHz)n-N N-R
_ H H
HN~N
No. Compound n R pAz value" Ref.
161 VUF4577 2 CH3 5.5 56
162 VUF4578 2 C2Hs 5.3 56
163 VUF4579 2 C3H7 5.4 56
164 VUF.4580 2 CH(CH3h 4.8 56
165 VUF4581 2 C-C6H l l 5.9 56
166 VUF4582 2 C6Hs 5.2 56
167 VUF4583 2 CH2C6HS 5.8 56
168 VUF4584 2 (CH2hC6Hs 5.9 56
169 norburimamide 3 CH3 6.1 (6.4b) 15,54,56
170 VUF4631 3 C2HS 7.1 56
171 VUF4632 3 C3H7 7.0 56
172 VUF4633 3 CH(CH3h 7.1 56
173 VUF4634 3 C-C6Hll 6.9 56
174 VUF4635 3 C6HS 6.9 56
175 VUF4636 3 CH2C6HS 6.7 56
176 VUF4637 3 (CH2hC6Hs 6.7 56
177 burimamide 4 CH3 7.1 (7.2b) 5,15,56
178 VUF4681 4 C2Hs 7.4 56
179 VUF·4682 4 C3H7 7.3 56
180 VUF4683 4 CH(CH3h 7.5 56
181 VUF4684 4 c-C6Hll 7.1 56
182 VUF4685 4 C6HS 7.6 56
183 VUF4686 4 CH2C6HS 6.8 56
184 VUF4687 4 (CH2hC6Hs 7.0 56
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Table 19 (Continued).
No. Compound n R pAz value" Ref.
185 VUF4613 5 CH3 8.0 56
186 VUF4614 5 C2Hs 8.0 56
187 VUF4615 5 C3H7 7.7 56
188 VUF4616 5 CH(CH3h 7.7 56
189 VUF4617 5 c-C 6Hll 7.5 56
190 VUF4618 5 C6Hs 7.6 56
191 VUF4619 5 CH2C6Hs 7.7 56
192 VUF4742 5 CH2C6Hs-(4)-CI 8.1 56
193 VUF4620 5 (CH2hC6HS 7.5 56
194 VUF4740 6 CH3 7.9 56
195 VUF4741 6 C6Hs 8.0 56
196 ~)'ND 7.3 53
HN N H H~
H H
197 metiamide H3C~S~Nî(KCH3 5.6b 5HN~N S
a Determined by evaluation of the influence of the compound on electrically
evoked, cholinergic conctractions of guinea pig intestine preparations, as
described by Vollinga et al.15
b Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
Derivatives ofburimamide as H3 antagonists
The good antagonistic activity of the Hz antagonist burimamide (177) for the H3
receptor led to the development of a large series of burimamide analogues (see table
19 and Chapter 8 for more details).
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In this series, the length of the alkyl chain, separating the imidazole ring from the
thiourea group, was varied from an ethylene chain to a hexylene chain. Elongation
of the alkyl chain clearly results in an increase of the H3 antagonistic activity.
Besides the activity, the selectivity also increased (see Chapter 8).56 The pentylene-
and hexylene analogues of burimamide are about ten times more potent than burim-
amide (177) ltself
The N-thiourea substituents however do not have much influence on the activity.
This could mean that this series of antagonists bind in a non-lipophilic environment
to the receptor, different from e.g. the amidine analogues, described in table 16 and
17. Also in this series, methylation of the imidazole ring seems to be disastrous, since
metiamide (197) is only a very weak antagonist. The replacement of the thiourea
group of YUF 4634 (173) with an urea group (compound 196) is obviously allowed.
Thioperamide derivatives
The first potent and selective antagonist for the H3 receptor was thioperamide (198),
which can be regarded as a rigid analogue of norburimamide (169) and VUF 4634
(173).
198, thioperamide
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Table 20 Histamine H3 antagonistic activity of some analogues of thioperamide.
X
p~R2
Rl-N~N
No. Rl X R2 pA2 value" Ref.
198 H S
-0 8.9b 5,15
199 H S
-Ql 7.5 48
CH3 48200 H NH
-c-<] 7.9
H
201 H 0
-0 7.4 48
202 H 0
-<ö> 6.8 48
203 H 0
-Q 7.6 48
F
c~204 H 0
-t 0 8.0 48
205 11-0 0
-0 7.6 48-C-~
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Table 20 (Continued).
No. Rl X R2 pA2 value" Ref.
0
---0206 -ë-It<O( 0 7.1 48
CH3 CH3
o CH-U CH-U11 I -~ 0 48207 -C-il-ü 0 0 7.7
208 ~f) 4.9 26
ON
209 cI~D < 5.0 57
210 rPY~D 7.4 48
HN~N S
a Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
b Same value determined byevaluation of the influence of the compound on e1ec-
trically evoked, cholinergic conctractions of guinea pig intestine preparations, as
described by Vollinga et al.l 5
According to patent literature,48 replacement of the cyclohexyl ring with the bulky
adamantane group results in a large decrease of antagonistic activity (compound
199). Moreover the replacement of the thiourea group of thioperamide by an urea
group, results in a less active compound (201). This is puzzling, since the substitu-
tion of a thiourea group of norburimamide (169), by an urea group (see table 19,
compound 196), did not result in a decrease of activity. Apparently norburimamide
(169) and its rigid analogue thioperamide (198), bind in a distinct manner to the
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receptor. Substituents on the t-position of the imidazole ring of some urea-contai-
ning thioperamide analogues, are allowed (e.g. compound 201 compared to
compound 205).
More substitutions on the imidazole ring of thioperamide have been performed (see
table 21). For thioperamide (198), methylation of the N't-position leads to a drastic
decrease of activity (Nl-methylthioperamide, 211), but methylation of the N1t-posi-
tion results in a completely inactive compound 215.
Table 21 Histamine H3 antagonistic activity of some substituted thioperamide ana-
logues.
pAz
No. Compound Rl Rz R3 R4 value" pKi value Ref.
198 thioperamide H H H 8.9 8.5b (7.4C) 58,59
211 N'-methylrhioperamide CH3 H H 6.8 6.8b,7.2d(5.9C) 58-60
212 Nt-benzylthioperamide CHZC6HS H H ND. <6.0<1 60
213 2-methylthioperamide H CH3 H N.A. 4.Sb (4.9C) 58,59
214 2-aminothioperamide H NHz - H NA. <4.0b,c 58,59
215 N't-methylthioperamide - H CH3 H NA. 5.6b (S.OC) 58,59
216 5-methylthioperamide H H CH3 8.4 6.8b (4.6C) 58,59
217 5-aminothioperamide H H NHz NA. < 4.0b,c 58,59
N.D. =Not Determined; N.A. =Not Active
a Determined by evaluation of the influence of the compound on electrically
evoked, cholinergic conctractions of guinea pig intestine preparations, as
described by Vollinga et al.IS
b Affinity value, determined on rat cortex, measuring the displacement of [3H] NU-
methylhistamine, as described by Bordi et al.59
C Affinity value, determined on rat cortex, measuring the displacement of [3H]
histamine, as described by Bordi et al.59
d Affinity value, determined on rat cortex, measuring the displacement of [3H] NU-
methylhistamine, as described by Amin Khan et al.60
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Whereas substituents on the 2-position are not allowed (2-methylthioperamide, 213),
5-methylthioperamide (216) has been reported to be still a potent antagonist.58
There is however a remarkable discrepancy between the antagonistic activity of 5-
methylthioperamide (216) as determined on the guinea pig intestine assay and
between the much lower affinity of this compound determined on a rat cortex
binding assay.
Miscellaneous to-functionalized 4(5)-alkyl imidazoles
Amides
The observation that the most simple NlX-acylated derivative of histamine, NlX_
acetylhistamine (218), displayed weak H3 antagonistic activity, led to the develop-
ment of a series of acylated analogues of histamine (see table 22). The introduetion
of a lipophilic group (e.g. a phenyl- or cycloalkyl group), to the amide group, sepa-
rated by an alkyl chain results in good antagonists.
Table 22 Histamine H3 antagonistic activity of several NlX-acylated histamine ana-
logues.
0)l
(CH~-N Z-RÁ n H
HN~N
No. n Z R pAz value" Ref.
218 2 methyl 5.9 61
219 2 CHz phenyl 6.0 45
220 2 (CHzh phenyl 6.2 45
221 2 CHzO phenyl 6.1 45
222 2 CHzS CH(phenyl)z 6.0 45
223 2 (CHzh CH(phenyl)z 6.0 45
224 2 (CHzh phenyl 7.1 45
225 2 CHzSCHz phenyl 6.2 45
226 2 (CHZ)3 cyclohexyl 7.3 45
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Table 22. . (Continued).
No. n Z R pA2 value" Ref.
227 2 (CH2h 4(5)-imidazolyl 6.0 45
228 2 (CH2h 2-pyridyl 6.0 45
229 2 CH2SCH2 2-pyridyl 5.7 45
230 2 (CHÛ4 phenyl 6.7 45
231 3 (CH2h phenyl 7.3 52
232 3 CH2CHCH3 phenyl 7.5 52
233 3 (CH2h cyclopentyl 7.2b(7.6C) 53
234 3 (CH2h cyclohexyl 7.3b (7.6C) 53
235 3 (CH2h cyclohexyl 7.2 52
H
236 p=(YN~ 6.0 61
HNvN CH3 0
~OCH'
237d H I 0 pKi = 6.3e 62~N Br
HNvN 0
H
238 H'C~N~ < 5.0 61
HNvN 0
CH3I
239~~ < 5.0 45
S
240 ~~ 7.4b(7.6C) 53HNvN H
O·
241 ~~ 7.5b (7.7C) 53HNvN H
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Table 22. (Continued).
No. Structure
242 ~N~HN~N H U
pA2 value" Ref.
49
243
244
7.4
7.3
52
48
a Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
b Determined byevaluation of the influence of the compound on the electrically
stimulated [3H]-noradrenaline release on mouse cortex, as described by Schlicker
et al.55
C Affinity value (pKj), determined on rat cortex, measuring the displacement of [3H]
Na-methylhistamine, as described by Kathmann et al.63
d Verongamine.
e Affinity value, determined on guinea pig brain tissue, measuring the displacement
of [3H] N<X..methylhistamine, as described by Korte et al.32
It appears, that the distance of the lipophilic group relatively to the imidazole ring is
determining the activity and not the position of the amide group, since 224 and 226
are equipotent as 231 respectively 234. Apparently the polar group in the side chain
is less important for this series of analogues. Also the exchange of the amide group
by a thioamide group does not influence the activity (if compound 233 and 240 are
compared). Whereas the introduetion of a lipophilic group enhances the activity, the
introduetion of a heterocycle, does not increase the potency (comparing 226 and
227). Branching of the side chain of these amide analogues leads to an increased
activity (see compound 234 and 242). Methylation in the n-posttion of 224
however, with the same stereochemistry as (R)-a-methylhistamine (21), leads to a
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weak antagonist 236. Methylation or replacement of the imidazole ring is again not
allowed.
A remarkable compound is verongamine (237), fitting perfectly in this series of
compounds. It has been reported as an H3 antagonist, but only affinity data was
provided.62,64 Verongamine (237) is isolated from the marine sponge Verongula
gigantea and is therefore probably the first discovered endogenous compound with
H3 antagonistic properties.
Table 23 Histamine H3 antagonistic activity of several carbonylic histaminergic
imidazole derivatives.
0
Jl
p=('(CH2)ilO X-R
HN,~N
No. n X R pA2 value" Ref.
245 3 (CHÛz cyclopentyl 8.5 52
246 3 NH phenyl 7.9 65
247 3 NH 3-F-phenyl 7.6 65
248 3 NH 4-F-phenyl 7.6 52
249 3 NH cyclohexyl 7.2 65
250 3 NHCHz phenyl 8.0 65
251 3 NHCHz 4-F-phenyl 7.6 65
252 3 NHCHz 4-NOz-phenyl 7.7 52
253 3 NHCHz cyclopentyl 7.2 65
254 3 NHCHz cyclohexyl 8.0 65
255 3 NHCHz 2-thiophenyl 7.7 65
256 3 NCH3CHz phenyl 7.7 52
257 3 NHCO phenyl 7.3 52
258 3 NH(CHzh phenyl 8.0 65
259 7.7 52
8 Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
Carbamates, esters and ketones
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Other carbonylic histamine derivatives have also been described as H3 antagonists,
like the carbamates presented in table 23. All these compounds are good antago-
nists, with comparable activities. The carbamate group may even be replaced by a
ketone and the activity remains (compound 259), again diminishing the importance
of the polar group for this series of antagonists. Replacement of the carbamate
group by a reversed ester group has resulted in a marked increase of activity
however (if 253 is compared with 245).
Ethers
The observation that with the carbonylic antagonists, discussed above, there is no
great importance of a functional polar group, seems to be confirmed by a series of
ether derivatives (see table 24). In this series, the functional group has been replaced
by an oxygen atom and a variety of lipophilic groups with different steric and elec-
tronie parameters have been introduced, but all the compounds are comparable
good antagonists. A recently reported new radioligand, [l25I]-iodoproxyfan (272) is
described to possess a very high affinity on the rat cortex, but there is a remarkable
discrepancy between the reported affinity and the observed antagonistic activity (a
hundred times less active) of iodoproxyfan (272) on a functional assay.
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Table 24 ethers
p=(CHViilX-(CH2)n- R
HNvN
No. m n R pA2 value" Ref.
260 2 0 4-CN-phenyl 8.0 52
261 2 0 4-C3H7-phenyl 7.7 52
262 2 0 4-N02-phenyl 7.5 52
263 2 0 2-naphthyl 7.0 52
264 3 0 4-CN-phenyl 7.9 52
265 3 0 4-CF3-phenyl 7.8 52
266 3 1 phenyl 7.7 66
267 3 1 3-F-phenyl 7.9 66
268 3 1 3-I-phenyl 8.2 67
269 3 1 4-Br-phenyl 7.9 66
270 3 1 4-CI-phenyl 7.7 67
271 3 1 4-F-phenyl 8.0 66
272b 3 1 4-I-phenyl 8.3 67
272b 3 1 4-[125I]-phenyl pKj= 10.2c 67
273 3 1 cyclohexyl 8.0 66
274 3 1 l-naphthyl 7.7 66
275 3 1 2-naphthyl 7.7 66
276 3 1 2-quinolyl 7.3 66
277 3 1 4-biphenyl 7.2 66
278 3 2 phenyl 7.6 67
279 3 3 phenyl 7.8 67
280 3 3 4-Br-phenyl 7.8 52
281 3 3 4-CI-phenyl 7.9 52
282 3 3 4-F-phenyl 8.2 52
283 . 3 3 cyclohexyl 7.7 52
3 Determined by evaluation of the influence of the compound on K+-stimulated
[3H]-histaminerelease on rat cortex, as described by Arrang et al.5
b Iodoproxyfan.
c Affinity value, determined on rat cortex.
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Derivatives ofdimaprit as H3 antagonists
53
In addition to impromidine (148), another H2 agonist that has been shown to display
H3 antagonistic activity is dimaprit (284).
284,dimaprit
Table 25 Histamine H3 antagonistic activity of some analogues of dimaprit.
n pA2 value pKi value" Ref.
3 6.2b (5.5C) 6.6 54,63
2 5.6b,d 6.0 63
4 6.0b (5,8e) 6.4 41,63
2 6.<1 41
No. Compound
284 dimaprit
285 nordimaprit
286 homodimaprit
99 VUF8332
287 VUF8333
(CH3hN
(CH3hN
(CH3hN
NH
H2N)lS/
NH
H2N)lS/
3 41
a Affinity value, determined on rat cortex, measuring the displacement of [3H] Nll_
methylhistamine, as described by Kathmann et al.63
b Determined byevaluation of the influence of the compound on electrically stimu-
lated [3H]-noradrenaline release on mouse cortex, as described by Schlicker et
al.55
C Determined by evaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
d Reversible non-competitive antagonism.
e Determined byevaluation of the influence of the compound on electrically
evoked, NANC conctractions of guinea pig intestine preparations, as described
by Menkveld et al.13
f Determined by evaluation of the influence of the compound on electrically-stimu-
lated [3H]-histamine release on rat cortex, as described by Van der Werf et al.27
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A few derivatives of dimaprit (284) have been described, which are presented in
table 25. Variation in the alkyl chain length, resulted in the compounds nordimaprit
(285) and homodimaprit (286). Whereas shortening the alkyl chain of dimaprit (284)
results in a decrease of activity, elongation does not effect the activity very much.
There is no change in activity when the dimethylamino group of dimaprit is replaced
by an isothiourea group (as in YUF 8333, 287). Shortening the alkyl chain of 287 to
two methylene units, does not effect the activity (VUF 8332, 99). This is not unex-
pected, since the distance between the amino group and the isothiourea group of
homodimaprit (286) is comparabie to the distance of a nitrogen atom from one of the
isothiourea groups of YUF 8332 (99) to the other isothiourea group.
Miscellaneous H3 antagonists
A few other compounds with activity at histaminergic receptors, but lacking an
imidazole ring, have been screened for H3 antagonism. The potent Hl antagonists
chlorpheniramine (289) (both enantiomers were tested), mepyramine (290) and
cyclizine (291) do not display any potent antagonistic H3 activity (see table 26).
Moreover the H2 antagonist zolantidine (292) is described to be inactive as an H3
antagonist as weIl. Betahistine (288) which has been described as a weak agonist
on the Hj-and the H2 receptor, displays a very weak antagonistic activity on the H3
receptor.
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Table 26 miscellaneous
No. Compound Structure pA2 value" Ref.
H
288 betahistine ~N'CH' 5.2 68
Cl
289 chlor- N(CH3h <7.2b 5
pheniramine
290 mepyramine
291 cyclizine
< 5.5
< 6.2
54
5
292 zolantidine O û r9 <5.0~O~N N
H
54
a Determined byevaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
b Both enantiomers; pA2 value < 7.2.
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Conclusions
H3 Agonists
When looking at the structures of all the potent histamine H3 agonists, that have
been developed over the last decade, it is clear that the 4(5)-substituted imidazole
ring is essential for activity on the H3 receptor. Whereas additional substituents on
the imidazole lead to strongly reduced activity, replacement of the imidazole by
other heterocycles, mostly results in compounds with no H3activity at all.
There seems to be more freedom in choice of the side chain. A large series of potent
derivatives of histamine has been prepared, based on the introduetion of substi-
tuents on the aminoethylene side chain connected to the 4(5)-positionof the 'imida-
zole ring (see table 4-7).
The discovery of the potent agonistic activity of imetit (75) however, indicates that
the amino group can be substituted by other basic functionality' s. It was therefore
assumed that an H3 agonist consisted of an imidazole ring and a basic function,
separated by an ethylene chain.
The reported potency ofSKF 91606 (76) proved that the sulphur atom of the
isothiourea group is not required. This suggests that for H3 agonism, the imidazole
ring and a basic function may therefore be separated by a longer alkyl chain than
the ethylene chain. This conclusion is confirmed by the activity of the new H3
agonist immepip (88) (see Chapter 6), since the amino group in the structure of
immepip is separated from the imidazole ring by a butylene chain.
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Table 27. Activity of some potent H3 agonists, not derived from histamine, as
determined on guinea pig jejunum.
No. Compound Structure pDz value"
88 immepip rrCNH 8.0
HN~N
r=(\ NHz
75 imetit
- s-i 8.1
HN~N NH
76 SKF 91606 r=rYNHz 9.0HN~N NH
110 VUF4701 ~NHz pAz = 7.7
HN~N
a Determined byevaluation of the influence of the compound on electrically
evoked, cholinergic conctractions of guinea pig intestine preparations, as
described by Vollinga et al.15
All the potent H3 agonists reported sofar, comprise a basic function with a cationic
nitrogen group. Therefore, it might be assumed that activation of the histamine H3
receptor by these derivatives, requires the imidazole ring and a cationic nitrogen, at a
certain distance in space, relatively to this heterocycle. Based on this assumption it
seems that there are two main classes of H3 agonists:
• the direct histamine analogues where a cationic nitrogen is separated from the
imidazole ring by an ethylene chain (see table 4-7) and
• the imetit and immepip analogues, where a cationic nitrogen is separated from the
imidazole ring by an alkyl spaeer with achain length, comparabie to a butylene
chain.
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This means that a general structure of a good H3 agonist at physiological pH, can be
represented as:
pfX- NRR
1
- 1+
HHN~N
Figure 1. General structure of an H3 agonist.
Chain length of X, comparable to ethylene or butylene chain.
According to the general structure of an H3 agonist, as presented in figure I, YUF
4701 (110), which can be seen as a flexible analogue of immepip, should be an
agonist. This compound however, is a potent H3 antagonist on the guinea pig intes-
tine, instead (see Chapter 7). We are currently investigating the activity of YUF
4701 on mouse cortex, measuring [3H]-noradrenaline release.55 Preliminary results
indicate that YUF 4701 is a potent, but partial agonist on this in vitro assay.69
Because YUF 4701 did not show any agonistic activity on the guinea pig jejunum
test system (see Chapter 3), this can be an indication for the existence of receptor
subtypes; further studies are required however for confrrmation.
H3 Antagonists
Also for the H3 antagonists it is clear that the 4(5)-substituted imidazole ring is
essential. There are however many possibility' s for variation of the side chain.
Most reported H3 antagonist may be classified into four distinct groups:
1) the elongated irnetit- and histamine analogues,
2) the burirnamide analogues,
3) the thioperamide analogues and
4) other ro-functionalized 4(5)-alkyl imidazoles, e.g. the amide-, carbamate-, ester-,
and ketone derivatives.
Chapter 2 S9
1) The elongated imetit- and histamine analogues, where a cationic nitrogen is sepa-
rated from the imidazole ring by a pentylene chain are potent antagonists on the
guinea pig intestine (see table 28). It might be possible that these derivatives have a
comparable binding behaviour and bind to the same sites in the receptor.
Table 28. Comparison of some H3 antagonists with a cationic nitrogen, located at a
comparable distance through bonds, from the imidazole ring.
No.
111
81
144
Compound
impentamine
VUF8328
SKF91486
Structure
~NH2
HN~N
pA2 value
a Determined by evaluation of the influence of the compound. on electrically
evoked, cholinergic conctractions of guinea pig intestine preparations, as
described by Vollinga et al.I5
b Determined by evaluation of the influence of the compound on electrically
evoked, NANC conctractions of guinea pig intestine preparations, as described
by Menkveld et al.13
C Determined by evaluation of the influence of the compound on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
Substitution of the elongated imetit analogue YUF 8328 (81) with a lipophilic
aralkyl moiety led to very potent antagonists like clobenpropit (131). Therefore, we
are currently investigating the effect of introduetion of these type of substituents on
the amino group of impentamine.
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2) Another group of H3 antagonists, probably binding in a distinct manner, are the
burimamide analogues (see table 19 and Chapter 8), with a non-protonated thiourea
group (at physiological pH). In contradiction to the elongated imetit analogues, the
introduetion of a lipophilic residue does not lead to a strong increase of antagonistic
potency. Variation of the chain length of the alkyl spaeer of these burimamide
analogues however, has a large influence on the H3 antagonistic activity, with the
H3 selective pentylene and the hexylene analogues being about ten times more
potent than burimamide. Because there is no large influence of the N-substituents of
the burimamide analogues on the pA2 value, an interaction with the H3 receptor via".
hydrogen bonding seems likely.
3) Thioperamide (198) can be regarded as a rigid analogue of norburimamide (169).
However thioperamide seems to exhibit a different binding behaviour towards the
H3 receptor than the more flexible norburimamide derivatives. For example YUF
4634 (173) is about hundred times less potent than thioperamide (see table 19 and
chapter 8). Moreover the replacement of the thiourea group of thioperamide by an
urea group, led to a strong decrease in H3 antagonistic activity and replacement of
the thiourea group of VUF 4634, did not. Therefore it seems that analogues of
burimamide and analogues of thioperamide, although having some structural
features in common, do not necessarily interact in a comparable manner with the H3
receptor.
4) For a fourth distinct group of potent H3 antagonists, a functional group located
at a certain distance in space from the imidazole ring, seems to be less important (see
table 22-24). Especially, because of the high potency of the ether analogues
presented in table 24, it appears that a lipophilic moiety, separated by an alkyl spaeer
from the imidazole ring is sufficient for H3antagonistic activity.
It must be stressed that it is dangerous to draw solid conclusions about structure
activity relationships between Hg Iigands and the H3 receptor, if the compounds are
not tested with the same biological assay. Several discrepancy's in activity of
ligands tested on different H3 in vitro assays have been reported in the mean time.
Chapter 3
A Simple and Rapid In Vitro Test System for
the Screening of Histamine H3 Ligands
Roeland C. Vollinga, Obbe P. Zuiderveld, Heleen Scheerens, Aalt Bast and
Hendrik Timmerman
based on publication :
Methods and Findings in Experimental and Clinical Pharmacology,
14 (10), 747-751 (1992).
Abstract
A simple and rapid functional test system for the screening of histamine H3 ligands is
described. It is based on the inhibitory effect of histamine H3 agonists on the electri-
cally-evoked contractile response of isolated guinea pig intestine. Whole jejunum
segments are continuously stimulated maximally (15-20 V) by electrical pulses with a
frequency of 0.1 Hz and a duration of 0.5 msec. The resulting twitches are recorded
isotonically (l.0 g) and can be completely abolished by atropine(O.l J.lM).
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Introduetion
The histamine H3 receptor was first identified by Arrang et al.5 .as a presynaptic
autoreceptor, regulating the release and synthesis of histamine in nerve endings in
the rat cerebral cortex. Until now only a few selective ligands for this receptor have
been prepared. The most widely accepted Hj-selective ligands are (Rj-u-
Methylhistamine as an H3 agonist and thioperamide as an H3 antagonist, both able
to cross the 'blood brain barrier'i''
(R)-a.-Methylhistamine and thioperamide have been characterized as selective H3
ligands by an in vitro assay based on the release of [3H]-histamine from slices of rat
cerebral cortex preloaded with [3H]-histidine.6 The release of [3H]-histamine can be
induced by depolarization with K+,5 but also an assay based on superfusion has
been described in which [3H]-histamine release is induced by electrical stimula-
tion.24,27
Both assays can be used as a test system, but serious drawbacks, make them less
attractive for the screening of compounds on H3 activity. With the K+-induced-
depolarization method, only about 50 % inhibition is found and with the electri-
caIly-induced assay, based on superfusion, the response seems to be frequency-
dependent, probably due to a frequency dependent receptor reserve.?O,71 Moreover,
both procedures are rather complex and laborious. In order to study the structure-
activity relationship (SAR) of a series of compounds on H3 activity, but also for
other screening purposes, there is a need for a simple, rapid and reproducible test
systemY
It is now known that the histamine H3 receptor also plays a regulatory role in the
release of other neurotransmitters (heteroreceptor). For instanee the inhibition of
noradrenaline-f and serotonine-release/ in the rat brain cortex has been described.
The role of the H3 receptor in the periphery has been established as well, since acti-
vation of this receptor inhibits the release of acetylcholine and other neurotransmit-
ters of the non-adrenergic non-cholinergic (NANC) type, in for instance the guinea-
pig intestine72 and guinea-pig airways.u,12
Chapter 3 63
The inhibitory action of histamine on electrically evoked, atropine-resistant contrac-
tions, of plexus-containing longitudinal muscle preparations from the guinea-pig
ileum, has first been demonstrated by Ambache et al.73 The histamine Hz antagonist
burimamide could block this inhibiting effect of histamine, but insensitivity to Hz
agonists74 made it doubtful that the responsible inhibitory receptor is of the Hz sub-
type. In a study by Fjalland et al.75 using whole ileum segments, a distinct difference
was demonstrated between the "classical" histamine Hz receptors in the heart and
the histamine-stimulated, contraction-inhibiting receptors on the guinea-pig ileum.
The antagonistic effect of burimamide on the inhibitory guinea-pig ileum receptor,
was about 25 times higher than that of cimetidine, whereas on the heart cimetidine
was found to be 10 to 50 times more potent than burimamide. With the development
of the selective H3 ligands, Trzeciakowski subsequently demonstrated that the
observed inhibition of field stimulated contractions of the ileum, was mediated by
the H3 receptor.Î'' With this knowledge several papers have been published, describ-
ing the existence of H3 receptors on the guinea-pig small intestine.13,14,77
In the present paper we describe a simple assay, based on the functional response of
electrically stimulated whole guinea-pig jejunum segments (contractions induced by
endogenous. acetylcholine-release), which is suitable as an in vitro test system for
the rapid screening of compounds on histamine H3 activity. The results are com-
pared with other possible test systems.
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Figure 1 (A) The effect of (Rj-u-methylhistamine on the contractile response
(twitch) of whole jejunum segments of the guinea pig intestine. (B)
Concentration-response curves of (R)-a-methylhistamine during the
course of the day, with a rightward parallel shift upon addition of thio-
peramide. The Schild plot of these results is shown in the inset.
Results
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A regular contraction pattem of twitches results from the described stimulation
conditions, due to the electrically stimulated release of acetylcholine from the myen-
teric plexus in the jejunum preparation. These contractions can be completely
blocked by atropine (0.1 ~M). Applying cumulative concentrations of a histamine
H3 agonist, a concentration dependent inhibition of the twitch response, of the jeju-
num preparation, is found (Fig. IA) and a concentration-response curve (CRC) can
be constructed (Fig. IB). A rightward parallel shift of the CRC of (R)-a-
Methylhistamine can be observed, after addition of an H3 antagonist. The maximal
relaxation (inhibition of the twitch response) that can be achieved by (R)-a-
Methylhistamine, lies between 80 and 100 % of the maximal twitch response (see
Fig. IA). A small decrease in this maximal response ofthe preparation, upon addition
of an H3 agonist, may be observed after several experiments during the course of the
day (see Fig. IB), possibly due to desensitization. The pD2 values however remain
the same when only CRC's of (R)-a-Methylhistamine are being recorded. About
five CRC' s can be constructed using one preparation. The first measurement is dis-
carded, because of its sometimes irregular response pattem. In this respect, the addi-
tion of a single dose of the H3 agonist, giving about 90 % of the maximal response,
instead of applying cumulative concentrations for the first CRC, is a good option.
To prevent activation of the histamine Hl receptors (also present in the preparation)
from interfering with the contraction pattem, pyrilamine or tripolidine can be added
(10-7 M; no interfering activities at that concentration). Activation of the Hl receptor
results in a rise of the basal tension of the muscle preparation.
It should be noted that there is some confusion in literature about the region of the
guinea-pig small intestine that is defined as the ileum. The section between 20-40 cm
proximal to the ileocaecal valve is called ileum,73,76 but also the sections between 5-
25 cm,13 and 10-20 cm.16 To avoid the anomalous part of the small intestine, we used
the section between 20-50 cm proximal to the ileocaecal valve, which we indicate as
jejunum according to literature.72,78
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Table I. Activities of some histamine H3 ligands, determined with the described
test system and compared with other in vitro assays
H3 activity Test
other H3 in vitro assays
H3 agonist parameter system! A B C D E F
(R)-a-methyl- pD2 7.8 ± 0.2 7.8 7.6 8.3 7.6 8.4
histamine
NlX.-methyl- pD2 7.7 ± 0.1 7.2 8.4 7.7 7.8 8.7
histamine
thioperamide pA2 8.9 ± 0.1 9.0 7.9 8.5 8.2 8.9 8.4
(Schild-slope) (1.0±0.1) (1.l±0.1) (l.O±O.l)
burimamide pA2 7.1 ± 0.1 7.5 7.0 7.2
(Schild-slope) (1.0±0.1) (1.3±O.1)* (0.9±0.1)
norburimamide pA2 6.4 ± 0.2 6.4 6.1
(Schild-slope) (1.0±0.1) (1.3±O.1)*
1 Values obtained with our test system represent mean ± SD from 4 different
animals in duplo.
* Schild slope significantly different from unity (p<O.05; t test).
A In vitro assay, based on the inhibitory effect of H3 agonists on electrically
evoked, cholinergic conctractions of guinea pig fleum preparations, as described
by Hew et al.77
B In vitro assay, based on the inhibitory effect of H3 agonists on electrically
evoked, cholinergic conctractions of guinea pig duodenum preparations, as
described by Coruzzi et al.14
C In vitro' assay, based on the inhibitory effect of H3 agonists on electrically
evoked, NANC conctractions of guinea pig ileum preparations, as described by
Menkveld et al.13
D In vitro assay, based on the inhibitory effect of H3 agonists on electrically
evoked, NANC conctractions of guinea pig ileum preparations, as described by
Taylor et al.16
E In vitro assay, based on the inhibitory effect of H3 agonists on K+-stimulated
[3H]-histamine release on rat cortex, as described by Arrang et al.5
F In vitro assay, based on the inhibitory effect of H3 agonists on electrically-stimu-
lated [3H]-histamine release on rat cortex, as described by Van der Werf et
al.24,27
Discussion
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In this test system, the capacity of a compound to stimulate or block the histamine
H3 receptor, is determined by its ability to inhibit the contractions of a jejunum
preparation, which are induced by the release of acetylcholine from myenteric nerve
endings in the guinea-pig small intestine, evoked by field stimulation. Such a system
has also been described by Fjalland et al.,75 Trzeciakowski'f and Hew et al.77 on
the ileum and by Coruzzi et al.14 on the duodenum. The action of H3 agonists on
non-adrenergic non-cholinergic (NANC) neurotransmitter(s) mediated contractions,
has been described by Ambache et al.,73,74 Menkveld et al.13 and Taylor et al.16
The results indicate the presence of H3 receptors on both cholinergic and non-
cholinergic nerves in the myenteric plexus of the small iritestine.
With the Ach-mediated as weIl as with the NANC-mediated response, a concentra-
tion dependent inhibition of the contraction-amplitude can be observed, upon addi-
tion of an H3 agonist. The H3 activities of some selective H3 ligands, determined by
the different in vitro assays in literature, are compared in Table I. From these data, it
is clear that all these methods can be used for the determination of the H3 activity of
compounds but that the variation between the values obtained by the different
assays, is too large for structure-activity relationship (SAR) studies. This means that
their is a need for one standard test system.
We already mentioned that the laborious rat cortex release assays6,24,27 are not
suitable for this purpose. The assays based on the release of NANC neurotransmit-
ter(s)13,16,73,74 can be used as an in vitro test system for H3 ligands.P but the vul-
nerable and troublesome preparations (longitudinal muscle strips containing the
myenteric plexus, which are difficult to prepare and handle) make this assay less
attractive for rapid screening purposes. Another disadvantage may be that it is not
known at all, what neurotransmitter(s) evoke(s) the contraction. Of the assays based
on the release of acetylcholine, the method described by Coruzzi et al.,14 using seg-
ments of the duodenum, is not applicable, because of the described marked desensi-
tization to H3 agonists (only one CRC for each H3 agonist can be constructed) and
the partial inhibition (50-60 %) of the evoked contraction of the preparation.
When comparing the data obtained from our described test system with the data
obtained from the in vitro assay described by Hew et al.77 (describing the use of
whole segments of the guinea-pig ileum) in Table I, it is clear that there is a great
resemblance (although with theileum preparation, the Schild-slope of Burimamide
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and Norburimamide is significantly different from unity). This means that the use of a
whole segment of the guinea-pig small intestine (not duodenum) gives reproducible
results and is therefore suitable as preparation for our purposes.
In this paper we have described a rapid and reliable in vitro test system. Whole
jejunum segments are used as preparations, which are easy too prepare and handle
and give a quick and reproducible response, using simple electrical stimulation
conditions. For these reasons, we think that this assay is most suitable for the
screening of compounds on R3 activity.
Material and methods
Male albino guinea-pigs (350-450 g) were killed by a blow on the head. A portion
of the small intestine, 20-50 cm proximal to the ileocaecal valve (jejunurn), was
removed and placed in Krebs buffer (composition (mM): NaC1118, KCI 5.6, MgS04
1.18, CaClz 2.5, NaH2P04 1.28, NaHC03 25 and glucose 5.5). Whole jejunum
segments (2 cm) were prepared and mounted between two platinum electrodes (4
mm apart) in 20 mi Krebs buffer, continuously gassed with 95% 02: 5% C02 and
maintained at 37°C.
Contractions were recorded isotonically under 1.0 g tension with a Hugo Sachs
Rebel -Messvorsatz (TL-2)IHF-modem (Hugo Sachs Elektronik, Hugstetten,
Germany) connected to a pen recorder. After equilibration for one hour with
washings every 10 min, the muscle segments were stimulated maximally between 15
and 20 Volt and continuously at a frequency of 0.1 Hz and a duration of 0.5 msec,
with rectangular-wave electrical pulses, delivered by a Grass Stimulator S-88 (Grass
Instruments Co., Quincy, USA). After 30 min of stimulation, cumulative concentra-
tion-response curves (half-log increments) of the histamine H3 agonists were
recorded U4til no change in response was found. H3 antagonists were added 20 min
before generation of concentration-response curves with (R)-a-Methylhistamine as
H3 agonist. Between two succeeding measurements, the preparations were washed
three times every 10 minutes, without any stimulation.
The following drugs were used: (R)-a-Methylhistamine dihydrogenmaleate and
thioperamide (kindly donated by J.-C. Schwartz, Centre Paul Broca de I'INSERM,
Paris), NlI-Methylhistamine (Calbiochem-Behring), burimamide (Smith-Kline &
French Laboratories) and norburimamide dioxalate (from our own laboratory stock).
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The data obtained with the described test system are expressed as mean ± SD Tissue
preparations from at least four different animals were used for each compound.
Statistical analysis was carried out with the Students' t-test. In all tests p < 0.05 was
considered statistically significant. The potency of an agonist, as an inhibitor of the
electrically evoked contractions, was expressed by its pD2 value. The potency of an
antagonist was expressed by its pA2 value, calculated from the Schild regres sion
analysis where at least three concentrations were used. All other data shown from
literature are expressed as pD2 respectively pA2as weIl, for easy comparison.
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Introduetion
Synthesis of 4(5)-substituted imidazoles
When comparing the structures of all the potent histamine H3 ligands, described in
Chapter 2, it is obvious that the 4(5)-substituted-imidazole moiety, is essential for
agonistic or antagonistic activity on the H3 receptor. Since the purpose of this
research was the development of new H3 ligands for SAR- and molecular pharmaco-
logical studies, we needed a suitable route for the synthesis of a variety of different
4(5)-substituted imidazoles.
Cyclization Reactions
The classical method of preparing 4(5)-substituted imidazoles derivatives, is based
on the use of a linear synthesis route, with a ring closure of the imidazole ring in the
final stages.
Some examples of these methods are shown in Figure 1. The most widely used
method is known as the Bredereek reaction; route (a).79-81 For instanee 4(5)-
hydroxymethyl-imidazole'ê and 4(5)-(2-hydroxyethyl)-imidazole83 have been
prepared by the reaction of the corresponding a-hydroxyketon, with formamidine,
respectively formaldehyde in ammonia. Frequently formamide is used for the ring-
closure. However, harsh conditions (like high temperatures) are often required for
the Bredereek reaction.
Another frequently used method is the Marck-Wald reaction; route (b). This route
has been used by Schunack for the synthesis of thioperamide.Î"
A milder ring-closure method has been described more recently by Shih; route (c).85
Here an N-trimethylsilylimine reacts with the anion of tosylmethylisocyanate
(reaction temperature; -78°C to room temperature), followed by hydrolysis to obtain
the imidazole.
In general and from our own experiences however, imidazole-cyclization reactions
are low yielding, time-consuming and give many side products, which are difficult to
remove. Also, the reagents for the cyclization reaction are often difficult to obtain.
Another large drawback is that this linear synthesis route is rather inflexible,
meaning that for most desired structural variations, a totally new route has to be
developed. It would be more convenient to use a convergent synthesis route, in
which the (intact) imidazole ring is our starting material, to which many different
substituents can be coupled directly to the 4(5)-position. We therefore developed a
new route for the synthesis of various 4(5)-substituted imidazoles.
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x=e.g. Hal,OH, OAe, NH2
Figure 1 Some classical routes to 4(5)-substitutedimidazoles,
Coupling Reactions
Not many preparative routes for the synthesis of 4(5)-substituted imidazoles, using a
direct coupling reaction, have been described yet. However several preliminary
investigations have been (and are currently) published.
Shirley86 and Roe87 demonstrated already more than 30 years ago, that l-substi-
tuted imidazoles can be metallated at the C2-position using n-butyllithium and
treated subsequently with an electrophile, leading to a 1,2-disubstituted imidazole.
About 15 years later it was demonstrated by Tang88 that it is also possible to lithiate
the C5-position of the imidazole ring, if both the 1- and the 2-position are substi-
tuted. The addition of carbonyl compounds resulted in the formation of the corre-
sponding alcohols in good yields. Since then, severallithiation procedures for the
imidazole ring and substitutions with a variety of electrophiles , have been
reported.89-100
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Not only direct metallation reactions, but also metal-halogen exchange reactions
with poly-iodinated or poly-brominated l-protected imidazoles have been
described.89,92,93,lOl-106 In theory it should be possible to lithiate and functionalize
any of the three carbon atom positions of a suitable N-protected polyhaloimidazole.
Halogen-metal exchange reactions are mostly used for the synthesis of 4,5-asym-
metrically-disubstituted imidazoles.102,103
Apart from mono-lithiation of the imidazole ring, 2,5-dilithiation is also possible, but
attempts to induce a regioselective electrophilic attack at the C-5 position have met
with limited success. Only in the case of methyliodide as electrophile, an excess of
the 5-substituted product in a reaction mixture of 5-methyl and 2,5-dimethyl deriva-
tives, has been reported.90
In the last few years, a few other potential substitution reactions for the synthesis of
a variety of 4(5)-substituted imidazoles, have been described, which still need to be
investigated further. For instanee allylation of a 1,2-diprotected-5-iodoimidazole
with a (rc-allyljnickel-complex'V' or the coupling of an alkyliodide to TMS-imidazole
using TiC4 (low yield)108 has been reported, but also the direct coupling of aromatic
halides to the imidazole ring.109,11O
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hydrolysis
..
We investigated the possibility to use direct C-S lithiation reactions of a suitable 1,2-
diprotected imidazole, for the synthesis of new H3 ligands. A general scheme of this
approach to 4(S)-substituted imidazoles is shown in Scheme I.
I \ 1) Base I \ 1)n-buli
H-N N ... P - N.. ~.N ....V 2) P1X 1·V 2) P2X
Scheme I. General procedure for the preparation of 4(S)-substituted-lH-imidazoles
via C-S lithiation, in which PI and P2 are protecting groups and Eis an
electrophile.
The synthesis of 4(S)-substituted imidazoles at a preparative scale through metalla-
tion at the CS-position requires an efficient proteetion of both the Nl- and C2-posi-
tions, in combination with an easy, preferably 'one pot' deprotection step, under
conditions that don't affect other functional groups present. Several different
protecting groups have been proposed89-91,93,94,96,111 and treatment of the metal-
lated intermediates with a suitable electrophile resulted in the corresponding substi-
tuted imidazoles. However, only few papers describe the actual synthesis of target
compounds, using this approach.88,94,95,98,IOO,112
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Most of the reported NH protecting groups reported, were not suitable for our
purposes. For instanee the benzyl group is not inert under the reaction conditlons'f"
88,90 and the removal of the methoxymethyl group requires severe deprotection
conditions.88,90 Several other groups where found to be too labile for the use as
protecting ~roup for the NH function.Î" We selected the N,N-dimethylsulfamoyl
group as a protecting group for the NH function of the imidazole ring in our proce-
dures, because it can be introduced and removed under simple and relatively mild
conditions and is stabie under the lithiation conditions, directing the lithiation to the
ortho-position next to the sulphonamide group.90,96
For proteetion of the C-2 position of the l-(N,N-dimethylsulfamoyl)imidazole, the
phenylthio group was tried initially , but we found that the deprotection of the C-2
position of the l,2-diprotected-5-substituted imîdazole, was not feasible under any
of the conditions described in literature.88,113 The tert-butyldimethylsilyl group
(TBDMS) proved to be the most convenient protecting group for our purposes, as it
is stabie to the metallation conditions and can be easily removed using the same
conditions as for the removal of the N,N-dimethylsulfamoyl group, thereby allowing
a 'ene-pot' deprotection step. Incidentally, we were able to use the economically
more attractive trimethylsilyl group, depending on the reactivity of the added elec-
trophile (see chapter 6 and 9).
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Abstract
A new route for the synthesis of 4(5)-(ro-aminoalkyl)-IH-imidazoles Ion a prepara-
tive scale through C5-lithiation of a 1,2-diprotected imidazole is described. When
the described 1,2-diprotected-5-lithio-imidazole is treated with a f-chloro-ro-
iodoalkane 5, selective substitution of the iodo group takes place. The chloro group
of the resultant 1,2-diprotected-5-(ro-chloroalkyl)imidazole can be easily converted
into an amino group, but obviously other functional groups can be introduced as
well. Subsequent deprotection of the 5-substituted imidazole affords 4(5)-(ro-
aminoalkyl)-lH-imidazoles 1, as precursors for a large range of histaminergic com-
pounds, in good overall yields.
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Introduetion
In the search for compounds that selectively bind to histamine receptors and, as a
result of this, stimulate (agonists) or block (antagonists) such receptors, several use-
ful drugs have been found. The natural agonist of the histamine receptors (until now
three subtypes have been identified; the histamine H1-,Hz-, and Hs-receptor) is
histamine (4(5)-(2-aminoethyl)-IH-imidazole). It is therefore not surprising that
several histamine ligands, like impromidine and burimamide (Figure I), possess an
4(5)-(ro-aminoalkyl)-IH-imidazole fragment in their structure.
H
~N ....
t=\ - H
H-N ~N
"'?
Histamine
Impromidine H2- agonist; Ha- antagonist
H H
.....~N. N
t=\ - - "C'" "CHaH-N N 11~ S
Burimamide H2- , Ha- antagonist
Figure 1. Three ligands of histamine receptors, all possessing a 4(5)-(<0-
aminoalkyl)-IH-imidazolefragment.
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A convenient synthesis route for the preparation of 4(5)-(ro-aminoalkyl)-IH-imida-
zoles 1 is therefore of interest.
1
The classical method of preparing this kind of imidazole derivative is by a linear
synthesis, with a ring closure (the actual preparation of the imidazole nucleus and
the most difficult and low yielding step) in the final and crucial stages.114-118 The
preparation of 4(5)-(3-aminopropyl)-IH-imidazole (la) for instance, has been
described by chain elongation of 4(5)-(2-chloroethyl)-IH-imidazole (prepared by
ring closure) with sodium cyanide and subsequent hydrogenation over Raney-
Nickel.l14 Also the reaction of l-bromo-5-phthalimido-2-pentanone (from 5-phthal-
imido-2-pentanone) with fonnamidine acetate, followed by hydrolysis, results in the
formation of la116,117 (highest reported overall yield is 14 %).
In general and from our own experiences, these kind of procedures are mostly low
yielding and rather time consuming.
Because of the importance of 4(5)-(c.o-aminoalkyl)-IH-imidazoles 1, as precursors for
a whole range of histaminergic compounds, we have developed an altemative route
for a more rapid synthesis of these compounds on a relatively large scale. The
tedious ringclosure is avoided within this route, by direct coupling of the alkyl part
to the imidazole 4(5)-position through metallation of the ring and subsequent
quenching with a bifunctional electrophile.
In the present paper a new, rapid procedure for the synthesis of the dihydrobro-
mides of 4(5)-(3-aminopropyl)- (la), 4(5)-(4-aminobutyl)- (Lb), and 4(5)-(5-
aminopentyl)-IH-imidazole (Ie), on a preparative scale (0.15 mol) is described.
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Results and Discussion
It has been shown that the imidazole ring can be metallated selectively at either the
C2_,86,87 or at the C5-position88 after treatment of a 1-protected or a 1,2-diprotected
imidazole respectively, with n-butyllithium. Several different protecting groups have
been proposed89-91,93,96,97 and treatment of the metallated intermediates with a suit-
able electrophile yields the corresponding substituted imidazoles. However, only
few papers describe the actual synthesis of target compounds, using this
approach.88,94,95,112
We selectedthe N,N-dimethylsulfamoyl group (Me2NS02-) as a protecting group for
the NH function of the imidazole in our procedure, because of its ease of introduc-
tion and removal under simple and relatively mild conditions.90,96 For the C2
proteetion of 1-(N,N-dimethylsulfamoyl)imidazole 2, the phenylthio group was used
as a protecting group initially , but the deprotection of the C2 position of the 1,2-
diprotected-5-substituted imidazole, was not feasible under any of the eonditions
deseribed in literature.88,113 The tert-butyldimethylsilyl group (TBDMS) proved to
be the most eonvenient protecting group in our synthesis, as it is resistant to the
metallation conditions and can be easily removed under the same conditions as used
for the removal of the N,N-dimethylsulfamoyl group, thereby allowing a 'one-pot'
deproteetion step.
The intermediate 2-(tert-butyldimethylsily1)-1-(N,N-dimethylsulfamoyl)imidazole (4)
can be isolated.Î! but it is more convenient to generate this compound in situ and to
lithiate at C5 directly by the addition of a second equivalent of n-butyllithium.
Preliminary ,experiments indicated that the 1,2-diprotected-5-lithioimidazole ean be
readily alkylated with n-alkyl iodides, but not with other n-alkyl halides. This selec-
tivity allowed us to use l-chloro-m-iodoalkanes 5 as bifunctional electrophiles. With
this method we can introduce an alkyl chain with a variabie chain length and a (0-
chloro group, which can be readily transformed into other groups. We converted the
chloro group into an amino group via the Gabriel synthesis.ll9 This has the advan-
tage that deproteetion of the imidazole and hydrolysis of the phthalimide, can be
realized in one step, avoiding a separate deproteetion step (actually, lH NMR indi-
cates that the 2-tert-butyldimethylsilyl group is already lost under the conditions
used for the formation of the phthalimide derivative).
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Scheme J. Reaction scheme for the preparation of 4(5)-(ro-aminoalky1)-IH-imida-
zoles.
The overall yields of the 4(5)-(ro-aminoalkyl)-IH-imidazoles 1, using the described
procedure (Scheme I), seem to increase with increasing chain-length (la 26%, lb
35% and Ie 51%). An explanation for this observation could be the relative ease of
HI-elimination of the l-chloro-ro-iodoalkanes (5), with the 5-lithio derivative of 4
reacting as a base, especially for the l-chloro-3-iodopropane (Sa).
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It can be concluded that our method offers a new, quick and high yielding route to
histamine analogues on a preparative scale, avoiding a tedious ringclosure. It is
obvious that this procedure is not only applicable for the synthesis of the 4(5)-(ro-
aminoalkyl)-lH-imidazoles, but also for a whole range of other functionalized 4(5)-
alkyl-1H-imidazoles.
Experimental Section
lH NMR and l3C NMR spectra were recorded on a Broker AC-200 (200 MHz, Fr)
spectrometer with tetramethylsilane or sodium 3-(trimethylsilyl)propionate as an
internal standard. Mass spectra were recorded on a Finnigan MAT-90. Melting
points were measured on a Mettler FP-5 + FP-52 apparatus and are uncorrected.
THF was distilled from LiAIH4, DMF was dried by passage through a column packed
with Ah03 and acetone was distilled from K2C03.
The l-chloro-ro-iodoalkanes 5 were prepared by refluxing the corresponding lro-
dichloroalkanes with 1 eq. of sodium iodide in acetone and purification of the
product by distillation.120
l-(N,N-Dimethylsulfamoyl)imidazole (2) was synthesized by the method described
by Chadwick and Ngochindo.l''' with the exception that toluene was used as a
solvent instead of benzene.
2-(tert-Butyldimethylsilyl)-5-(3-chloropropyl)-1-(N,N-dimethylsulfamoyl)-
imidazole (6a) (general procedure)
l-(N,N-Dimethylsulfamoyl)imidazole (2) (26.0 g, 0.15 mol) was dissolved in dry THF
(500 ml) under an atmosphere of dry nitrogen and cooled to -70°C. n-Butyllithium
in hexane (100 ml, 0.16 mol) was added dropwise (temperature should not exceed
-65°C). After 15 min, a solution of tert-butyldimethylsilyl chloride (3) (25.0 g, 0.17
mol) in dry THF (60 ml) was added (10 min) and the solution was stirred at room
temperature.for 1 h. The mixture was cooled to -70°C again and n-butyllithium in
hexane (100 ml, 0.16 mol) was added dropwise (temperature should not exceed
-65°C). After 0.5 h, a solution of 1-chloro-3-iodopropane (5a) (35.0 g, 0.17 mol) in
dry THF (50 ml) was added gradually and the mixture was allowed to (slowly) warm
to room temperature ovemight. The reaction mixture was poured into water (200 ml)
and the THF was removed under reduced pressure. The product was extracted with
CHCh (3 x 150 ml), dried (Na2S04) and concentrated in vacuo. 53.8 g Of a viscous
orange coloured oil was obtained which was used without further purification.
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Analysis of the oil by lH NMR showed formation of the product 6a and the 1,2-
diprotected imidazole 4 in a ratio of 1.5 : 1.
lH NMR (CDCh): Ö 0.38 (s, 6H, Si(Cfuh), 1.02 (s, 9H, C(Cfuh), 2.17 (rn, 2H,
CH2CfuCHÛ, 2.85 (s, 6H, N(Cfuh), 2.94 (t, 2H, J = 8 Hz, imidazole-5-Cfu), 3.63 (t,
2H, J =8 Hz, CfuCI), 6.96 (s, lH, imidazole-4H)ppm.
2-( tert-Butyldimethylsilyl)-5-(4-chlorobutyl)-1-(N,N-dimethylsulfamoylïimidazole
(6b)
Employing the same procedure as for the preparation of 6a using 1-chloro-4-
iodobutane (Sb) (37.0 g, 0.17 mol), 60.9 g of a viscous orange coloured oil was
obtained which was used without further purification. Analysis of the product by
1H NMR showed formation of the product 6b and the 1,2-diproteeted imidazole 4 in
a ratio of 4 : 1.
lH NMR (CDCh): Ö 0.38 (s, 6H, Si(Cfuh), 1.00 (s, 9H, c(ClLh), 1.86 (m, 4H,
CH2(Cfu)2CH2), 2.67 (t, 2H, J =8 Hz, imidazole-5-Cfu), 2.83 (s, 6H, N(Cfu)2), 3.56
(t, 2H, J = 7 Hz, CfuCl), 6.94 (s, lH, imidazole-4H)ppm.
2-(tert-Butyldimethylsilyl)-5-(5-chloropentyl)-1-(N,N-dimethylsulfamoylïimidazole
(6c)
Employing the same procedure as for the preparation of 6a, using 17.5 g (0.1 mol) of
1-(N,N-dimethylsulfamoyl)imidazole (2) in 400 mI dry THF, 65 mI (0.1 mol) n-butyl-
lithium, 15 g (0.1 mol) tert-butyldimethylsilyl chloride (3) and 23.3 g (0.1 mol) 1-
chloro-5-iodopentane (Sc). 37.7 g of a viscous orange coloured oil was obtained.
Analysis of the product by lH NMR showed formation of the product 6c and the
1,2-diprotected imidazole 4 in a ratio of 9 : 1.
lH NMR (CDCh): Ö 0.38 (s, 6H, Si(Cfuh), 1.00 (s, 9H, C(ClLh), 1.57 (m, 2H,
(CH2)2Cfu(CH2h), 1.80 (m, 4H, (CH2Cfu)2CH2),2.73 (t, 2H, J =8 Hz, imidazole-5-
Cfu), 2.84 (s, 6H, N(Cfuh), 3.55 (t, 2H, J =7 Hz, CfuCI), 6.93 (s, lH, imidazole-4H)
ppm.
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4(5)-(3-Aminopropyl)-lH-imidazole dihydrobromide (la) (general procedure)
The crude product 6a (53.8 g) and phthalimide (22.0 g, 0.15 mol) were dissolved in
OMF (500 ml), Na2C03 was added (18.0 g, 0.17 mol) and the mixture was heated at
90°C. After 7 h the mixture was filtrated and the solvent was evaporated under
reduced pressure. The residue was dissolved in CHCh (150 ml), washed with H20 (3
x 150 ml), dried (Na2S04) and concentrated in vacuo. The substitution of the chloro
atom by a phthalimido group and the removal of the 2-tert-butyldimethylsHyl group
were complete. The formation of 1-(N,N-dimethylsulfamoyl)-5-(3-phthalimido-
propyl)imidazole (7a) was demonstrated by lH NMR.
lH NMR (COCI3): Ö2.09 (m, 2H, CH2CH2CH2), 2.86 (t, 2H, imidazole-5-CHz),2.90 (s,
6H, N(Clli)2), 3.80 (t, 2H, CHz-phthalimide), 6.94 (s, 1H, imidazole-4H), 7.80 (m, 5H,
phthalimide-H + imidazole-2H) ppm.
The crude product was dissolved in 30 % HBr (500 ml) and heated under reflux.
After 16 h the mixture was cooled, filtrated and concentrated in vacuo. The residue
was dissolved in absolute EtOH (300 ml), heated under reflux for 0.5 h and coneen-
trated under reduced pressure. The remaining dark oil was washed (under stirring)
with portions (100 mI) of acetone. After several washings, the oil crystallized. After
filtration of the grey crystals, 11.2 g (26 % overall) of the product la was obtained.
Recrystallization from EtOHlEtOAc gave white crystals.
mp : (193.8-195.2) °C (the melting point of la as a di-HeI salt is given in ref. 114).
rn NMR (020): Ö 2.08 (m, 2H, J =8 Hz, CH2CH2CH2), 2.88 (t, 2H, J =8 Hz, imi-
dazole-4(5)-CHz), 3.09 (t, 2H, J = 8 Hz, CHzNH2), 7.31 (s, 1H, imidazole-5(4)H), 8.63
(s, 1H, imidazole-2H) ppm.
BC NMR (020): Ö22.5,27.2,40.1,117.2,133.5,134.6 ppm.
MS (Cl, methanol): rnJe 126 (100 %, MH+), 109 (43 %, MH+- NH3+), 95 (18 %,
MH+- CNH4), 79 (11 %).
4(5)-(4-Aminobutyl)-1H-imidazole dihydrobromide (I b)
Employing the same procedure as for the preparation of Ib, using the crude product
6b (60.9 g). This time the intermediate 1-(N,N-dimethylsulfamoyI)-5-(4-phthalimi-
dobutyl)imidazole (7b) was purified further by washing with petroleum ether
(40/60), and trituration with iso-propanol. The product crystallized as a beige
coloured solid (12.5 g, 31 %).
lH NMR (COCI3): Ö 1.77 (m,4H, CH2(CHzhCH2), 2.82 (1, 2H, J =7 Hz, imidazole-5-
en», 2.92 (s, 6H, N(Cfuh), 3.76 (t, 2H, J =7 Hz, Cfu-phthalimide), 6.85 (s, lH,
imidazole-4H), 7.80 (m, 5H, phthalimide-H + imidazole-2H) ppm.
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After hydrolysis of this material, 6.0 g (13.5 % overall) of 1b was isolated as a
brownish solid. In another experiment using the crude 1-(N,N-dimethylsulfamoyl)-5-
(4-phthalimidobutyl)imidazole (7b), an overall yield of 35 % of the product 1b was
obtained.
lH NMR (D20): 0 1.77 (m, 4H, CH2(CH2hCH2), 2.80 (t, 2H, J = 8 Hz, imidazole-4(5)-
Cfu), 3.06 (t, 2H, J =8 Hz, CfuNH2),7.28 (s, lH, imidazole-5(4)H), 8.59 (s, lH, imida-
zole-2H) ppm.
l3C NMR (D20): 024.8,26.3,27.5,40.7,116.9,134.3,134.6 ppm.
MS (CIIMeOH): mie 140 (100 %, MH+), 123 (70 %, MH+- NH3+), 79 (55 %).
4(5)-(5-Am{nopentyl)-1H-imidazole dihydrobromide (Ie)
Employing the same procedure as for the preparation of la, using the crude product
6e (37.7 g). 1-(N,N-dimethylsulfamoyl)-5-(5-phthalimidopentyl)imidazole (7e) was
isolated as a brownish oil,
.n NMR (CDCh): 0 1.41 (m, 2H, (CH2hCfu(CHÛÛ, 1.70 (m, 4H, (CH2CfuhCH2),
2.69 (t, 2H, J = 8 Hz, imidazole-5-Cfu), 2.85 (s, 6H, N(Cllih), 3.67 (t, 2H, J = 7 Hz,
Cfu-phthalimide), 6.79 (s, lH, imidazole-4H), 7.73 (m, 5H, phthalimide-H + imida-
zole-2H) ppm.
Hydrolysis of this material gave 16.0 g (51 % overall) of product Ie,
lH NMR (D20): 0 1.45 (m, 2H, (CH2hCfu(CH2h), 1.72 (m, 4H, (CH2CfuhCH2), 2.76
(t, 2H, J = 7 Hz, imidazole-4(5)-Cfu), 3.00 (t, 2H, J = 7 Hz, CfuNH2), 7.23 (s, lH,
imidazole-5(4)H), 8.58 (s, lH, imidazole-2H) ppm.
l3C NMR (D20): 024.3,25.1,26.5,28.0,41.1,116.8,134.2,135.2 ppm.
MS (Cl, methanol): mie 154 (100 %, MH+), 137 (25 %, MH+- NH3+), 123 (79 %,
MH+- CNH~).
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Abstract
In the search for new selective histamine H3 receptor ligands, we have identified the
new potent histamine H3 agonist 4-(lH-imidazol-4-ylmethyl)piperidine (immepip)
(3). The agonistic activity and the binding affinity of immepip (3) for the H3 receptor
is comparable to the two H3 agonists (R)-a.-methylhistamine (1) and imetit (2).
Immepip (3) fulfils the criteria for a selective histamine H3 agonist, displaying low
affinity for the Hl- and the Hz receptor. It can be conc1uded that immepip (3) can be
useful as a pharmacological taal and perhaps as a therapeutical agent, but also,
because of its distinctive structure, for SAR- and Molecular Modelling studies.
88 A New Potent and Selective Histamine H3 Agonist, Immepip
Introduetion
It has been shown that the presynaptic histamine H3 receptor' regulates not only
the release and synthesis of histamine, but also the release of other neurotransmit-
ters26,41 and can be regarded as a potential target for new therapeuticsp,54 Until
now only a few potent and selective agonists for the histamine H3 receptor have
been described. Methylation of the side chain of histamine has resulted in agonists
like N<X-methylhistamine5 and the chiral agonists (Rj-u-methylhistamine'' (1) and
(R)a,(S)13-dimethylhistamine.28,29 Out of this series of methylated histamine
analogues, the (R)-enantiomer of e-methylhistamine 1 has been used extensively as
a pharmacological tooI. Recently the non-chiral histamine H3 agonist, imetit (2) has
been described.37-40 This agonist is different from histamine and its methylated
analogues, because it has a planar basic isothiourea group instead of an amino
group. Imetit (2) and (Rj-c-methylhistamine (1) are equipotent on the H3 receptor as
reported by Van der Goot et al. and Howson et al. on the inhibition of the electri-
cally evoked twitches of the guinea pig ileum Uejunum).37,38
1, (R)-a-methylhistamine 2, imetit
We now describe a new, potent and selective non-chiral histamine H3 agonist,4-
(lH-imidazol-4-ylmethyl)piperidine (immepip) (3) as prepared from a series of
histamine analoguesf" in which we incorporated the amino group in various ring
structures, in order to obtain more information about the influence and the optimal
location of the amino group relative to the imidazole ring. For immepip (3) the alkyl
side chain was extended to a length of 4 methylene groups and the amino group
was incorporated in a piperidine ring.
~NH
HN~N
3, immepip
Chemistry
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Immepip (3) was synthesized by the direct coupling of 4-pyridinecarboxaldehyde to
the 5-position of a suitable 1,2-diprotected imidazole 6 by lithiation (Scheme I) (see
also Chapter 5 and 9).121 The hydroxyl group of 7 was removed by acylation and
subsequent hydrogenation at 50 atm using Pd/C asa catalyst. Under these condi-
tions the pyridine ring is also reduced to a piperidine ring and the tert-
butyldimethylsilyl protecting group is hydrolyzed. After removal of the N,N-
dimethylsulfonamide protecting group, immepip (3) was isolated as the dihydro-
bromide (overall yield was 70%). The reaction sequence has also been performed,
using the trimethylsilyl group (cheaper) for proteetion of the 2-position of the imida-
zole ring (overall yield was 40%).
I \ a I \ b,c I \
HN~N .. NyN-S02NMe2 ... NyN-S02NMe2
4 5 -Si- 6
+
rrCNH ~.ONh t,g
3 ol NyN-S02NMe2 ... NyN-S02NMe2
8 -S;- 7
+
Seheme I Reagents used : (a) N,N-dimethylsulfamoylchloride, Et3N, toluene. (b) n-
BuLi, THF, -70°C. (c) tert-butyldimethylsilyl chloride. (d) n-BuLi, THF,
-70°C. (e) 4-pyridinecarboxaldehyde. (f) DBU, AC20. (g) H2, Pd/C, 50
atm. (h) 30% HBr, reflux.
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Pharmacology
The H3 activity was functionally determined, on an in vitro test system based on the
concentration dependent inhibition of electrically evoked twitches of isolated
guinea pig jejunum segments by histamine H3 agonists (see Chapter 3).15
The binding affinity for the Hl receptor was determined by the displacement of
[3H]mepyramine, bound to membranes of CHO cells expressing guinea pig Hl recep-
tors. 122
The binding affinity for the H2 receptor was established by the displacement of
[l25I]iodoaminopotentidine, bound to membranes of CHO cells expressing human H2
receptors.123
Results and Discussion
Average concentration response curves (CRC's) for immepip (3) and (R)-«-
Methylhistamine (1) (for comparison) are shown in Figure 1.
• immepip
--e- (R)-a -methylhistamine
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Figure 1 Concentration response curves for immepip (n = 8) and (Rj-ce-methylhis-
tamine (n = 22), constructed from the inhibition of the electrically
evoked twitches of the guinea pig jejunum.U n Represents the number
of animals used. Values shown in the graph are expressed as mean ± SD
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From this graph it is clear that immepip (3) is equipotent as (or even slightly more
active than) (Rj-u-methylhistamine (1) on the H3 receptor. The pD2 value for
immepip (3) as determined on jejunum preparations of eight different animals was
8.0 ± 0.1 (mean ± SD). For comparison, (R)-a-methylhistamine (1) has a pD2 value of
7.8 ± 0.2 (n = 22) on this test system. The H3 antagonist thioperamide caused a
rightward parallel shift of the CRC for immepip (3). The pA2 value of thioperamide,
using immepip (3) as an agonist, was 8.2 ± 0.2 with a Schild slope of 0.8 ± 0.1 (n =
3) (not significantly different from unity). This is slightly lower than the pA2 value of
thioperamide, obtained using (Rj-c-methylhistamine (1) on this assay.15 This lower
affinity has also been reported, using imetit (2) as agonist.39
The potent agonistic activity of immepip (3) on the H3 receptor, was confinned in
radioligand binding studies (Figure 2).
-
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Figure 2 Receptor selectivity of immepip as measured by radioligand binding
studies. Displacement of the specific binding ligands in representative
experiments is shown. Competition of immepip with [3H]mepyramine
binding to membranes of CHü cells expressing guinea pig Hl recep-
tors,122 [l25I]iodoaminopotentidine binding to membranes of CHü cells
expressing human H2 receptors123,124 and [l25I]iodophenpropit binding
to membranes from rat cortex50 was measured in at least three indepen-
dent experiments, perfonned in triplicate.
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Displacement of the H3 antagonist [l25I]iodophenpropit49,50 binding to rat cortex
membranes resulted in shallow displacement curves for immepip (3). Computer anal-
ysis of these data reveals two binding sites (using the program LIGAND).125 This is
in agreement with the described displacement curves for other H3 agonists and
indicative for the interaction of the H3 receptor with a G-protein. The KH and the KL
for immepip (3) on the H3 receptor, are 2.7 ± 0.5 nM and 1.01 ± 0.2 f.lM respectively.
For comparison (R)-a-methylhistarnine (1) showed a KH and a KL of 4.3 ± 3.4 nM
and 0.22 ± 0.15 f.lM respectively, on the same assay.50 From figure 2 it is also clear
that immepip (3) is highly selective for the H3 receptor. The pKi of immepip (3) for
the guinea pig Hl receptor was 4.79 ± 0.10 (using [3H]mepyramine as a radioli-
gand),122 whereas its affinity for the human H2 receptorl24 was too low to be deter-
mined accurately (using [l25I]iodoarninopotentidine as a radioligand; pKi < 3.5).
If we compare the structure of the methylated histamine analogues, imetit (2) and
immepip (3), some interesting observations can be made. The arnino group of
histamine and its methylated analogues is protonated at physiological pHl26 and is
located at a distance of 2 methylene groups ("=' 4.5 Á) away from the imidazole ring.
This ammonium group could interact with a carboxylate group in the receptor, as
postulated for the H2 receptor.127,128 The isothiourea group of imetit (2), is also
protonated at a pH of 7.4.40 This means that the isothiouronium group can also
interact with a carboxylate group. However, since only the imino nitrogen of the
isothiourea group can be protonated, the distance between the imidazole ring and
the hydrogen donating nitrogens is not 2 methylene groups ("=' 4.5 Á) as in histamine
and its methylated analogues, but longer ("=' 8 Á). For immepip (3) it is obvious that
the proton donating ammonium group is located at a distance of 4 methylene groups
from the imidazole ring ("=' 7.5 Á). These observations make immepip (3), together
with imetit (2) and the methylated analogues a valuable tool in Molecular Modelling
studies.
It can be concluded that immepip (3) is a new and selective histamine H3 agonist,
equipotent as (R)-a-methylhistarnine (1) and imetit (2), which can be useful as a
pharmacological tool and perhaps as a therapeutical agent, but also, because of its
distinctive structure, for SAR- and Molecular Modelling studies.
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Experimental Section
Chemistry
4-[1-(N,N-Dimethylsuifamoyl)-2-tert-butyldimethylsilyl-imidaz01-5-
ylhydroxymethyl]pyridine (7)
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10.0 g (57 mmol) 1-(N,N-Dimethylsulfamoyl)imidazole (5) was dissolved in dry THF (
200 ml) under an atmosphere of dry nitrogen and cooled to -70°C. n-Butyllithium in
hexane (36.0 ml, 58 mmol) was added dropwise (temperature should not exceed
-65°C). After 15 min, a solution of tert-butyl-dimethylsilyl chloride (9.0 g, 60 mmol)
in dry THF (20 ml) was added and the solution was stirred at room temperature for 1
h. The mixture was cooled to -70°C again and n-butyllithium in hexane (36.0 ml, 58
mmol) was added dropwise (temperature should not exceed -65°C). After 0.5 h, a
solution of 4-pyridinecarboxaldehyde (6.5 g, 61 mmol) in dry THF (15 ml) was
added gradually and the cooling bath was removed. After the reacting mixture
reached room temperature, the solution was poured into water (200 ml) and the THF
was removed under reduced pressure. The product was extracted with ether (3 x
150 ml), dried (NaZS04) and concentrated in vacuo. 17.0 g (75%) Of a yellow solid
remained.
IH NMR (CDC13) : Ö0.40 (s, 6H, SiCH3),1.00 (s, 9H, CCH3),2.82 (s, 6H, NCH3), 6.10
(s, lH, CH), 6.68 (s, lH, Im-4H), 7.37 (d, 2H, J =7Hz, Pyr-3,5-H), 8.12 (d, 2H, J = 7Hz,
Pyr-2,6-H) ppm.
4-[1-(N,N-Dimethylsuifamoyl)imidazol-5-ylmethyl]piperidine (8)
11.53 g (29 mmol) 7 Was dissolved in 150 ml of acetonitrile. 5.2 ml (35 mmol) DBU
was added and 3.6 ml acetic anhydride (38 mmol) was added after 10 min. After 15
min. stirring at ambient temperature, the reaction mixture was concentrated in
vacuo. The residue was dissolved in CHzClz and washed with HzO (three times).
The organic layer was dried on NaZS04 and concentrated removed under reduced
pressure. Yield 12.7 g (100%).
IH NMR (CDC!3) : Ö0.38 (s, 6H, SiCH3), 0.98 (s, 9H, CCH3), 2.12 (s, 3H, OCCH3),
2.80 (s, 6H, NCH3),6.98 (s, lH, CH), 7.10 (s, lH, Im-4H), 7.24 (d, 2H, J = 7Hz, Pyr-3,5-
H), 8.60 (d, 2H, J =7Hz, Pyr-2,6-H) ppm.
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7.3 g Of this product (16.7 mmol) was dissolved in 50 mI acetic acid. 0.7 g 10% Pd/C
Was added and this mixture was hydrogenated for 16 hours under hydrogen
pressure (50 atm) in an autoclave. The reaction mixture was filtrated over a short
celite column, concentrated in vacuo and washed with absolute ethanol (2 times
with 20 ml.). The hydrogenation was incomplete and repeated once more as
described above. This time the hydrogenation was complete. Yield 5.5 g (99%)
(acetate salt)
The residue was dissolved in 100 mI H20 and the pH was raised to 12 by the addi-
tion of K2C03. The basic water layer was extracted with CH2Ch (3 x 100 ml). The
organic laye!s were combined, dried on Na2S04 and concentrated in vacuo.
lH NMR (CDCI3): Ö0.95-1.28 (m, 2H, Pip-3,5-Hax), 1.59-1.81 (m, 3H, Pip-3,5-Heq +
Pip-4H), 2.50 (m, 2H, Pip-2,6-Hax), 2.60 (d, 2H, J =7Hz, CH2), 2.83 (s, 6H, NCH3),
3.02 (m, 2H, Pip-2,6-Heq), 6.78 (s, 1H, Im-4H), 7.82 (s, 1H, Im-2H) ppm.
BC NMR (CDCI3): Ö32.0,33.1,35.5,37.8,46.3,129.2,130.3,138.0 ppm.
4-(lH-Imidazol-4-ylmethyl)piperidine dihydrobromide (immepip) (3)
5.5 g (16.6 mmol) 8 Was refluxed in 30% HBr for 16 hours. The solution was
concentrated under reduced pressure and the residue was dissolved and refluxed in
absolute ethanol for one hour. This mixture was concentrated in vacuo and washed
with acetone (three times). 5.1 g (94%) White crystals were collected. Melting point
221.1-222.7 °C.
lH NMR (D20) : Ö1.48 (qd, 2H, J = 13, 3 Hz, Pip-3,5-Hax), 1.94 (dm, 2H, J = 13 Hz,
Pip-3,5-Heq), 2.00 (m, 1H, Pip-4-H), 2.72 (d, 2H, J =7 Hz, CH2), 2.98 (tm, 2H, J =13
Hz, Pip-2,6-Hax), 3.41 (dm, 2H, J =13 Hz, Pip-2,6-Heq), 7.28 (s, 1H, Im-4(5)H), 8.59
(s, 1H, Im-2H) ppm.
BC NMR (D20): Ö29.2, 31.3, 34.5, 45.3,117.8,132.4,134.5 ppm.
High resolution mass: m/z 165.1265; calcd. for C9HlSN3 : 165.1266
Anal. (C9HlSN3-2HBr) : 32.86 %C, 5.23 %H, 12.6 %N, 49.0 %Br;
calcd : 33.05 %C, 5.24 %H, 12.8 %N, 49.0 %Br.
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The histamine H3 activity of immepip (3), was detennined on an in vitro assay, based
on the inhibitory effect of histamine H3 agonists on electrically evoked twitches
(induced by endogenous acetylcholine release) of guinea pig jejunurn preparations
(see Chapter 3).15 The addition of cumulative concentrations of immepip (3), results
in a concentration-dependent inhibition of these evoked twitches, from which a
concentration-response curve can be constructed. The binding affinity of the
described compounds for the Hl receptor was determined in at least three indepen-
dent experiments, performed in triplicate, by the displacement of [3H]mepyrarnine,
bound to membranes of CHO cells expressing guinea pig Hl receptors.122 The
binding affinity of the described compounds for the H2 receptor was established in
at least three independent experiments, performed in triplicate, by the displacement
of [l25I]iodoarninopotentidine, bound to membranes of CHO cells expressing human
H2 receptors.123
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Abstract
The influence of alkyl chain length variation on the histamine H3receptor activity of
histamine homologues I was investigated. A series of 4(5)-(ro-aminoalkyl)-lH-imida-
zoles I was prepared with an alkyl chain length varying from one methylene group
to 10 methylene groups. Besides the H3 activity, the affinities of these compounds
for the Hl and Hz receptors were determined. The ethylene chain of histamine is
optima1 for agonistic activity on all three histamine receptor subtypes. For the H3
receptor, elongation of the alkyl chain from three methylene groups on leads to
compounds with antagonistic properties. 4(5)-(5-Aminopentyl)-lH-imidazole
(impentamine, Ie) is the most potent and selective H3 antagonist from this series of
4(5)-(ro-aminoalkyl)-lH-imidazoles 1, with a pAz va1ue of 8,4 (on guinea pig
jejunum). A.specific antagonistic binding site for this compound is proposed.
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Introduetion
The histamine H3 receptor has been described to play a role as a general regulatory
receptor system, regulating not only the release and synthesis of histamine, but also
the release of other neurotransmitters." Therefore, this receptor can be regarded as a
potential target for new therapeutics.l7,26,41 To characterize its role in physiology
however, there is still a need for selective, preferably nontoxic ligands. The most
potent H3 ligands described so far are the H3 agonist imetit (3a) and the H3 antago-
nist clobenpropit (3e), both containing an isothiourea group. We directed part of our
research to the development of non-isothiourea-containing selective histamine H3
receptor ligands using the natural agonist histamine (lb) as a 'lead'.
Areasonabie number of analogues of histamine and their effect on the histamine H3
receptor, have been described in literature. Most successful alterations of the struc-
ture of histamine have been performed by functionalization of the ethylene chain,
resulting in, for instance, the potent and selective H3 agonist (Rj-u-methylhistamine
(2a).6 Alkylations of the amino group of histamine are tolerated when small alkyl
groups are used. NfL-Methylhistamine (2b) and NfL,NfL-dimethylhistamine (2e) are
slightly more active than histamine (lb).5 Replacement of the amino group with
other polar cationic groups resulted in the potent and selective H3 agonist imetit
(3a).37-40 Replacement of the imidazole ring of histamine and its analogues by other
heterocycles or structural imidazole mimics resulted in less active (e.g., betahistine
acts as a weak H3 antagonist), but more frequently in inactive compounds.26,41
Substituents on the imidazole ring of histamine (lb) are also not allowed (e.g., N-
methyl-, 2-methyl- and 4(5)-methylhistamine are inactive).5
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p=«CH2)n- NH2
HN~N
1 n =1-10
,r=("yNR2R3
HN .....: N Ä1 28 R1=Me; R2=R3=H
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Figure 1. Discussed structures.
Recently, we reported a new potent and selective agonist for the H3 receptor, which
is not an ethylene chain analogue of histamine (lb) (see Chapter 6).42 This
compound, immepip (4), has an aminobutylene chain, incorporated in a piperidine
ring; yet in activity (pD2 = 8.0 on guinea pig jejunum), it is comparable to (R)-a-
methylhistamine (2a) (PD2 value of 7.8 on the same test system).15 If we compare
the structures of histamine (Ib) and immepip (4), it is clear that the amino groups in
both structures are separated by alkyl spacers different in length. The amino group
of histamine (lb) is located at a distance of two methylene groups (~.5 Á) from the
imidazole ring, compared to a distance offour methylene groups (",,7.5 Á) in immepip
(4). Since immepip (4) is more potent than histamine (lb) on this receptor, we
wanted to investigate the H3 effect of chain length variation of the alkyl spaeer in a
series of histamine homologues.
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In literature, not much is known about the histamine H3 activity of 4(5)-(00-
aminoalkyl)-lH-imidazoles 1. It has been reported that a histamine homologue with a
chain length of only one methylene group (la) is inactive on the H3 receptor
(guinea pig ileum).41 Elongation of the alkyl chain to three methylene groups (Ie)
also has been described by LippZ6 to result in a compound with no H3 agonistic
properties (rat cortex) and by Leurs41 to result in a compound with weak H3 anta-
gonistic properties (pAz value of 6.0 on rat cortex).
In order to investigate the effect of the chain length of the alkyl spaeer of histamine
homologues 1 on the histamine H3 receptor activity, we have prepared a series of
4(5)-(oo-aminoalkyl)-lH-imidazoles 1 with an alkyl chain length varying from one
methylene group to 10 methylene groups. We determined the H3 activity of these
compounds functionally on an in vitro test system using guinea pig jejunum prepa-
rations. In order to establish the selectivity of these compounds for the H3 receptor,
we determined the affinities of the 4(5)-(ro-aminoalkyl)-lH-imidazoles Ion the Hl-
and the Hz receptor as well.
Chemistry
The 4(5)-(ro-aminoalkyl)-lH-imidazoles Ic-h were prepared by a method described
earlier by our group (Scheme 1) (see also Chapter 5).121 This method is based on the
direct coupling of an alkyl chain to the imidazole ring, by lithiation of a suitable 1,2-
diprotected imidazole 7 and subsequent treatment with L-chloro-ro-iodoalkanes. The
m-chloro group of the resulting products Sc-h can be converted into an amino
group via the Gabriel synthesis.119 The protecting group on the 2-position of the
imidazole ring (the tert-butyldimethylsilyl group) hydrolyses under the basic condi-
tions of the Gabriel synthesis. The free amino group can be obtained, either by
hydrolysis of the phthalimide group under acidic conditions resulting directly in
compounds Ic-h or by reaction with hydrazine .resulting in compounds 10c-h. The
advantage of hydrolysis of the phthalimide group under acidic conditions is that the
N-protecting group on the imidazole ring can be removed in the same step. If
however the protecting group is required in further reactions (like addition reactions
on the amino group), hydrazine should be used, because the protecting group is
unaffected under these conditions.
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Ilo N.:::vNS02NMe2
6
d,e
Ilo
h
(CH2)n-NH2Á
N.:::vNS02NMe2
10c-h
t=«CH2)n- NH2
HN~N
1c-h
Scheme I. Reagents used: (a) N,N-Dimethylsulfamoyl chloride, Et3N, toluene; (b) n-
BuLi, THF, -70°C; (c) tert-butyldimethylsilyl chloride; (d) n-BuLi, THF,
-70°C; (e) l-chloro-m-iodoalkane; (f) potassium phthalimide, DMF,
+70°C; (g) 30% HBr, reflux; (h) H2NNH2·H20,EtOH.
After conversion of the chloro group into an amino group and removal of the
protecting groups, the desired histamine analogues Ic-h were obtained. Using this
method we have prepared histamine analogues with an alkyl chain of up to 10
methylene groups. Some of the compounds were isolated as salts of oxalic acid
because of better stability and isolation. We observed no problems using oxalates in
our in vitro test system.
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Pharmacology
The H3 activity of the compounds was determined on an in vitro test system, on the
basis of the concentration-dependent inhibitory effect of histamine H3 agonists on
the electrically evoked contractile response of isolated guinea pig jejunum segments
(see Chapter 3).15
The binding affinity for the Hl receptor was determined by the displacement of
[3H]mepyramine, bound to membranes of CHü cells expressing guinea pig Hl recep-
tors.122
The binding affinity for the H2 receptor was established by the displacement of
[l25I]iodoaminopotentidine, bound to membranes of CHü cells expressing human H2
receptors. 123
Results and Discussion
All the compounds have been tested for H3 agonism and H3 antagonism on guinea
pig jejunum. From the results shown in Table 1 (see also Figure 2), it is clear that
variation of the alkyl chain length in 4(5)-(ro-aminoalkyl)-IH-imidazoles 1 has a
drastic effect on the activity of these compounds on the histamine H3 receptor. The
histamine homologue with an alkyl chain shortened to one methylene group, YUF
8319 (la), is inactive on this receptor. The ethylene chain of histamine (lb) is clearly
optimal for activation of the H3 receptor in the series of 4(5)-(ro-aminoalkyl)-IH-
imidazoles 1, since it is the only compound in this series with H3 agonistic activity.
Elongation of the alkyl chain results in compounds with a surprisingly high anta-
gonistic activity on the histamine H3 receptor (no agonistic activity was observed
on the used test system). 4(5)-(3-Aminopropyl)-IH-imidazole (VUF 8326, 1e), for
example, possesses moderate antagonistic activity, but the pentyl homologue of
histamine, 4(5)-(5-aminopentyl)-IH-imidazole (impentamine or YUF 4702, 1e), is a
potent H3 antagonist with a pA2 value of 8.4 on the described in vitro test system.
A further increase in the chain length to eight methylene groups, results in a
decrease of antagonistic activity to a pA2 value of 6.0, which does not change on
further lengthening (up to 10 methylene groups).
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Table 1. H3 antagonistic activity of the Histamine homologues 1 as tested on the
in vitro test system on the guinea pig jejunum.
Compound Name or Code a n b pA2H3c Slope d Ne
la VUF8319 1 <3 4
lb histamine 2 pD2 =6.2 ± 0.3 4
Ie VUF8326 3 5.9 ± 0.3 0.9 ± 0.3 4
ld VUF4701 4 7.7 ± 0.2 0.8 ± 0.1 4
le VUF4702 5 8.4 ± 0.2 1.1 ±0.1 7
1f VUF4732 6 7.8 ± 0.2 1.2 ± 0.1 7
19 VUF4733 8 6.0 ± 0.2 1.2 ± 0.1 6
tb VUF4734 10 6.0 ± 0.3 0.9 ± 0.2 7
a Compound code number.
b Alkyl chain length of 1 (number of methylene units).
C Antagonistic parameter as determined on the described in vitro H3 assay repre-
senting the negative logarithm of the abscissal intercept from the Schild plot ±
SD.
d Slope of Schild plot ± SD, not significantlydifferent from unity.
e Number of different animal preparations.
From these results it is clear that in a series of 4(5)-(ro-aminoalkyl)-lH-imidazoles 1
the ethylene chain is essential for activation of the histamine H3 receptor. The opti-
mal chain length (through bonds) for antagonistic activity in this series seems to be
five methylene groups (between the primary amino group and the imidazole ring).
These results indicate that both the imidazole ring and the amino group play an
important role in the activation mechanism of the H3 receptor. It seems likely that
there are specific binding sites for the imidazole ring and the protonated amine (at
physiological pH) in the receptor. As soon as histamine binds to these sites, the
receptor is activated. Apparently the higher alkyl analogues can not fulfil these
requirements for activation (probably for steric reasons).
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Fjgure 2. The influence of the alkyl chain length (n) of the histamine homologues
1 on the affinity on the Hl- and the Hz receptor and the antagonistic
activity on the H3 receptor.
The observation that the histamine homologue with an alkyl chain comprising five
methylene groups (impentamine, Ie) has a much higher affinity than for instanee the
propyl homologue (YUF 8326, te) or the octyl homologue (YUF 4733, 19) seems to
indicate an additional binding site, for specific antagonists, in the H3 receptor.
Occupation of this additional binding site by either the ammonium group (at physio-
logical pH) or the imidazole ring of impentamine (Ie) increases the affinity, but the
receptor is not activated; in figure 3 this speculation is represented in a graphical
manner. In this respect it is interesting to note that similar observations can be made
in the series of analogues of imetit (3a), described by Van der Goot.37 Imetit (3a), is a
potent agonist for the H3 receptor (pDz value of 8.1 on guinea pig ileum), but when
the ethylene chain between the imidazole ring and the isothiourea group is elon-
gated to a propylene chain, a potent H3 antagonist, YUF 8328 (3b), is obtained (pAz
value of 8.0 on guinea pig ileum). The distance (through bonds) between the imida-
zole ring and the protonated nitrogen is comparable for both the elongated imetit
analogue YUF 8328 (3b) and impentamine (Ie). This observation supports the idea
of an extra binding site for antagonists to which either a protonated cationic nitro-
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gen or the imidazole ring can bind, thereby enhancing the affinity, but not activating
the H3 receptor.
I activation H a no activation H b no activation
Figure 3. Simplistic graphical representation of a possible additional binding site
for antagonists in the H3 receptor, which can be occupied by either the
protonated cationic nitrogen (triangle) or the imidazole ring (circle) of
impentamine (Ie) and VUF 8328 (3b). I : An H3 agonist activates the
receptor by binding to the 'active site'. 11 : An H3 antagonist (like
impentamine (Ie) or YUF 8328 (3b» binds with the protonated cationic
nitrogen (Ha) or the imidazole ring (Ilb) to an additional specific anta-
gonistic binding site. No activation occurs.
Since introduetion of substituents (aralkyl groups) on the isothiourea group of YUF
8328 (3b) resulted in even more potent antagonists, like clobenpropit (3e) (pAz
value of 9.9 on guinea pig ileum), we are currently investigating the effect of intro-
duetion of these types of substituents on the amino group of the described 4(5)-(00-
aminoalkyl)-IH-imidazoles 1, on their Hj activity.
A rather striking observation can be made when comparing the butyl homologue of
histamine YUF 4701 (ld) and immepip (4), which can be considered as its rigid ana-
logue. YUF .4701 (ld) is a rather potent antagonist, whereas immepip (4) is a potent
and selective agonist on the H3 receptor. The difference in activity may be due to
specific steric and/or confonnational effects.
Chain length variation in a series of 4(5)-(ro-aminoalkyl)-IH-imidazoles 1 has a large
effect on the affinity of these compounds for the Hl- and the Hz receptor as weIl. It
has been reported already more than 60 years ago115 that there is a marked decrease
in the effect of the propylene- (Ie) and butylene (ld) homologues of histamine on
the Hl activity. For the Hz receptor, both shortening to the methylene chain (la) and
elongation to the propylene chain (Ie) have been reported to result in histamine
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analogues with an agonistic activity less than 0.5% of the activity of histamine
(lb).129 This is in agreement with the affinities for the Hl and H2 receptors of the
4(5)-(ro-aminoalkyl)-IH-imidazoles 1 that we have determined.
Table 2. Binding affinity of the Histamine analogues 1 on the HI- and the H2
receptor.
Compound Name or Code a n b pKiHI C pKi H2 d
la VUF8319 1 <3 <3
lb histamine 2 4.9 4.4
le VUF8326 3 <3 <3
ld VUF4701 4 3.4 ±0.1 3.1:f0.l
le VUF4702 5 3.9 ±0.1 3.6 ± 0.1
lf VUF4732 6 3.9 ± 0.1 3.7 ± 0.1
19 VUF4733 8 5.6 ±0.1 4.5 ±0.1
tb VUF4734 10 6.2 ±0.1 4.7 ± 0.1
a Compound code number.
b Alkyl chain length of 1 (number of methylene units).
C Negative logarithm value of the binding affinity for the histamine Hl receptor ±
SEM.
d Negative logarithm value of the binding affinity for the histamine H2 receptor ±
SEM.
From Table 2 and Figure 2 it can be seen that variation in the length of the alkyl
spaeer of histamine results in compounds with a low affinity for the HI- and the H2
receptor, although the affinity increases with increasing chain length. The histamine
homologue with a decyl chain (lh) has areasonabIe affinity for the Hl receptor (pKi
= 6.2), whieh was confirmed to be a weak antagonist by a conventional in vitro
assay on the guinea pig ileum (not shown).
We conclude that the ethylene chain is the optimal spaeer in 4(5)-(ro-aminoalkyl)-
lH-imidazoles 1 for agonistic activity on all three known histamine receptor sub-
types. For the histamine Hl and H2 receptors, variation of the alkyl chain length only
results in compounds with a low affinity, although the affinity increases with
increasing chain length. The histamine analogue with a decyl chain (lh) is even a
moderate Hl antagonist, which is rather surprising for an imidazole-based structure.
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For the H3 receptor, the effect of chain elongation of histamine is most pronounced,
resulting e.g., in the potent and selective H3 antagonist 4(5)-(5-aminopentyl)-lH-
imidazole (impentamine, te). This high activity suggests an additional specific
antagonistic binding site in the H3 receptor to which either the ammonium group or
the imidazole ring can bind, leading to enhanced affinity but not to activation.
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Experimental Section
Chemistry
1H NMR and 13C NMR spectra were recorded on a Broker AC-200 (200 MHz)
spectrometer with tetramethylsilane or sodium 3-(trimethylsilyl)propionate as an
internal standard. Mass spectra were recorded on a Finnigan MAT-90. Melting
points were measured on a Mettler FP-5 + FP-52 instrument and are uncorrected.
THF was distilled from LiAII4, DMF was dried by passage through a column packed
with Ah03, and acetone was distilled from K2C03. n-Butyllithium was purchased
from Janssen Chimica as a 15% solution in hexane.
The l-chloro-m-iodoalkanes were prepared by refluxing the corresponding 1,00-
dichloroalkanes with 1 equiv of sodium iodide in acetone and purification of the
product by distillation.120
1-(N,N-Dimethylsulfamoyl)imidazole 6 was synthesized by the method described by
Chadwick and Ngochindo.ï" with the exception that toluene was used as a solvent
instead of benzene.
4(5)-(l-Aminomethyl)-IH-imidazole (la) was prepared according to literature proce-
dure.130 Histamine dihydrochloride (lb) was purchased from Janssen Chimica. 4(5)-
(3-Aminopropyl)-IH-imidazole dihydrobromide (Ie), 4(5)-(4-aminobutyl)-IH-imida-
zole dihydrobromide (ld), and 4(5)-(5-aminopentyl)-IH-imidazole dihydrobromide
(Ie) were prepared as described earlier by our group (see Chapter 3).121
2-(tert-Butyldimethylsilyl)-5-(6-chlorohexyl)-l-(N,N-dimethylsulfamoyl)imidazole
(8f)
1-(N,N-Dimethylsulfamoyl)imidazole (6) (26.0 g, 0.15 mol) was dissolved in dry THF
(500 ml) under an atrnosphere of dry nitrogen and cooled to -70°C. n-Butyllithium
in hexane (100 mI, 0.16 mol) was added dropwise (internal temperature did not
exceed -65°C). After 15 min, a solution of tert-butyldimethylsilyl chloride (25.0 g,
0.17 mol) in dry THF (50 ml) was added (internal temperature did not exceed -65°C)
andthe solution was allowed to warm to room temperature and stirred for an addi-
tional hour. The mixture was cooled to -70°C again, and n-butyllithium in hexane
(100 mI, 0.16 mol) was added dropwise (intemal temperature did not exceed -65°C).
After 0.5 h,.a solution of l-chloro-6-iodohexane (44.3 g, 0.17 mol) in dry THF (50
ml) was added gradually and the mixture was allowed to (slowly) warm to room
temperature overnight. The reaction mixture was poured into water (200 ml), and
the THF was removed under reduced pressure. The product was extracted with
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CHCl3 (3 x 150 ml), dried (Na2S04) and concentrated in vacuo. 73.2 g Of a viscous
orange coloured oil was obtained which was used without further purification. IH
NMR Analysis of the oil showed complete coupling of the 6-chlorohexyl chain to
the 1,2-diprotected irnidazole 7.
IH NMR (CDCI3): Ö0.39 (s, 6H, Si(Clh)z), 1.01 (s, 9H, c(Cfuh), 1.38 (m, 4H, central
CHz's), 1.80 (m, 4H, 2*Cfu), 2.71 (t, 2H, J = 8 Hz, irnidazole-5-Cfu), 2.88 (s, 6H,
N(CH3)z), 3.55 (t, 2H, J = 7 Hz, CfuCI), 6.93 (s, 1H, irnidazole-4H) ppm.
2-(tert-Butyldimethylsilyl)-5-(8-chlorooctyl)-l-(N ,N-dimethylsulfamoyl)imidazole
(8g)
The same procedure as for the preparation of Sf was employed, using 9.64 g (55
mmol) 1-(N,N-dimethylsulfamoyl)imidazole (6) in 100 ml dry THF, 37.5 ml (60 mmol)
n-butyllithium solution, 9.0 g (60 mmol) tert-butyldimethylsilyl chloride and 18.0 g
(65 mmol) 1-chloro-8-iodooctane. 32.6 g Of a viscous orange oil was obtained
which was used without further purification. IH NMR Analysis of the oil showed
complete coupling of the 8-chlorooctyl chain to the 1,2-diprotected irnidazole 7.
IH NMR (CDC13): Ö0.39 (s, 6H, Si(CH3)z), 1.01 (s, 9H, C(CH3h), 1.37 (m, 8H, central
CH2'S), 1.37 (m, 4H, 2*CH2), 2.71 (t, 2H, J =8 Hz, imidazole-5-Cfu), 2.85 (s, 6H,
N(CH3)z), 3.55 (t, 2H, J =7 Hz, CfuCI), 6.95 (s, 1H, imidazole-4H) ppm.
2-(tert-Butyldimethylsilyl)-5-(1 O-chlorodecyl)-l-(N,N-dimethylsulfamoyl)imidazole
(8h)
The same procedure as for the preparation of Sf was employed, using 4.9 g (28
mmol) l-(N,N-dimethylsulfamoyl)irnidazole (6) in 100 ml dry THF, 20.0 ml (32 mmol)
n-butyllithium solution, 4.7 g (31 mmol) tert-butyldimethylsHyl chloride and 9.2 g
(31 mmol) l-chloro-Iû-iododecane. 18.3 g Of a viscous orange oil was obtained
which was used without further purification. IH NMR Analysis of the oil showed
complete coupling of the 10-chlorodecyl chain to the 1,2-diprotected irnidazole 7.
IH NMR (CDCI3): Ö0.38 (s, 6H, Si(Cfuh), 1.00 (s, 9H, C(Cfu)3), 1.32 (m, 12H,
central Cfu's), 1.80 (m, 4H, 2*Cfu), 2.73 (t, 2H, J =8 Hz, irnidazole-5-Cfu), 2.85 (s,
6H, N(Cfuh), 3.53 (t, 2H, J = 7 Hz, CfuCI), 6.94 (s, 1H, imidazole-4H) ppm.
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i-(N,N-Dimethylsulfamoyl)-5-(6-phthalimidohexyl)imidazole (9f)
The crude product 8f (73.2 g) was dissolved together with potassium phthalimide
(40.3 g, 0.2 mol) in DMF (900 ml) and the mixture was heated at 70°C. After 7 h the
mixture was filtered and the solvent was evaporated under reduced pressure. The
residue (86.8 g) was stirred in iso-propanol (400 ml) and the precipitate (beige
powder) was removed by filtration (1,6-diphthalimidohexane). The filtrate was
concentrated in vacuo and the residue was dissolved in CHCl3 (150 ml), washed
with H20 (3 x 150 ml), dried (Na2S04) and concentrated in vacuo. A dark brown oil
remained (47.6 g), which was pure enough for further use. A portion of this oil was
purified by flash chromatography with ethyl acetate as eluent (Rf= 0.4). The IH
NMR spectrum of the purified oil indicated complete removal of the protective
group on the 2-position.
IH NMR (CDCI3): Ö1.42 (m, 4H, central Cfu's), 1.69 (m, 4H, 2*Cfu), 2.72 (t, 2H, J =
8 Hz, imidazole-5-Cfu), 2.90 (s, 6H, N(Cfuh), 3.70 (t, 2H, J = 7 Hz, Cfu-phthalim-
ide), 6.82 (s, 1H, imidazole-4H), 7.72 (m, 5H, phthalimide-H + imidazole-2H)ppm.
i-(N,N-Dimethylsulfamoyl)-5-(8-phthalimidooctyl)imidazole (9g)
The same procedure as for the preparation of 9f was employed, using the crude
product 8g (32.6 g) in 150 ml DMF and 13.6 g (73 mmol) potassium phthalimide.
After work up, a dark brown oil remained (23.8 g), which was pure enough for
further use. A portion of this oil was purified by flash chromatography with ethyl
acetate as eluent (Rf = 0.4). The IH NMR spectrum of the purified oil indicated
complete removal of the protective group on the 2-position.
IH NMR (CDCh): Ö1.35 (m, 8H, centra!Cfu's), 1.66 (m, 4H, 2*Cfu), 2.71 (t, 2H, J =
8 Hz, imidazole-5-Cfu), 2.88 (s, 6H, N(CH3h), 3.68 (t, 2H, J = 7 Hz, Cfu-phthalim-
ide), 6.82 (s, 1H, imidazole-4H), 7.75 (m, 5H, phthalimide-H + imidazole-2H)ppm.
i-(N,N-Dimethylsulfamoyl)-5-(lO-phthalimidodecyl)imidazole (9h)
The same procedure as for the preparation of 9f was employed, using the crude
product 8h (18.3 g) in 150 ml DMF and 9.3 g (50 mmol) potassium phthalimide.
After work up a dark brown oil remained (11.2 g), which was pure enough for
further use. A portion of this oil was purified by flash chromatography with ethyl
acetate as eluent (Rf= 0.4). The IH NMR spectrum of the purified oil indicated
complete removal of the protective group on the 2-position.
Chapter 7 111
IH NMR (CDCl3): Ö1.31 (m, 12H, centra! C.lh's), 1.68 (m, 4H, 2*CHz), 2.71 (t, 2H, J =
8 Hz, imidazole-5-Cfu), 2.88 (s, 6H, N(Cfuh), 3.68 (t, 2H, J =7 Hz, Cfu-phthalim-
ide), 6.83 (s, IH, imidazole-4H), 7.78 (m, 5H, phthalimide-H + imidazole-2H) ppm.
i-eN,N-Dimethylsuljamoyl)-5-(6-aminohexyl)imidazole (lOf)
0.7 g (1.7 nimol) Of 9f was dissolved in 40 mlo wann ethanol. 0.3 mlo (6.2 mmol)
hydrazine monohydrate was added and this solution was heated under reflux for 4
hours. After cooling of the solution to room temperature, a white precipitate formed
and was removed by filtration. The filtrate was concentrated in vacua and 0.4 g
(84%) of a light oil was isolated.
IH NMR (CDCh): Ö1.33 (m, 6H, central CHz's+ NHz), 1.60 (m, 4H, 2*CHz), 2.64 (m,
4H, imidazole-5-Cfu + CHzNHz), 2.83 (s, 6H, N(CH3h), 6.75 (s, IH, imidazole-4H),
7.78 (s, IH, imidazole-2H) ppm.
i-(N,N-Dimethylsuljamoyl)-5-(8-aminooctyl)imidazole (lOg)
7.6 g ( 17.6 mmol) Of 9g was dissolved in 100 mlo warm ethanol. 2.5 mlo (51 mmol)
hydrazine monohydrate was added and this solution was heated under reflux for I
h. A white precipitate formed and was removed by filtration. The filtrate was
concentrated in vacuo and 5.2 g (98 %) of a light oil was isolated.
IH NMR (CDCI3): Ö 1.32 (m, lOH, central CHz's + NHz), 1.62 (m, 4H, 2*CHz), 2.68
(m, 4H, imidazole-5-Cfu + CHzNHz), 2.87 (s, 6H, N(Cfuh), 6.72 (s, IH, imidazole-
4H), 7.84 (s, IH, imidazole-2H) ppm.
i-eN,N-Dimethylsulfamoyl)-5-(lO-aminodecyl)imidazole (lOh)
The same procedure as for the preparation of lOg was employed, using 2.0 g (4.4
mmol) of 911 in 50 ml ethanol and 0.6 ml (14 mmol) hydrazine monohydrate. 1.2 g (
84%) Of a light oil was isolated.
IH NMR (CDCI3): Ö1.32 (m, 14H, central CHz's+ NHz), 1.62 (m, 4H, 2*CHz, 2.66 (m,
4H, imidazole-5-Cfu + CHzNHz), 2.87 (s, 6H, N(Cfuh), 6.72 (s, IH, imidazole-4H),
7.84 (s, IH, imidazole-2H) ppm.
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4(5)-(6-Aminohexyl)-lH-imidazole dioxalate (If)
44.9 g Of 9f.was dissolved in 30 % HBr (500 ml) and heated under reflux. After 16 h
the mixture was cooled, filtered and concentrated in vacuo. The residue was
dissolved in absolute ethanol (300 ml), heated under reflux for 0.5 hand concen-
trated under reduced pressure. The remaining dark oil was washed (under stirring)
with 100 ml portions of acetone (removal of the formed ethyl N,N-dimethylsul-
famoate group). After several washings, the oil crystallized. After filtration of the
brown solid, 17.6 g (66% overall) of the product was obtained.
Thedihydrobromide was converted into the dioxalate, using the following proce-
dure: the dihydrobromide was dissolved in absolute EtOH and 2 equiv of sodium
ethanolate was added. This was refluxed for 0.5 hand after filtration of sodium
bromide the filtrate was concentrated in vacuo. The residue was dissolved in iso-
propanol, filtrated (removal of some remaining sodium bromide) and a saturable
solution of oxalic acid in iso-propanol was added dropwise until a white precipitate
was formed. The precipitate was collected by centrifugation and the pellet was
washed three times with iso-propanol, dried and recrystallized from hot iso-
propanol.
A white powder was collected. M.p. 132.0 °C.
lH NMR (D20): Ö1.33 (m, 4H, central Cfu's), 1.61 (m, 4H, 2*C,fu), 2.68 (t, 2H, J=7
Hz, imidazole-4(5)-C.H2), 2.93 (t, 2H, J=7 Hz, C.H2NH), 7.14 (s, lH, imidazole-5(4)H),
8.50 (s, lH, imidazole-2H) ppm.
13C NMR (D20) : Ö25.0,26.7,28.0,28.9,40.9, 116.5, 134.0, l35.4, 166.7.
MS (EI) : rnJz 167 (M+, 2%), 151 (M+-NH2, 6%), 137 ([ImCSHlO]+, 4%), 123
([ImC4Hs]+, 3%),109 ([ImC3lI(;]+, 5%), 95 ([ImC214]+,39%), 82 ([ImCH3+,31%),81
([ImCH2]+, 15%),45 ([C2H7N]+, 100%).
High resolution mass: mlz 167.1426; calcd. for C9H17N3: 167.1422.
4(5)-(8-Aminooctyl)-lH-imidazole dioxalate (lg)
The same procedure as for the synthesis of lfwas used with the exception that 2.3 g
of 9g was heated under reflux in 30% HBr (30 ml). After several washings with
acetone, 1.14 g (67% overall) of a brown solid was collected. The dihydrobromide
was converted into a dioxalate. A white powder was obtained. M.p. (95.0-97.0) °C.
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lH NMR (D20 ) : Ö1.38 (m, 8H, central Clli's), 1.60 (m, 4H, 2*Clli), 2.66 (t, 2H, J=7
Hz, imidazole-4(5)-Cfu), 2.93 (t, 2H, J=7 Hz, CfuNH), 7.13 (s, lH, imidazole-5(4)H),
8.49 (s, lH, imidazole-2H) ppm.
13C NMR (D20) : Ö 25.1, 27.0, 28.1, 29.0, 29.3, 29.49, 29.51, 41.0, 116.4, 133.8,
135.7,165.6.
MS (EI): mlz 195 (M+, 0.6%),179 (M+-NHz, 1%), 165 ([ImC7H14]+, 1%), 151
([ImCóH12]+, 1%),137 ([ImCsHlQ]+, 2%),123 ([ImC4Hs]+, 1%),109 ([ImC3Hó]+, 2%),
95 ([ImCzf4]+, 8%), 82 ([ImCH3+, 9%), 81 ([lmCH2]+, 5%),45 ([CZH7N]+, 100%).
High resolution mass: mlz 195.1732; calcd. for CllHzlN3: 195.1736.
Anal. (CllHzlN302.15C2Hz04) : 47.13 %C, 6.87 %H, 10.9 %N;
calcd. : 47.26 %C, 6.56 %H, 10.8 %N.
4(5)-(1 O-Aminodecyl)-lH-imidazole dioxalate (lh)
The same procedure as for the synthesis of 1f was used with the exception that 2.2 g
of 9h was heated under reflux in 30% HBr (30 mI). After several washings with
acetone, 0.6 g (27% overall) of a brown solid was collected. The dihydrobromide
was converted into a dioxalate. A white powder was obtained. M.p. (154.5-155.0)
°C.
lH NMR (DzO ) : Ö1.27 (m, 12H, central Clh's), 1.62 (m, 4H, 2*Cl12), 2.67 (t, 2H, J=7
Hz, imidazole-4(5)-Cfu), 2.94 (t, 2H, J=7 Hz, CfuNH), 7.14 (s, lH, imidazole-5(4)H),
8.50 (s, lH, imidazole-2H) ppm.
l3C NMR (D20) : Ö25.1,27.0,28.2,29.1,29.4,29.6,29.7,29.88,29.93,41.0, 116.4,
133.8, 135.7, 167.3.
MS (EI) : mlz 223 (M+, 3%), 207 (M+-NHz, 4%), 193 ([ImC9HlS]+, 5%), 179
([ImCSH16]+, 6%), 165 ([ImC7H14]+, 5%),151 ([lmC6H12]+, 6%), 137 ([ImCsHlQ]+,
6%),123 ([ImC4Hs]+,3%),109 ([ImC3Hó]+, 6%), 95 ([lmCz14]+, 27%),82 ([lmCH3+,
26%),81 ([lmCHz]+, 13%),45 ([CZH7N]+, 100%).
High resolution mass: mlz 223.2049; calcd. for C13H25N3 : 223.2048.
Anal. (C13HzsN301.7CzHz04)
calcd.
: 52.15 %C, 7.62 %H, 11.3 %N;
: 52.33 %C, 7.60 %H, 11.2 %N.
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Pharmacology
The histamine H3 activity of the histamine homologues (1), was determined on an in
vitro assay, on the basis of the inhibitory effect of histamine H3 agonists on electri-
cally evoked twitches (induced by endogenous acetylcholine release) of guinea pig
jejunum preparations (see Chapter 3).15 The addition of cumulative concentrations
of an H3 agonist, results in a concentration-dependent inhibition of these evoked
twitches, from which a concentration-response curve can be constructed. All
histamine homologues (1) were tested for H3 agonism and antagonism. H3 antago-
nism was determined against (R)-a.-methylhistamine. The potency of the antagonists
was expressed by its pA2 value, calculated from the Schild regression analysis, and
at least three different concentrations were used. Statistical analysis was carried out
with the Students' r-test and p < 0.05 was considered statistically significant. Each
compound was tested on tissue preparations of at least four different animals in trip-
licate.
The binding affinity of the described compounds for the Hl receptor was determined
in at least three independent experiments, performed in triplicate, by the displace-
ment of [3H]mepyramine, bound to membranes of CHü cells expressing guinea pig
Hl receptors.122
The binding affinity of the described compounds for the H2 receptor was established
in at least three independent experiments, performed in triplicate, by the displace-
ment of [l25I]iodoaminopotentidine, bound to membranes of CHü cells expressing
human H2 receptors.123
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Abstract
Burimamide was one of the first compounds reported to antagonize the activation of
the histamine H3 receptor by histamine. We have prepared a large series of buri-
mamide analogues by variation of the alkyl spaeer length of burimamide from two
methylene groups to six methylene groups and also by replacement of the N-methyl
group with other alkyl and aryl groups. All analogues are reversible competitive H3
antagonists as determined on the guinea pig intestine. Elongation of the alkyl chain
from an ethylene chain to a hexylene chain, results in an increase of the H3 antago-
nistic activity. The H3 selective pentylene and the hexylene analogues of buri-
mamide are about ten times more potent than burimamide. The N-thiourea
substituents however, have no beneficial influence on the affinity.
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Introduetion
The existence of a third histamine receptor subtype, inhibiting the synthesis and
release of histamine, located presynaptically in histaminergic nerve endings in rat
cerebral cortex, was suggested in 1983 by Arrang et al.5 Confinnation of the exis-
tence of this new histamine receptor subtype was provided by the development of
the H3 selective agonist (R)-a-methylhistamine and the H3 selective antagonist thio-
peramide.P The H3 receptor has since been shown to play an important regulatory
role in the release of other neurotransmitters in the central nervous system7-10 and in
the periphery.ll-16
Histamine; 1.2
Thioperamide
Burimamide; 3.4a
H
H H N\\H3C~s~NyN~N
HN~N NH
Impromidine
Imetit ; n=2, R=H
VUF 8621 ; n=2, R=me
VUF 8328 ; n=3, R=H
Clobenpropit; n=3, R=4-chlorobenzyl
Figure 1. Discussed structures.
Na-Methylhistamine
p(yNH2
HN~N ëH3
(R)-a-Methylhistamine
Immepip
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A few years before the identification of the H3 receptor, the antagonistic effect of
the Hz antagonist burimamide on the inhibitory action of histamine on electrically
evoked contractions of guinea pig intestine preparations was described.Î" This
inhibitory effect of histamine was reversible and not mediated by adrenergic- nor Hl
receptors.P The histamine Hz antagonist burimamide was able to block this
inhibitory effect of histamine, but the insensitivity of the evoked contractions to Hz
agonists made it doubtful that this effect was mediated by the Hz receptor. Further
evidence for the distinct difference between the "classicai" Hz receptors in the
heart and these histamine-stimulated, contraction-inhibiting receptors on the guinea
pig ileum was given by Fjalland et al.75 The antagonistic effect of burimamide on the
inhibitory guinea pig ileum receptor was described to be about 25 times higher than
that of another Hz antagonist, cimetidine, whereas on the Hz receptor in the heart,
cimetidine was described to be at least 10 times more potent as an Hz antagonist
than burimamide.
After the discovery of the histamine H3 receptor and the description of theantago-
nistic effectof burimamide on this receptor, the inhibitory histamine receptor on the
guinea pig intestine was suggested to be of the H3 subtype as weU.76 Burimamide
was therefore one of the first compounds discovered, to antagonize the H3 receptor
and played a major role in its elucidation. The compounds' lack of selectivity
however, makes it less attractive as a pharmacological tooI for this receptor.
The first potent and selective antagonist for the histamine H3 receptor was thio-
peramide, as derived from a series of rigid analogues of histamine.î This compound
possesses several distinct structural features, which are also present in the structure
of burimamide; an N-alkyl substituted thiourea group and an alkyl spaeer on the
4(5)-position of an imidazole ring. The cyclohexyl group in the structure of thio-
peramide has been reported to be optimal for a high affinity on the H3 receptor.48
Thioperamide can be seen as a rigid analogue of burimamide, but is more potent and
selective as an H3 antagonist. Two important differences in the structure of buri-
mamide and thioperamide are the length of the alkyl spaeer between the imidazole
and the thiourea group (a butylene chain in the structure of burimamide and a
propylene chain in the structure of thioperamide), and the N-alkyl substituent on the
thiourea group (a methyl group for burimamide and a cyclohexyl group for thio-
peramide).
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This raises the question if burimamide has the optimal structure for its H3 antagonis-
tic properties and whether the antagonistic activity and its selectivity for the H3
receptor can be increased with some structural modifications. Not many structural
variations of burimamide and their activity on the histamine H3 receptor are known.
A strong influence of the chain length of the alkyl spaeer of burimamide on the H3
activity has been demonstrated, since a burimamide analogue with a propylene
chain (norburimamide) is only a weak antagonist. with a pA2 value of 6.1 for the H3
receptor, compared to a pA2 value of 7.2 of burimamide (both on rat cortex).54
We wanted to study the influence of the chain length of the alkyl spaeer in the
structure of burimamide derivatives on the H3 activity. We additionally wished to
evaluate the influence of the N-thiourea substituents on the activity of this receptor.
Therefore we have prepared a large series of analogues of burimamide and deter-
mined the H3 activity of these compounds functionally on an in vitro test system
using guinea pig jejunum preparations.P In this series we varied the length of the
alkyl spaeer of burimamide from two to six methylene groups and additionally
replaced the methyl group by other alkyl and aryl groups. We investigated the
selectivity of the most potent analogues as weIl, by determining their affmity for the
Hl and the H2 receptors.
R-Nes
1
1.2; n=2
1.3; n=3
1.4; n=4
1.5; n=5
1.6; n=6
2a-1
a; R=methyl
b; R=ethyl
e: R=n-propyl
d; R=J.propyl
e ; R=cyclohexyl
f ; R=phenyl
g; R=benzyl
h ; R=phenylethyl
I ; R=4-chlorobenzyl
3
3.2 a-h; n=2
3.3 a-h ; n=3
3.4 a-h ; n=4
3.5 a-I; n=5
3.6 aJ f ; n=6
Scheme 1. Synthesis of the burimamide analogues 3 from 4(5)-(ro-aminoalkyl)-IH-
imidazoles 1.
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Chemistry
The burimamide analogues were prepared by reaetion of the eorresponding 4(5)-(ro-
aminoalkyl)-IH-imidazoles with a series of alkyl- eq. aryl isothioeyanates (see
seheme 1). The 4(5)-(ro-aminoalkyl)-IH-imidazoles 1.3-1.6, were prepared using a
method described earlier by our group.121 All isothiocyanates were commereially
available. Most of the compounds were isolated as oxalates, because of better stabi-
lity and isolation.
Pharmacology
The H3 activity of the compounds was determined on an in vitro test system, on the
basis of the concentration-dependent inhibitory effect of histamine H3 agonists, on
the electrically evoked contractile response of isolated guinea pig jejunum
segments.P
-e- (R)-a-Methylhistamine
-e-- + 3.10-8 M VUF 4613
-+-+ 1.10.7 M VUF 4613
-er- + 3.10'7 M VUF 4613
-+-- + 1.10-6M VUF 4613
~2
100 cl:
e.
Q) El
~ 80
8- 0C/l
~
(ij 60
E
.~
E 40
~0
20
0
-9 -8 -7 -6 -5 -4
log [(R)-a-Methylhistamine]
Figure 2. Concentration-response curves of (Rj-u-methylhistamine, with a right-
ward parallel shift upon addition of VUF 4613 (corrected to 100%). The
Schild plot of these results is shown in the inset.
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The affinity of the selected compounds for the Hl receptor was determined by the
displacement of [3H]mepyramine, bound to membranes of CHO cells expressing
guinea pig Hl receptors. 122 The affinity of the selected compounds for the H2 recep-
tor was established by displacement of [l25I]iodoaminopotentidine, bound to
membranes of CHO cells expressing human H2receptors.123
Results and Discussion
All the synthesized analogues of burimamide are reversible competitive antagonists
on the histamine H3 receptor, as determined on guinea pig jejunum, with Schild
slopes not significantly different from unity (see tabIe 1).
The burimamide analogues 2.2a-2.2h, with an ethylene chain, which can be seen as
derivatives of histamine, are only weak H3 antagonists. This means that replacement
of the positively charged, ammonium group (at physiological pH) of histamine, by a
neutral N-substituted thiourea group, results in loss of intrinsic activity on the H3
receptor. This might be due to steric hindrance, since NlX-methylhistamine is a potent
agonist for the H3 receptor, and replacement of the N-methyl group by a propyl
group results in a compound without H3 activity.54 Moreover the reduced affinity
might be the result of the altered electronic properties. Most of the described potent
H3 agonists so far are compounds with an imidazole ring and anamino group (e.g.,
(Rj-c-methylhistamine and immepip), separated by an alkyl spacer.
The imidazole ring seems to be essential for activation, since replacement of the
imidazole ring by other heterocyclic rings, resulted in less active compounds, or
compounds deprived of any agonistic activity.26,41 The amino group of histamine
however, which is protonated at physiological pH, has been replaced with other
basic groups, like an isothiourea group, resulting in potent H3 agonists (e.g.,
imetit).37-40 The pKa of the isothiourea group (pKa =9-10) has been described to be
similar to aliphatic amines (pKa =9-11).40 Monomethylation of the isothiouronium
moiety in imetit does not drastically affect the agonistic activity on the H3 receptor
(pD2 value of YUF 8621 is 7.3, compared to a pD2 value of 8.1 of imetit on the
guinea pig ileum),13,37,40 whereas the ethylene derivative of burimamide, YUF 4577
(3.2a) is a weak H3 antagonist. Because the thiourea group of YUF 4577 (3.2a) is
uncharged at physiological pH, it seems that aspecific ionic binding site at the H3
receptor for cationic groups of H3 agonists, probably a carboxylate (e.g., an aspar-
tate residue), exists.
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Table 1. Histamine H3 antagonistic activity of the burimamide analogues 3 as
determined on the in vitro test system on the guinea pig jejunum.
Compound VUFa n b Re pA2 d Slope e N f
3.2a 4577 2 methyl 5.5 ± 0.2 1.0± 0.1 3
3.2b 4578 2 ethyl 5.3 ± 0.2 1.1 ± 0.2 4
3.2c 4579 2 n-propyl 5.4 ± 0.2 1.0 ± 0.1 4
3.2d 4580 2 i-propyl 4.8 ± 0.1 0.9 ± 0.1 3
3.2e 4581 2 cyclohexyl 5.9 ± 0.2 1.1 ±0.1 3
3.2f 4582 2 phenyl 5.2 ± 0.2 1.0 ± 0.1 3
3.2g 4583 2 benzyl 5.8 ± 0.2 1.1 ± 0.2 3
3.2h 4584 2 phenylethyl 5.9 ± 0.1 1.0 ± 0.1 3
3.3a 4630 3 methyl 6.4 ± 0.2 1.0 ± 0.1 4
3.3b 4631 3 ethyl 7.1 ± 0.2 1.0 ± 0.1 4
3.3c 4632 3 n-propyl 7.0± 0.2 1.2± 0.1 4
3.3d 4633 3 i-propyl 7.1 ± 0.2 1.0 ± 0.1 4
3.3e 4634 3 cyclohexyl 6.9 ± 0.2 1.1 ± 0.1 4
3.3f 4635 3 phenyl 6.9 ± 0.1 1.1 ± 0.1 4
3.3g 4636 3 benzyl 6.7 ± 0.2 1.1 ± 0.1 4
3.3h 4637 3 phenylethyl 6.7 ± 0.2 1.1 ±0.1 4
3.4a 4680 4 methyl 7.0± 0.2 1.0± 0.1 5
3.4b 4681 4 ethyl 7.4 ± 0.2 1.1 ± 0.2 4
3Ac 4682 4 n-propyl 7.3 ± 0.3 1.2 ± 0.3 4
3.4d 4683 4 i-propyl 7.5 ± 0.1 1.0 ± 0.3 4
3.4e 4684 4 cyclohexyl 7.1 ± 0.2 1.1 ± 0.3 4
3.4f 4685 4 phenyl 7.6 ± 0.2 1.0 ± 0.3 4
3.4g 4686 4 benzyl 7.1 ± 0.3 1.2 ± 0.3 4
3.4h 4687 4 phenylethyl 7.0 ± 0.2 1.3 ± 0.1 3
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Table 1. (continued)
Compound VUF a n b Re pA2 d Slope e N f
3.5a 4613 5 methyl 8.0 ± 0.1 1.0± 0.1 3
3.5b 4614 5 ethyl 8.0 ± 0.1 1.0± 0.1 4
3.5c 4615 5 n-propyl 7.7 ± 0.1 1.2 ± 0.1 4
3.5d 4616 5 i-propyl 7.7 ± 0.1 1.2± 0.1 4
3.5e 4617 5 cyclohexyl 7.5 ± 0.1 1.0± 0.1 4
3.5f 4618 5 phenyl 7.6 ± 0.2 1.0 ± 0.2 3
3.5g 4619 5 benzyl 7.7 ± 0.2 1.0± 0.1 3
3.5h 4620 5 phenylethyl 7.5 ± 0.2 1.1 ± 0.2 3
3.5i 4742 5 4-CI-benzyl 8.1 ± 0.2 0.9±0.1 3
3.6a 4740 6 methyl 7.9 ± 0.1 1.0± 0.1 5
3.6f 4741 6 phenyl 8.0± 0.2 0.9 ± 0.2 3
a Compound code number.
b Alkyl chain length of 3 (number of methylene units).
e Substituent of 3.
d Antagonistic parameter as determined on the described in vitro H3 assay repre-
senting the negative logarlthm of the abscissal intercept from the Schild plot ±
SD.
e Slope of Schild plot ± SD, not significantly different from unity.
f Number of different animal preparations.
Elongation of the alkyl chain of the burimamide analogues from a propylene chain
to a hexylene chain, results in an increase of the H3 antagonistic activity. The
pentylene chain seems to be optimal in length for H3 antagonistic activity for these
analogues. Replacement of the pentylene chain of YUF 4613 (3.5a) for instance, by
a hexylene chain, does not lead to increased H3 activity (VUF 4740 (3.6a».
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Table 2. Selectivity of the pentylene analogues of burimamide 3.5a-3.5h for the
~3 receptor.
Comp VUFa n b Re pKjHI d pKjHze pAZ H3 f
3.5a 4613 5 methyl 4.7±0.1 4.7±0.1 8.0 ± 0.1
3.5b 4614 5 ethyl 4.8±0.1 5.0±0.1 8.0 ± 0.1
3.5c 4615 5 n-propyl 5.5±0.1 5.3±0.1 7.7 ± 0.1
3.5d 4616 5 i-propyl 4.9±O.1 5.0±0.1 7.7 ± 0.1
3.5e 4617 5 cyclohexyl 5.1±O.1 5.4±0.1 7.5 ± 0.1
3.5f 4618 5 phenyl 5.6±O.1 4.9±0.1 7.6 ± 0.2
3.5g 4619 5 benzyl 5.4±O.1 5.8±0.2 7.7 ± 0.2
3.5h 4620 5 phenylethyl 5.5±O.1 5.5±0.3 7.5 ± 0.2
3.5i 4742 5 4-CI-benzyl 5.8±O.1 5.8±0.2 8.1 ± 0.2
a Compound code number.
b Alkyl chain length of 3 (number of methylene units).
e Substituent of 3.
d Log value of the binding affinity for the histamine Hl receptor ± SEM.
e Log value of the binding affinity for the histamine Hz receptor ± SEM.
f Antagonistic parameter as determined on the described in vitro H3 assay repre-
senting the negative logarithm of the abscissal intercept from the Schild plot ±
SD.
The affinity for the HI- and the Hz receptor is determined for these potent pentylene
analogues (3.5a-3.5i) (see Table 2). Clearly these compounds are selective for the
H3 receptor, although the N-methyl substituted pentylene analogue, YUF 4613
(3.5a) is more selective than the more lipophilic N-4-chlorobenzyl substituted
analogue VUF 4742 (3.5i). This highly selective pentylene analogue of burimamide
YUF 4613 (3.5a), is ten times more potent than burimamide.
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Figure 3. The influence of the alkyl chain leng th (n) and the N-thiourea
substituent (R) of the burimamide analogues 3 on the pAz value on the
histamine H3 receptor. Lines have been drawn for easy recognition of
these influences.
The large influence of the length of the alkyl spacer, on the H3 activity of the
burimamide analogues, is clearly visible in Figure 3. From this figure, the lack of
influence of the N-thiourea substituents on the H3 activity however, is also appa-
rent. If we consider the analogues with a pentyl chain (n=5), there is not a great
difference in pAz value between the compounds containing a small alkyl group, a
large alkyl group or an aromatic substituent.
This suggests that the receptor binding of this part of the burimamide analogues is
not through a hydrophobic interaction, nor through an electrostatic 1t-1t interaction
between aromatic systems. These results are rather surprising, since it has been pro-
posed that an H3 antagonist should consist of an N-containing heterocycle, linked
to apolar group by an alkyl chain, with a lipophilic residue attached to the polar
group, for enhancement of the affinity.Z6
A clear example of the affinity enhancing effect of lipophilic residues can be
observed in the series of analogues of imetit, as described by Van der Goot et al.37 In
this series, derivatization of the potent H3 antagonist YUF 8328 (pAz value of 8.0 on
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guinea pig ileum), leads to compounds with even higher affinity for the H3 receptor.
The introduetion of a p-chlorobenzyl group on the isothiourea group of VUF 8328,
resulted in the most potent H3 antagonist described so far (clobenpropit), with a pA2
value of 9.9 on the guinea pig ileum.
The introduetion of lipophilic residues on the thiourea group of the burimamide
analogues however, does not enhance the H3 antagonistic activity. This seems to
rule out a possible interaction of this series of antagonists in the same manner as the
isothiourea derivatives of Van der Goot.24
Thioperamide also binds in a distinct manner to the H3 receptor, other than the buri-
mamide analogues, since YUF 4634 (3.3e) is about hundred times less potent, as an
H3 antagonist, than thioperamide, which can be seen as its rigid analogue. Because
there is no large influence of the N-thiourea substituents of the burimamide
analogues on the pA2 value, only an interaction of the thiourea group with the
receptor via hydrogen bonding seems likely.
1t can be concluded that the intrinsic activity of histamine on the H3 receptor is lost
when the arnino group is replaced by an N-substituted thiourea group. Elongation
of the alkyl spaeer leads to an increase of affinity, with a pentylene chain being
optimal, indicating an additional binding site for the pentylene and higher analogues
of burimarnide. Burimamide is not the optimal antagonist in this series. The chain
length of the alkyl spaeer has a large influence on the H3 antagonistic activity, with
YUF 4613 being ten times more potent than burimamide. The N-thiourea
substituents 'however, have no great influence on the affinity. These results indicate
a binding behaviour for the burimamide analogues in a non-lipophilic environment,
different from other H3 antagonists like thioperamide and clobenpropit. Although
burimarnide was originally described as an H2 antagonist, the more potent pentylene
analogues of burimamide are highly selective for the H3 receptor.
Experimental Section
Chemistry.
lH NMR spectra were recorded on a Broker AC-2oo (200 MHz) spectrometer with
tetramethylsilane or sodium 3-(trimethylsilyl)propionate as an internal standard.
Mass spectra were recorded on a Finnigan MAT-90. Melting points were measured
on a Mettler FP-S + FP-S2 apparatus and are uncorrected. Histamine dihydrochlo-
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ride (1.2) was purchased from Janssen Chimica. 4(5)-(3-Aminopropyl)-IH-imidazole
dihydrobromide (1.3), 4(5)-(4-aminobutyl)-IH-imidazole dihydrobromide (1.4) and
4(5)-(5-aminopentyl)-IH-imidazole dihydrobromide (1.5) were prepared as described
earlier by our group.l21 4(5)-(6-aminohexyl)-lH-imidazole (1.6) was prepared using
the same method. 121,131 Methyl-, (2a) and ethyl isothiocyanate (2b) were purchased
from Aldrich; n-propyl-, (2c) i-propyl-, (2d) benzyl-, (2g) and phenylethyl isothio-
cyanate (2h) from Maybridge Chemical Co. (MCC); Cyclohexyl-, (2e) and phenyl
isothiocyanate (2f) from Janssen Chimica and chlorobenzyl isothiocyanate (2i) was
purchased from Lancaster. The isothiocyanates were used without purification. The
purity of the products was checked on thin layer chromatography (Merck silica gel
60, F254, 0.25mm). The free bases ofall compounds gave one spot using either ethyl
acetate (Rf"" 0-0.1), methanol (Rf"" 0.9-1.0) or CHCl3 (Rf"" 0.5). The yields of the
purified salt are given.
General Procedure
The required 4(5)-(ro-aminoalkyl)-IH-imidazole (1.2-1.6) either as dihydrochloride or
as dihydrobromide, was added to 2 equivalent sodium ethanolate in absolute
ethanol. This solution was refluxed for 30 min., and cooled to room temperature. The
formed precipitate was removed ~ filtration and 3 equivalent of the needed iso-
thiocyanate was added to the filtrate. The ethanol was removed under reduced
pressure, after 2 h refluxing. The residue was purified by column-chromatography,
by washing with ethyl acetate as eluent (isothiocyanate eluted Rf = 1.0). The
product was subsequently eluted with methanol as eluent (unreacted amine
remained on column). After removal of the methanol under reduced pressure, the
free base was converted into a hydrobromide or an oxalate.
The hydrobromides were prepared by solvation of the free base in 10% HBr-solu-
tion. After stirring at room temperature for 15 min, the acidic solution was coneen-
trated in vacuo, triturated three times with absolute ethanol and recrystallized from
ethanol/ethyl acetate.
The oxalates were prepared by solvation of the free base in ethyl acetate and the
addition of an excess of a saturated solution of oxalic acid in ethyl acetate (slowly).
The formed precipitate was collected by centrifugation, washed with ethyl acetate
(three times) and recrystallized from absolute ethanol.
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N-Methyl-N' -[2-(4(5)~imidazolyl)ethyljthioureahydrobromide (VUF 4577) (3.2a)
Melting point 99.9-1OO.8°C. Yield 49%.
lH NMR (D20) : Ö 2.87 (s, 3H, Cfu), 3.03 (t, 2H, J =7 Hz, imidazole-Cjjj), 3.78 (t,
2H, J =7 Hz, CfuNH), 7.30 (s, IH, imidazole-5(4)H), 8.62 (s, lH, imidazole-2H) ppm.
MS (EI) : mlz 184 (M+, 57%), 153 (M+-CH3NH2,47%), 150 (M+-H2S, 54%), 95
([ImC2H4]+, 100%),81 ([ImCH2]+, 84%).
High resolution mass : mlz 184.0782; calcd. for C7H12N4S : 184.0783.
Anal. (C7H12N4S-2HBr)
Calcd.
: 24.33 %C, 4.19 %H, 16.16 %N;
: 24.29 %C,4.08 %H, 16.19 %N.
N-Ethyl-N'-[2-(4(5)-imidazolyl)ethyljthiourea hydrobromide (VUF 4578) (3.2b)
Melting point 164.5-165.0°C. Yield 74%.
inNMR (D20) : Ö 1.12 (t, 3H, J =7 Hz, Cfu), 3.03 (t, 2H, J =7 Hz, imidazole-Cfu),
3.32(q, 2H, J =7 Hz, CfuCH3), 3.78 (t, 2H, J =7 Hz, CfuNH), 7.39 (s, lH, imidazole-
5(4)H), 8.62 (s, lH, imidazole-2H) ppm.
MS (EI) : mlz 198 (M+, 50%), 164 (M+-H2S, 32%), 153 (M+-C2HSNH2, 18%),95
([ImC2H4]+, 100%),81 ([ImCH2]+, 51%).
High resolution mass : mlz 198.0940; calcd. for CgHl4N4S : 198.0939.
Anal. (CgH14N4S-1.96HBr)
Calcd.
: 26.94 %C, 4.65 %H, 15.78 %N;
: 26.93 %C, 4.51 %H, 15.70 %N.
N-(n-Propyl)-N'-[2-(4(5)-imidazolyl)ethyljthiourea hydrobromide (VUF 4579)
(3.2c)
Melting point 172.6-173.1°C. Yield 36%.
lH NMR (D20) : Ö0.88 (t, 3H, J =7 Hz, cao, 1.53 (m, 2H, CfuCH3), 3.04 (t, 2H, J =
7 Hz, imidazole-Cfu), 3.10-3.45 (m, 2H, CfuCH2CH3), 3.70-3.92 (m, 2H, CfuNH),
7.30 (s, lH, imidazole-5(4)H), 8.64 (s, lH, imidazole-2H) ppm.
MS (EI) : mlz 212 (M+, 62%), 178 (M+-H2S, 5%), 153 (M+-C3H7NH2, 13%),95
([ImC2H4]+, 100%),81 ([ImCH2]+, 35%).
High resolution mass : mlz 212.1100; calcd. for C9H16N4S : 212.1096.
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Anal. (C9HlóN4S·HBr)
Calcd.
: 37.10 %C, 6.00 %H, 19.31 %N;
: 36.87 %C, 5.84 %H, 19.11 %N.
N-(iso-Propyl)-N' -[2-(4(5)-imidazolyl)ethyljthiourea oxalate (VUF 4580) (3.2d)
Melting point 123.1°C. Yield 53%.
lH NMR (D20) : Ö 1.01 (d, 6H, J = 7 Hz, 2*Clli), 2.90 (t, 2H, J = 7 Hz, imidazole-
ca», 3.58-3.75 (m, 2H, CfuNH), 3.75-4.10 (b s, 1H, CH), 7.16 (s, 1H, imidazole-
5(4)H), 8.49 (s, 1H, imidazole-2H) ppm.
MS (EI) : m/z 212 (M+, 59%), 178 (M+-H2S, 12%), 153 (M+-C3H7NH2, 19%),95
([ImC:zH4]+, 100%),81 ([ImCH2]+,52%).
High resolution mass: m/z 212.1090; calcd. for C9H16N4S : 212.1096.
Anal. (C9HlóN4S·C2H204)
Calcd.
: 43.69 %C, 6.08 %H, 18.70 %N;
: 43.70 %C, 6.00 %H, 18.53 %N.
N-Cyclohexyl-N'-[2-(4(5)-imidazolyl)ethyljthiourea oxalate (VUF 4581) (3.2e)
Melting point 161.7°C. Yield 92%.
lH NMR (D20) : Ö 0.99-1.85 (m, lOH, cyclohexyl-Cfu's), 2.97 (t, 2H, J = 7 Hz,
imidazole-CH2), 3.50-3.90 (m, 3H, CH + CH2NH), 7.22 (s, 1H, imidazole-5(4)H), 8.53
(s, 1H, imidazole-2H) ppm.
MS (EI) : m/z 252 (M+, 57%), 218 (M+-H2S, 12%), 153 (M+-C6HllNH2, 30%), 95
«(ImC2H4]+, 100%),81 ([ImCH2]+' 72%).
High resolution mass: m/z 252.1401; calcd. for C12H20N4S : 252.1409.
Anal. (C12H20N4S·0.5C2H204) : 52.37 %C, 7.23 %H, 18.79 %N;
Calcd. : 52.50 %C, 7.12 %H, 18.84 %N.
N-Phenyl-N' -[2-(4(5)-imidazolyl)ethyljthiourea hydrobromide (VUF 4582) (3.2f)
Melting point 148.6-148.9°C. Yield 74%.
lH NMR (D20) : Ö 2.94-3.03 (m, 2H, imidazole-Cfu), 3.75-3.97 (m, 2H, CfuNH),
7.11-7.57 (m, 6H, phenyl-H + imidazole-5(4)H), 8.61 (s, 1H, imidazole-2H) ppm.
MS (EI) : m/z 246 (M+, 3%), 212 (M+-H2S, 7%), 153 (M+-C6HSNH2, 41%), 135
([C~sNCS]+, 100%),93 ([C6HSNH2]+, 62%), 95 ([ImC2H4]+, 12%), 81 ([ImCH2]+,
72%), 77 ([C~s]+, 51%).
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High resolution mass : mlz 246.0931; calcd. for C12Hl4N4S : 246.0939.
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Anal. (C12Hl4N4S-HBr)
Calcd.
: 44.11 %C, 4.66 %H, 17.24 %N;
: 44.04 %C,4.62 %H, 17.12 %N.
N-Benzyl-N'-[2-(4(5)-imidazolyl)ethyl]thiourea oxalate (VUF 4583) (3.2g)
Melting point 153.7-155.0°C. Yield 18%.
lH NMR (DMSO-d6) : Ö 2.89 (t, 2H, J =7 Hz, imidazole-Cfu), 3.59-3.83 (m, 2H,
CfuNH), 4.53-4.77 (m, 2H, Cfu-phenyl), 7.18-7.38 (m, 6H, phenyl-H + imidazole-
4(5)H), 7.85-8.00 (m, lH, NID, 8.72 (t, lH, J =6 Hz, NH), 8.72 (s, lH, imidazole-2H),
11.15-11.85 (m, NH + oxalate) ppm.
MS (EI) : mlz 260 (M+, 28%), 226 (M+-H2S, 8%), 153 (M+-C7H7NH2, 20%), 95
([ImC2H4]+, 44%), 91 ([C7H7]+, 100%),81 ([ImCH2]+, 38%).
High resolution mass: mlz 260.1101; calcd. for C13H16N4S : 260.1096.
Anal. (C13H16N4S-C2H204)
Calcd.
: 51.12 %C, 5.27 %H, 16.11 %N;
: 51.42 %C, 5.18 %H, 15.99 %N.
N-(2-Phenylethyl)-N' -[2-(4(5)-imidazolyl)ethyl]thiourea oxalate (VUF 4584)
(3.2h)
Melting point 145.1-145.5°C. Yield 18%.
lH NMR (D20) : Ö 2.66-2.91 (m, 4H, imidazole-Cfu + Cfu-phenyl), 3.32-3.80 (m,
4H, 2*CfuNH), 7.15 (s, lH, imidazole-5(4)H), 7.10-7.34 (m, 5H, phenyl-H), 8.47 (s,
lH, imidazole-2H) ppm.
MS (EI) : mlz 274 (M+, 39%), 220 (M+-H2S, 2%), 153 (M+-CsH9NH2, 22%), 105
([CSH9]+, 42%), 95 ([ImC2H4]+, 100%),91 ([C7H7]+, 64%), 81 ([ImCH2]+,43%).
High resolution mass : mlz 274.1253; calcd. for C14HlSN4S : 274.1252.
Anal. (Cl4HlSN4S-C2H204)
Calcd.
: 52.56 %C, 5.54 %H, 15.31 %N;
: 52.73 %C, 5.53 %H, 15.37 %N.
N-Methyl-N' -[3-(4(5)-imidazolyl)propyljthiourea oxalate (VUF 4630) (3.3a)
Melting point 126.1-128.9 °C. Yield 49%.
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lH NMR (D20 ) : Ö 1.96 (m, 2H, CfuCH2NH), 2.77 (t, J = 7 Hz, 2H, imidazole-Cfu),
2.86 (br s, 3H, Cfu), 3.30-3.67 (m, 2H, CfuNH), 7.23 (s, lH, imidazole-5(4)H), 8.57 (s,
lH, imidazole-2H) ppm.
MS (EI) : rnJz 198 (M+, 20%), 167 (M+-CH3NH2, 6%), 164 (M+-H2S, 5%), 109
([ImC31I<>]+, 12%),95 ([ImC214]+, 94%), 82 ([ImCH3]+, 100%).
High resolution mass: rnJz 198.0929; calcd. for CSHl4N4S : 198.0939.
Anal. (CSH14N4S·0.84C2H204) : 42.43 %C, 5.41 %H, 20.75 %N;
Calcd. : 42.44 %C, 5.77 %H, 20.46 %N.
N-Ethyl-N'-[3-(4(5)-imidazolyl)propyl]thiourea oxalate (VUF 4631) (3.3b)
Melting point 116.1 °C. Yield 44%.
1H NMR (D20 ) : Ö1.12 (t, 3H, J = 7 Hz, Cfu), 1.95 (m, 2H, CfuCH2NH), 2.77 (t, 2H, J
= 8 Hz, imidazole-Cfu), 3.15-3.62 (m, 4H, 2*CfuNH), 7.23 (s, lH, imidazole-5(4)H),
8.57 (s, lH, imidazole-2H) ppm.
MS (EI) : rnJz 212 (M+, 53%),178 (M+-H2S, 10%), 167 (M+-C2HSNH2, 4%),109
«(lmC31I<>]+, 31%),95 «(lmC214]+, 85%), 82 ([ImCH3]+, 100%).
High resolution mass: rnJz 212.1092; calcd. for C9H16N4S : 212.1096.
Anal. (C9Hl6N4S·C2H204)
Calcd.
: 43.93 %C, 5.91 %H, 18.74 %N;
: 43.70 %C, 6.00 %H, 18.53 %N.
N-(n-Propyl)-N'-[3-(4(5)-imidazolyl)propyl]thiourea oxalate (VUF 4632) (3.3c)
Melting point 123.2-125.2 °C. Yield 24%.
lH NMR (D20): Ö0.87 (t, 3H, J = 7 Hz, Cfu), 1.53 (m, 2H, CfuCH3), 1.97 (m, 2H,
CH2CH2NH), 2.77 (t, 2H, J =7 Hz, imidazole-Cjlj), 3.10-3.65 (m, 4H, 2*CH2NH),
7.23 (s, lH, imidazole-5(4)H), 8.56 (s, lH, imidazole-2H) ppm.
MS (EI) : tuh: 226 (M+, 9%), 192 (M+-H2S, 4%), 167 (M+-C3H7NH2, 4%), 109
«(lmC31I<>]+, 9%),95 ([ImC214]+, 100%),82 ([ImCH3]+, 33%).
High resolution mass : rnJz 226.1265; calcd. for ClOHlSN4S : 226.1252.
Anal. (Cu#lsN4S·0.8C2H204) : 46.95 %C, 6.31 %H, 18.79 %N;
Calcd. : 46.70 %C, 6.62 %H, 18.78 %N.
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N-(iso-Propyl)-N' -[3-(4(5)-imidazolyl)propyl]thiourea oxalate (VUF 4633) (3.3d)
Melting point 146.0 oe. Yield 43%.
lH NMR (020 ) : 0 1.13(d, 6H, J = 7 Hz, Cfu), 1.94(m, 2H, CfuCH2NH), 2.77 (t, 2H,
J = 7 Hz, imidazole-Cfu), 3.37-3.58 (m, 2H, CfuNH), 3.89-4.17 (m, lH, CH), 7.23 (s,
lH, imidazole-5(4)H), 8.57 (s, lH, imidazole-2H) ppm.
MS (EI) : m/z 226 (M+, 30%), 192 (M+-HzS, 6%), 167 (M+-C3H7NH2, 7%), 109
([ImC3Hó]+, 23%), 95 «(ImCzH4]+, 79%),82 ([ImCH3]+, 66%).
High resolution mass: m/z 226.1271; calcd. for ClOHlSN4S : 226.1252.
Anal. (ClOHlSN4S·0.8CzHz04) : 46.52 %C, 6.55 %H, 19.15 %N;
Calcd. : 46.70 %C, 6.62 %H, 18.78 %N.
N-Cyclohexyl-N' -[3-(4(5)-imidazolyl)propyl]thiourea oxalate (VUF 4634) (3.3e)
Melting point 102.2 oe. Yield 50%.
in NMR (DzO): 00.93-1.97 (m, 12H,CfuCH2NH + cyclohexyl-Cllj's), 2.70 (t, 2H,
J =8 Hz, imidazole-Cfu), 3.23-3.90(m, 3H, CfuNH + CHNH), 7.18 (s, lH, imidazole-
5(4)H),8.52 (s, lH, imidazole-2H) ppm.
MS (EI) : m/z 266 (M+, 29%), 232 (M+-H2S, 8%), 167 (M+-C6HUNH2, 6%), 109
([ImC3Hó]+, 24%), 95 ([ImC2H4]+, 73%),82 ([ImCH3]+, 100%).
High resolution mass : m/z 266.1572;calcd. for C13HzZN4S : 266.1565.
N-Phenyl-N'-[3-(4(5)-imidazolyl)propyl]thiourea oxalate (VUF 4635) (3.31)
Melting point 126.7 °C. Yield 47%.
lH NMR (DzO): 0 1.90 (m, 2H, CfuCH2NH), 2.70 (t, 2H, J =7 Hz, imidazole-Cfu),
3.39-3.65 (m, 2H, CfuNH), 7.27 (m, 6H, imidazole-5(4)H + phenyl-H's), 8.50 (s, lH,
imidazole-2H) ppm.
MS (EI) : m/z 260 (M+, 2%), 226 (M+-H2S, 3%), 135 ([C6HSNCS]+, 63%), 108
([ImC3HS]+, 19%), 95 ([ImCZH4]+, 68%), 93 ([C6HSNH2]+, 74%), 82 ([ImCH3]+,
100%),77 ([C6HS]+, 30%).
High resolution mass : m/z 260.1108; calcd. for C13H16N4S : 260.1096.
Anal. (C13H16N4S·0.8C2H204) : 52.59 %C, 5.26 %H, 16.94 %N;
Calcd. : 52.76 %C, 5.34 %H, 16.86 %N.
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N-Benzyl-N'-[3-(4(5)-imidazolyl)propyl]thiourea oxalate (VUF 4636) (3.3g)
Melting point 117.2 °C. Yield 33%.
1H NMR C020 ) : Ö 1.84 (m, 2H, CfuCH2NH), 2.39-2.79 (m, 2H, ill1idazole-Cfu),
3.30-3.57 (m, 2H, CfuNH), 4.42-4.73 (m, 2H, Cfu-phenyl), 7.10 (s, lH, imidazole-
5(4)H), 7.29 (m, 5H, phenyl-H),8.47 (s, lH, imidazole-2H) ppm.
MS (EI) : rn/z 274 (M+, 50%), 240 (M+-H2S, 2%), 168 (M+-C7H7NH, 10%), 109
([ImC3Ht>]+, 31%),95 ([ImC214]+, 79%), 91 ([C7H7]+, 100%),82 ([ImCH3]+, 94%).
High resolution mass: rn/z 274.1250; calcd. for Cl41flgN4S : 274.1252.
Anal. (Cl41flgN4S·0.84C2H204) : 53.69 %C, 5.59 %H, 16.39 %N;
Calcd. : 53.81 %C, 5.66 %H, 16.01 %N.
N-(2-Phenylethyl)-N'-[3-(4(5)-imidazolyl)propyl]thiourea oxalate(VUF 4637)
(3.3h)
Melting point 125.5 °C. Yield 27%.
lH NMR (D20): Ö1.73 (m, 2H, CfuCH2NH), 2.58 (t, 2H, J = 8 Hz, imidazole-Cfu),
2.82 (t, 2H, J = 7 Hz, Cfu-phenyl), 3.10-3.44 (m, 2H, CfuNH), 3.44-3.79 (m, 2H,
CfuCH2-phenyl), 7.12 (s, lH, imidazole-5(4)H), 7.16-7.36 (m, 5H, phenyl-H), 8.49 (s,
lH, imidazole-2H) ppm,
MS (EI): rn/z 288 (M+, 0.2%), 95 ([ImC2H4]+,8%), 91 ([C7H7]+, 47%),82 ([lmCH3]+'
18%),45 ([C2HSNH2]+, 100%).
High resolution mass : rn/z 288.1414; calcd. for ClsH20N4S : 288.1409.
Anal. (ClsH20N4S·0.8C2H204) : 55.34 %C, 5.83 %H, 15.79 %N;
Calcd. : 55.32 %C, 6.04 %H, 15.55 %N.
N-Methyl-N' -[4-(4(5)-imidazolyl)butyl]thiourea oxalate (VUF 4680) (3.4a)
Melting point 120.1-122.6 °C. Yield 18%.
lH NMR (020) : Ö 1.61 (m, 4H, central CH2'S), 2.72 (t, 2H, J = 7 Hz, imidazole-Clh),
2.82 (m, 3H; Cfu), 3.22-3.62 (m, 2H, CfuNH), 7.17 (s, lH, imidazole-5(4)H), 8.52 (s,
lH, imidazole-2H) ppm.
MS (EI) : rn/z 212 (M+, 79%), 181 (M+-CH3NH2, 20%), 179 (M+-HS, 9%), 123
([lmC4Hg]+, 42%), 109 ([ImC3H6]+, 43%), 95 ([ImC2H4]+, 100%), 81 ([ImCH2]+,
69%).
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High resolution mass : m/z 212.1091; calcd. for C9Hl6N4S : 212.1096.
Anal. (C9H16N4SeO.8C2H2Û4) : 44.74 %C, 6.33 %H, 19.34 %N;
Calcd. : 44.78 %C, 6.24 %H, 19.70 %N.
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N-Ethyl-N' -[4-(4(5)-imidazolyl)butyl}thiourea oxalate (VUF 4681) (3.4b)
Melting point 120.3 °C. Yield 29%.
inNMR (D2û ) : Ö 1.08 (t, 3H, J =7Hz, cao. 1.61 (m, 4H, central CH2'S), 2.72 (t, 2H,
J =7 Hz, imidazole-Cfu), 3.22-3.51 (m, 4H, 2*CfuNH), 7.17 (s, lH, imidazole-5(4)H),
8.52 (s, lH, imidazole-2H) ppro.
MS (EI) : m/z 226 (M+, 81%), 193 (M+-HS, 7%), 181 (M+-C2HSNH2, 25%), 123
([IroC4HS]+, 47%), 109 ([ImC3H6]+, 40%), 95 ([ImC2H4]+, 100%), 81 ([IroCH2]+,
75%).
High resolution roass : m/z 226.1250; calcd. for ClQHlSN4S : 226.1252.
Anal. (ClQHlSN4S·1.8C2H2Û4) : 41.85 %C, 5.47 %H, 14.40 %N;
Calcd. : 42.06 %C, 5.60 %H, 14.42 %N.
N-(n-Propyl)-N' -{4-(4(5)-imidazolyl)butyl}thiourea oxalate (VUF 4682) (3.4c)
Melting point 146.9 °C. Yield 55%.
lH NMR (D2Û) : Ö 0.84 (t, 3H, J = 7Hz, Clli), 1.42-1.78 (m, 6H, central CH2'S +
ClliCH3), 2.73 (t, 2H, J = 7 Hz, imidazole-Clj-), 3.10-3.62 (m, 4H, 2*CfuNH), 7.18 (s,
IH, imidazole-5(4)H), 8.53 (s, lH, imidazole-2H) ppro.
MS (EI) : m/z 240 (M+, 69%), 207 (M+-HS, 7%), 181 (M+-C3H7NH2, 23%), 123
([ImC4Hs]+, 55%),109 ([ImC3Hó]+, 38%),95 ([ImC2H4]+, 100%), 81 ([ImCH2]+' 80%),
45 ([C2HSNH2]+, 71%).
High resolution roass : m/z 240.1409; calcd. for CllH20N4S : 240.1409.
Anal. (CllH20N4S·C2H2Û4)
Calcd.
: 47.06 %C, 6.62 %H, 16.83 %N;
: 47.25 %C, 6.71 %H, 16.96 %N.
N-(iso-Propyl)-N'-{4-(4(5)-imidazolyl)butyl}thiourea oxalate (VUF 4683) (3.4d)
Melting point 151.3 oe. Yield 64%.
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lH NMR (DzO) : Ö1.16 (d, 6H, J =7 Hz, 2*Clli), 1.65 (m, 4H, central CHz's), 2.76 (t,
2H, J = 7 Hz, imidaiole-CH.2), 3.43 (m, 2H, CH.2NH), 4.08 (m, lH, CID, 7.21 (s, lH,
imidazole-5(4)H), 8.55 (s, lH, imidazole-2H) ppm.
MS (EI) : m1z 240 (M+, 60%), 207 (M+-HS, 5%), 181 (M+-C3H7NHz, 17%), 123
([ImC4Hs]+, 51%),109 ([ImC3H6]+, 25%), 95 ([ImCz14]+, 70%), 81 ([ImCHz]+, 52%),
45 ([CzHsNHz]+, 100%).
High resolution mass: m1z 240.1401; calcd. for CllHzoN4S : 240.1409.
Anal. (CllH2QN4S·1.76CZHZ04) : 43.71 %C, 5.71 %H, 14.37 %N;
Calcd. : 43.73 %C, 5.94 %H, 14.05 %N.
N-Cycloheiyl-N'-[4-(4(5)-imidazolyl)butyl]thiourea oxalate (VUF 4684) (3.4e)
Melting point 109.5 °C. Yield 24%.
lH NMR (DMSO-d6): Ö1.00-1.95 (m, 14H, central CHz's + cyclohexyl-CH.2's), 2.64
(m, 2H, imidazole-Cjlj), 3.37 (m, 2H, CH.2NH), 3.93 (m, lH, CID, 7.20 (s, lH, imida-
zole-5(4)H), 7.28-7.62 (m, 4H, NH + COili), 8.50 (s, lH, imidazole-2H) ppm.
MS (EI) : m1z 280 (M+, 66%), 247 (M+-HS, 7%), 181 (M+-C6HllNHz, 28%), 123
([ImC4Hs]+, 62%),109 ([ImC3H6]+, 32%), 95 ([ImCz14]+, 100%), 81 ([ImCHz]+, 76%),
45 ([CzHsNHz]+, 65%).
High resolution mass : m1z 280.1724; calcd. for Cl4H24N4S : 280.1722.
Anal. (C14H24N4S·1.15CzHz04) : 50.52 %C, 6.93 %H, 15.04 %N;
Calcd. : 50.98 %C, 6.90 %H, 14.60 %N.
N-Phenyl-N' -[4-(4(5)-imidazolyl)butyl]thiourea oxalate (VUF 4685) (3.4/)
Melting point 153.7 °C. Yield 42%.
lH NMR (DzO ) : Ö1.59 (m, 4H, central CHz's), 2.70 (t, 2H, imidazole-Cjjj), 3.49 (m,
2H, CH.2NH), 7.31 (m, 6H, imidazole-5(4)H + phenyl-H), 8.50 (s, lH, imidazole-2H)
ppm.
MS (EI) : m1z 274 (M+, 4%),241 (M+-HS, 2%), 181 (M+-C6HSNHz, 10%), 135
([C6HSNCS]+, 100%),95 ([ImCZH4]+, 61%), 93 ([CóHsNHz]+, 78%), 77 ([C6HS]+,
47%).
High resolution mass : m1z 274.1251; calcd. for Cl4HlSN4S : 274.1252.
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Anal. (Cl4HlgN4S·1.4C2H204) : 50.18 %C, 5.00 %H, 14.31 %N;
Calcd. : 50.39 %C, 5.24 %H, 14.00 %N.
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N-Benzyl-N'-[4-(4(5)-imidazolyl)butyljthiourea oxalate (VUF 4686) (3Ag)
Melting point 109.1 °C. Yield 42%.
in NMR (DMSO-d(j): Ö 1.53 (m, 4H, central CH2'S), 2.59 (t, 2H, J = 7 Hz, imidazole-
Cfu), 3.40 (m, 2H, CfuNH), 4.63 (m, 2H, Cfu-benzyl), 7.13 (s, lH, imidazole-5(4)H),
7.28 (m, 5H, phenyl-H), 7.71 (m, lH, N-H), 7.99 (m, lH, N-H), 8.39 (s, lH, imidazole-
2H)ppm.
MS (EI) : m/z 288 (M+, 42%),255 (M+-HS, 3%), 181 (M+-C7H7NH2, 14%), 123
([ImC4Hg]+, 28%), 109 «(ImC3H6]+, 15%), 106 «(C7H7NH]+, 38%), 95 «(ImC2H4]+,
57%),91 «(C7H7]+, 100%), 81 ([ImCH2]+, 37%).
High resolution mass: m/z 288.1400; calcd. for C15H20N4S : 288.1409.
Anal. (C15H20N4S·0.85C2H204) : 54.98 %C, 5.91 %H, 15.57 %N;
Calcd. : 54.96 %C, 5.99 %H, 15.35 %N.
N-(2-Phenylethyl)-N' -[4-(4(5)-imidazolyl)butyl]thiourea oxalate (VUF 4687)
(3.4h)
Melting point 130.8-132.2 °C. Yield 24%.
lH NMR (DMSO-d(j) : Ö 1.55 (m, 4H, central CH2'S), 2.62 (t, 2H, J = 7 Hz, imidazole-
CH2), 2.78 (t, 2H, J =7 Hz, CH2-phenyl), 3.37 (m, 2H, CH2NH), 3.57 (m, 2H,
CH2CH2-phenyl), 7.27 (m, 6H, imidazole-5(4)H + phenyl-H), 7.63 (m, 2H, 2*N-H),
8.67 (s, lH, imidazole-2H) ppm.
MS (EI) : m/z 302 (M+, 55%), 269 (M+-HS, 5%), 181 (M+-CgH9NH2, 26%), 123
([ImC4Hg]+, 50%),109 «(ImC3Hó]+, 32%),105 «(CgH9]+, 36%), 95 ([ImC2H4]+, 91%),
91 «(C7H7]+, 100%),81 ([ImCH2]+, 66%).
High resolution mass : m/z 302.1560; calcd. for C16H22N4S : 302.1565.
N-Methyl-N' -[5-(4(5)-imidazolyl)pentyl]thiourea oxalate (VUF 4613) (3.5a)
Melting point 111.0 -c.Yield 10%.
lH NMR (D20): Ö1.31 (m, 2H, (CH2CH2)2Cfu), 1.62 (m, 4H, (CH2CfuhCH2), 2.67
(t, 2H, J =7 Hz, imidazole-Cfu), 2.82 (m, 3H, Cfu), 3.33 (m, 2H, CfuNH), 7.14 (s, lH,
imidazole-5(4)H), 8.50 (s, lH, imidazole-2H) ppm.
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MS (EI): rnlz 226 (M+, 58%),195 (M+-CH3NH2, 58%),137 ([ImCSHlO]+, 36%),123
([ImC4Hs]+, 25%), 109 ([ImC3H6]+, 15%), 95 ([ImC2H4]+, 93%), 82 ([ImCH3]+,
100%).
High resolution mass: rnJz 226.1251; calcd. for CIQHlSN4S : 226.1252.
N-Ethyl-N'-[5-(4(5)-imidazolyl)pentylJthiourea oxalate (VUF 4614) (3.5b)
Melting point 77.6 °C. Yield 8%.
lH NMR (D20 ) : Ö1.12 (t, 3H, J = 7 Hz, Cfu), 1.35 (m, 2H, (CH2CH2hCH2), 1.65 (m,
4H, (CH2CH2hCH2), 2.72 (t, 2H, J =7 Hz, imidazole-CH2), 3.47 (m, 4H, 2*CH2NH),
7.19 (s, l H, imidazole-5(4)H), 8.55 (s, lH, imidazole-2H) ppm.
MS (EI) : rnlz 240 (M+, 75%), 207 (M+-HS, 5%), 195 (M+-C2HSNH2, 12%), 137
([ImCsHlQ]+, 52%), 123 ([ImC4Hs]+, 32%), 109 ([ImC3H6]+, 20%), 95 ([ImC2H4]+,
100%),82 ([ImCH3]+, 95%).
High resolution mass : rnJz 240.1410; calcd. for CnH2oN4S : 240.1409.
Anal. (CnH2oN4S·0.8C2H204) : 48.55 %C, 6.95 %H, 17.74 %N;
Calcd. : 48.44 %C, 6.97 %H, 17.93 %N.
N-(n-Propyl)-N'-[5-(4(5)-imidazolyl)pentyl]thiourea oxalate (VUF 4615) (3.5c)
Meltingpoint 115.5-116.6 °C. Yield 7%.
lH NMR (D20 ) : Ö 0.82 (t, 3H, J =7 Hz, C!:b), 1.30 (m, 4H, (CH2CH2hCfu) +
CH2CH3), 1.60 (m, 4H, (CH2CH2hCH2), 2.67 (t, 2H, J = 7 Hz, imidazole-CH2), 3.30
(m, 4H, 2*CH2NH), 7.13 (s, lH, imidazole-5(4)H), 8.50 (s, lH, imidazole-2H) ppm.
MS (EI) : rnlz 254 (M+, 60%), 221 (M+-HS, 4%), 195 (M+-C3H7NH2, 12%), 137
([ImCsHlQ]~, 56%), 123 ([ImC4Hs]+, 28%), 109 ([ImC3H6]+, 17%),95 ([ImC2H4]+,
100%),82 ([ImCH3]+,88%).
High resolution mass : rnJz 254.1563; calcd. for C12H22N4S : 254.1565.
Anal. (C12H22N4S·0.8C2H204) : 50.33 %C, 7.22 %H, 16.70 %N;
Calcd. : 50.04 %C, 7.28 %H, 17.16 %N.
N-(iso-Propyl)-N' -[5-(4(5)-imidazolyl)pentyl]thiourea oxalate (VUF 4616) (3.5d)
Melting point 97.1 °C. Yield 8%.
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in NMR (D20 ) : 0 1.08 (s, 6H, 2*Cfu), 1.28 (m, 2H, (CH2CH2hCH2), 1.57 (m, 4H,
(CH2CfuhCH2), 2.65 (t, 2H, imidazole-Cljj), 3.32 (m, 2H, CfuNH), 4.00 (m, lH, C.ID~
7.13 (s, lH, imidazole-5(4)H), 8.47 (s, lH, imidazole-2H) ppm.
MS (EI): mlz 254 (M+, 77%),196 (M+-C3H7NH, 18%), 137 ([ImCSHlO]+, 74%),123
([ImC4!Is]+,.27%),95 ([ImC2H4]+, 100%),81 ([ImCH2]+, 80%).
High resolution mass : mlz 254.1563; calcd. for C12H22N4S : 254.1565.
Anal. (C12H22N4S·0.8C2H204) : 50.09 %C, 7.06 %H, 17.07 %N;
Calcd. : 50.04 %C, 7.28 %H, 17.16 %N.
N-Cyclohexyl-N'-[5-(4(5)-imidazolyl)pentyl]thiourea oxalate (VUF 4617) (3.5e)
Melting point 116.5 °C. Yield 6%.
lH NMR (D20): 0 1.05-2.05 (m, 16H, (CH2CH2hCfu + (CH2CfuhCH2 + cyclo-
hexyl-Cfu's), 2.73 (t, 2H, J = 7 Hz, imidazole-Cfu), 3.43 (m, 3H, CfuNH + CHNH),
7.22 (s, lH, imidazole-5(4)H), 8.58 (s, lH, imidazole-2H) ppm.
MS (EI) : mlz 294 (M+, 45%), 261 (M+-HS, 4%), 195 (M+-CóHl1NH2, 16%), 137
([ImCsHlO]+, 48%), 123 ([ImC4HS]+, 22%), 109 ([ImC3Hó]+, 17%),95 ([ImC2H4]+,
100%),82 ([ImCH3]+' 85%).
High resolution mass : mlz 294.1875; calcd. for ClSH26N4S : 294.1878.
Anal. (ClsH2óN4S·0.8C2H204) : 54.52 %C, 7.48 %H, 15.34 %N;
Calcd. : 54.40 %C, 7.59 %H, 15.29 %N.
N-Phenyl-N'-[5-(4(5)-imidazolyl)pentyl]thiourea oxalate (VUF 4618) (3.5f)
Melting point 108.9 °C. Yield 5%.
in NMR (020) : 0 1.35 (m, 2H, (CH2CH2hCfu), 1.67 (m, 4H, (CH2CfuhCH2), 2.75
(t, 2H, J = 7 Hz, imidazole-Cfu), 3.53 (m, 2H, CHzNH), 7.37 (m, 6H, imidazole-5(4)H
+ phenyl-H), 8.59 (s, lH, imidazole-2H) ppm.
MS (EI) : mlz 288 (M+, 5%),196 (M+-CóHsNH, 14%), 137 ([ImCSHlO]+, 18%), 135
([CóHsNCS]+, 100%), 123 ([ImC4HS]+, 7%),109 ([ImC3Hó]+, 13%),95 ([ImC2H4]+,
84%),93 ([CóHSNH2]+, 37%), 82 ([ImCH3]+, %),77 ([CóHs]+, 52%).
High resolution mass: mlz 288.1402; calcd. for ClSH20N4S : 288.1409.
Anal. (ClsH20N4S·C2H204)
Calcd.
: 54.18 %C, 6.09 %H, 14.91 %N;
: 53.95 %C, 5.86 %H, 14.80 %N.
138 Analogues ofBurimamide as Histamine H3 Receptor Antagonists
N-Benzyl-N' -[5-(4(5)-imidazolyl)pentyljthiourea oxalate (VUF 4619) (3.5g)
Melting point 152.1-152.4 °C. Yield 10%.
lH NMR (D20 ) : Ö1.27 (m, 2H, (CH2CH2hCfu), 1.60 (m, 4H, (CH2CfuhCH2), 2.67
(t, 2H, J = 7 Hz, imidazole-Cfu), 3.43 (m, 2H, CfuNH), 4.63 (m, 2H, CH.2-phenyl),
7.17 (s, lH, imidazole-5(4)H), 7.36 (m, 5H, phenyl-H), 8.53 (s, lH, imidazole-2H) ppm.
MS (EI) : mlz 302 (M+, 38%), 269 (M+-HS, 3%),195 (M+-C7H7NH2, 11%), 137
([ImCsHlO]-l:, 30%),123 ([ImC4Hg]+, 14%), 109 ([ImC3Hó]+, 11%),106 ([C7H7NH]+,
32%),95 ([ImC2H4]+, 74%), 91 ([C7H7]+, 100%),81 ([ImCH2]+'56%).
High resolution mass : mlz 302.1560; calcd. for C16H22N4S : 302.1565.
Anal. (ClóH22N4S·C2H204)
Calcd.
: 54.89 %C, 6.12 %H, 14.20 %N;
: 55.09 %C, 6.16 %H, 14.27 %N.
N-(2-Phenylethyi)-N' -[5-(4(5)-imidazolyl)pentyljthiourea oxalate (VUF 4620)
(3.5h)
Melting point 118.5-119.5 °C. Yield 5%.
lH NMR (D20): Ö 1.14-1.78 (m, 6H, (CH2(CfuhCH2), 2.72 « 2H, J = 7 Hz, imida-
zole-Cfu), 2.88 (t, 2H, J = 7 Hz, CH.2-phenyl), 3.32 (m, 2H, CH.2NH), 3.67 (m, 2H,
CfuCH2-phenyl), 7.17 (s, lH, imidazole-5(4)H), 7.32 (m, 5H, phenyl-H), 8.52 (s, lH,
imidazole-2H) ppm.
MS (EI) : mlz 316 (M+, 33%), 283 (M+-HS, 3%), 196 (M+-CgH9NH, 22%), 137
([ImCSHlO]+, 50%), 123 ([ImC4Hg]+, 23%), 109 ([ImC3H6]+, 15%), 105 ([CgH9]+,
41%),95 ([ImC2H4]+, 61%),91 ([C7H7]+, 94%),82 ([ImCH3]+,100%).
High resolution mass : mlz 316.1716; calcd. for C17H24N4S : 316.1722.
Anal. (C17H24N4S·C2H204)
Calcd.
: 56.32 %C, 6.55 %H, 13.94 %N;
: 56.14 %C, 6.45 %H, 13.78 %N.
N-(4-Chloro-benzyl)-N' -[5-(4(5)-imidazolyl)pentyljthiourea oxalate (VUF 4742)
(3.5i)
Melting point 139.1-139.9 °C. Yield 43%.
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inNMR (DMSO-d6) : Ö1.29 (m, 2H, (CHzCHzhCfu), 1.56 (m, 4H, (CHzCHzhCHz),
2.68 (t, 2H,,J =8 Hz, imidazole-CHz), 3.37 (m, 2H, CHzNH), 4.63 (m, 2H, CH.2-
phenyl), 7.17 (s, 1H, imidazole-5(4)H), 7.29 (d, 2H, 2,6-phenyl-H), 7.49 (d, 2H, 3,5-
phenyl-H), 7.68 (m, 1H, NH-CHz), 7.98 (m, 1H, NH-benzyl), 8.53 (s, 1H, imidazole-2H)
ppm.
MS (EI): mfz 336 (M+-2, 0.07%), 127 ([C7~CI37]+, 32%), 125 ([C7~Cl3S]+, 100%).
High resolution mass : mfz 336.1177; calcd. for Cl~ZlN4SCl : 336.1176.
Anal. (C16HzIN4SCl·CzHz04) : 50.70 %C, 5.48 %H, 13.19 %N;
Calcd. : 50.64 %C, 5.43 %H, 13.12 %N.
N-Methyl-N' -[6-(4(5)-imidazolyl)hexyljthiourea oxalate (VUF 4740) (3.6a)
Melting point 106.5-110.0 °C. Yield 18%.
1H NMR (OzO ) : Ö1.20-1.78 (m, 8H, CHZ(Cl!z)4CHZ), 2.72 (t, 2H, J = 7Hz, imidazole-
Cl!z), 2.90 (s, 3H, Cfu-N), 3.18-3.58 (m, 2H, Cl!zNH), 7.18 (s, 1H, imidazole-4(5)H),
8.53 (s, 1H, imidazole- 2H) ppm.
MS (EI) : mfz 240 (M+, 44%), 210 (M+-CH4N, 7%), 151 ([ImC6H12]+, 56%), 137
([ImCsHlO]+, 38%), 123 ([ImC4Hg]+, 12%), 109 ([ImC3H6]+, 19%),95 ([ImCzH4]+,
100%),82 ([ImCH3]+,78%), 81 «(Im-CHz]+, 78%), 45 ([CZH7N]+, 45%).
High resolution mass : mfz 240.1411; calcd. for CllHzoN4S : 240.1409.
Anal. (Cl1HZON4S·CzHz04)
Calcd.
: 46.98 %C, 6.66 %H, 16.87 %N;
: 47.26 %C, 6.71 %H, 16.96 %N.
N-Phenyl-N' -[6-(4(5)-imidazolyl)hexyljthiourea oxalate (VUF 4741) (3.6f)
Melting point 126.7-130.2 °C. Yield 8%.
lH NMR (OzO): Ö1.22-1.79 (m, 8H, im-CHZ(Cl!z)4CHz), 2.70 (t, 2H, J = 7 Hz, imida-
zole-CH.2), 3.34-3.59 (m, 2H, CH.2NH), 7.09-7.52 (m, 6H, phenyl-H + imidazole-
4(5)H), 8.50 (s, lH, imidazole-2H) ppm.
MS (EI): mfz 302 (M+, 1%), 151 ([ImC6H12]+, 36%),137 ([ImCSHlO]+, 15%), 123
([ImC4Hg]+, 7%), 109 ([ImC3~]+, 16%),95 ([ImCzH4]+, 100%),82 ([ImCH3]+, 84%),
81 «(Im-CHz]+, 72%), 77 ([C6Hs]+, 2%), 45 ([CZH7N]+, 1%).
High resolution mass : mfz 302.1562; calcd. for C16HZZN4S : 302.1565.
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Anal. (CI6H22N4S·C2H204)
Calcd.
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: 55.01 %C, 6.00 %H, 14.42 %N;
: 55.09 %C, 6.16 %H, 14.28 %N.
The histamine H3 activity was determined on an in vitro assay, using a guinea pig
jejunum preparation, according to literature procedures.P Each compound was
tested on tissue preparations of at least four different animals in triplicate. The
potency of the antagonists was expressed by its pA2 value, calculated from the
Schild regression analysis, and at least three different concentrations were used.
Statistical analysis was carried out with the Students' t-test and p < 0.05 was
considered statistically significant. The Schild slopes were not significantly different
from unity.
The affinity of the described compounds for the Hl receptor was determined in at
least three independent experiments, performed in triplicate, by the displacement of
[3H]mepyrarnine, bound to membranes of CHO cells expressing guinea pig Hl recep-
tors. 122
The affinity of the described compounds for the H2 receptor was established in at
least three independent experiments, performed in triplicate, by the displacement of
[l25I]iodoaminopotentidine, bound to membranes of CHO cells expressing human H2
receptors.123
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Chapter 9
The Effects of Analogues of Immepip and
Thioperamide on the Histamine H3 Receptor
Roeland C. Vollinga, Franciscus G.J. Custers, Erika W. van Tilburg, Wiro
M.P.B. Menge and Hendrik Timmerman.
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Introduetion
Analogues of Immepip and Thioperamide
The H2 agonist impromidine and the H2 antagonist burimamide were among the first,
antagonists with reasonable potency, found for the histamine H3 receptor; lack of
selectivity made them less attractive as pharmacological tools for this receptor.l Not
long after the discovery of the histamine H3 receptor, its existence was confmned by
the development of the H3 selective agonist (R)-a-methylhistamine and the H3
selective antagonist thioperamide (1).6
rPl~D
HN~N
1, thioperamide
The potent and selective H3 antagonist thioperamide (1) was developed from a series
of rigid analogues of histamine. This compound comprises several distinct structural
features, also present in the structure of burimamide, such as an alkyl substituted
thiourea group linked through an alkyl chain to the 4(5)-position of an imidazole
ring. The cyclohexyl group in the structure of thioperamide (1) appears to be
favoured for a high H3 affinity (see Chapter 2; Table 20).48
Further modifications on the structure of thioperamide (1), like substitutions on the
imidazole ring, only resulted in loss of activity,58,60 although a methyl group on the
5-position of the imidazole only impairs a small decrease of the antagonistic activity
(pA2 value is 8.4, compared to 9.0 for thioperamide (guinea pig ileum); see Chapter
2; Table 21).58
The substituted thiourea function of thioperamide appears to be very important for a
high affinity, because replacement of this moiety by an amino group leads to the
weak antagonist 2, with a pA2 value of 5.7 (rat cortex; see Chapter 2; Table 15).26
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Recently, we reported another rigid analogue of histamine; immepip (3a). This
compound also contains a piperidine ring, just as in the structure of, thioperamide (1)
and 2. The only difference in structure, compared to the weak H3 antagonist 2 is the
introduetion of a methylene spaeer between the imidazole ring and the piperidine
ring. Yet immepip is a potent and selective histamine H3 agonist, with a pD2 value of
8.0 (guinea pig jejunum; see Chapter 6).42
~H
HNvN
38, immepip
Apparently a basic amino function is important for activation of the receptor, but the
position of the amino group relative to the imidazole ring is very critical.
In order to obtain more information about the optimallocation and orientation of the
amino group, relative to the imidazole ring, we have prepared a series of analogues
of immepip (3a). In this series the position of the amino group on the piperidine ring
of immepip (3a) has been altered (compound 3b and 3e).
Moreover the piperidine ring was replaced by the smaller pyrrolidine ring. leading to
compounds 20 and 23. The amino group in these compounds is separated from the
imidazole ring by a butylene spacer, as in immepip (3a), or by a propylene chain, as
in 2, depending on the spatial orientation of the group.
In addition we prepared a few, more rigid analogues of thioperamide (1), by the
replacement of the piperidine ring with a 1,2,3,6-tetrahydropyridine ring.
For the synthesis of the compounds with a six-membered ring, a synthesis route was
developed, based on the direct coupling of a suitable electrophile to a 1,2-dipro-
tected imidazole. In addition, this route proved to be an elegant, inexpensive new
method for the synthesis of thioperamide, on a preparative scale.
The pyrrolidine derivatives were prepared by the addition of a metallated 1-
protected-2-pyrrolidinone to a l-protected-imidazol-4-ylcarboxaldehyde.
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Chemistry
Thioperamide analogues
I \a
-_11 N~N-S02N(CH3h
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1, thioperamide
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10a, VUF 4737
10b, VUF 4738
10c, VUF 4739
a; R= methyl
b; R =cyclohexyl
c; R =phenyl
Scherne 1. Reagents used: (a) N,N-Dimethylsulfamoyl chloride, Et3N, toluene; (b) n-
BuLi, THF, -70°C; (c) trimethylsilyl chloride; (d) n-BuLi, THF, -70°C; (e)
l-benzyl-4-piperidone; (f) Pd/C, HCOzNH4, methanol, reflux; (g) 30%
HBr, reflux; (h) Na, ethanol, reflux; (i) R-NCS; (j) Pd/C, 20 atm Hz,
methanol; (k) cyclohexylisothiocyanate.
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Thioperamide (1) and a few, more rigid analogues (10a-c) were prepared by the
addition of l-benzyl-4-piperidone to lithiated 1,2-diprotected imidazole 6 (see
scheme 1). The N,N-dimethylsulfamoyl group was used for the proteetion of the 1-
position of the imidazole ring (see Chapter 5). For the proteetion of the 2-position
the trimethylsilyl group was used. The tert-butyldimethylsilyl group can be used
effectively as well, but is more expensive. The trimethylsilyl group is hydrolyzed
during the aqueous workup.
The benzyl group of the resulting alcohol 7 was effectively removed by a catalytic
transfer hydrogenation, using ammonium formate as hydrogen donor with palladium
as catalyst,132,133
Dehydration and deprotection of 8 to the 1,2,3,6-tetrahydropyi-idine derivative 9
(YUF 4736) was easily achieved by acidic hydrolysis.
The rigid thioperamide analogues 10a-c were prepared, starting from this compound
9, by the addition of the corresponding isothiocyanates (see Chapter 8).
Reduction of the double bond of YUF 4736 (9) by hydrogenation with palladium as
catalyst, led to YUF 4735 (2) (overall yield, 50%).
Thioperamide (1) can be prepared from the reaction of VUF 4735 (2) with cyclo-
hexylisothiocyanate.
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Immepip analogues
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Scheme 2. Reagents used: (a) n-BuLi, THF, -70°C; (b) trimethylsilyl chloride; (c) n-
BuLi, THF, -70°C; (d) pyridinecarboxaldehyde; (e) Et3N, DMAP, acetic
anhydride, DCM; (f) Et3N, Pd/C,50 atm H2, EtOH; (g) 30% HBr, reflux;
(h) Pd/C, 50 atm H2, 50% EtOH.
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The analogues of immepip (3b,c) were prepared as shown in scheme 2. This route is
based on the method described for the synthesis of immepip (3a) (see Chapter 6).42
The lithiated 1,2-diprotected imidazole 6 was treated with the corresponding
pyridinecarboxaldehyde, The trimethylsilyl group hydrolyzed during workup.
The alcohol 11 was treated with acetic anhydride under basic conditions and the
acetate group of the resulting compound 12 was removed by hydrogenation.
Hydrolysis of this compound under acidic conditions led to the deprotected deriva-
tive 14, which was subsequently hydrogenated, using palladium as catalyst, to 3a-c.
The main difference with the method described for the synthesis of immepip (3a), as
described in Chapter 6 is the selective removal of the acetate group by hydrogeno-
lysis under basic conditions. For the synthesis of immepip (3a) as described in
Chapter 6, this was achieved by hydrogenolysis under acidic conditions, which
resulted in the reduction of the pyridine ring as weIl. The selective hydrogenolysis
under basic conditions made it possible to isolate the unprotected pyridine deriva-
tives 14a-c.
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Scheme 3. Reagents used: (a) n-BuLi, THF, -70°C; (b) trimethylsilyl chloride; (c) n-
HuLi, THF, -70°C; (d) CICOzEt; (e) acidic workup; (f) DIBAL-H, toluene,
-60°C; (g) l-benzyl-3-lithio-2-pyrrolidinone, THF, -60°C; (h) LiAIH4,
THF, reflux; (i) Pd/C, HCOzNH4, methanol, reflux; (j) POCI3' pyridine,
reflux; (k) PdlC, 15 atm Hz, EtOH; (1) Pd(OH)z, 35 atm Hz, MeOH.
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The key step in the synthesis of the pyrrolidine derivatives 20 and 23 was the
successful coupling of l-benzyl-3-lithio-pyrrolidinone with l-protected-imidazol-4-
ylcarboxaldehyde 17.
A few methods have been described in literature for the synthesis of imidazole
derivatives with a carboxaldehyde function on the 4- or 5 position, starting from
imidazole.93,IOO,103,104,134 In these procedures a lithiated imidazole derivative,
prepared either by halogen-metal exchange l03,104,134 or by direct lithiation,93,IOO
was quenched with DMF.*
Our attempts to quench a 1,2-diprotected 5-lithiated imidazole 6 with DMF were
successful on a small scale (1-10 mmol). However, low yields and difficult workup
procedures were encountered during large scale reactions, which prompted us to
search for a preparative alternative.
Quenching of 6 with chloro ethylformate and subsequent workup led to compound
16 with the ethyl carboxylate function on the 4-position. This thermodynamically
more stable 4-ester derivative 16 was found to be the result of a rearrangement of 15
under the acidic workup conditions. Under neutral to basic workup conditions, the
5-ester derivative 15 was isolated. The 4-ester derivative 16 was used for further
reactions, because the ester function could be readily reduced to the aldehyde using
diisobutylaluminum hydride (DmAL-H) at low temperatures. The reduction of the
isomerie 5-ester derivative proved to be difficult (low yield and more side products)
probably due to steric hindrance of the N,N-dimethylsulfamoyl group.
The addition of aldehyde 17 to l-benzyl-3-lithio-2-pyrrolidinone resulted in alcohol
18, from which both the pyrrolidine derivatives 20 and 23 were prepared.
The reduction of the amide of 18 by LiAIH4and subsequent basic workup, led to the
removal of the N,N-dimethylsulfamoyl group as well. Reduction of the amide func-
tion using BH30THF or NaBH4in CF3COzH failed.
The hydroxymethyl pyrrolidine derivative of immepip 20, was obtained by debenzy-
lation of 19 by a catalytic transfer hydrogenation, using ammonium formate as
hydrogen donor and palladium as catalyst,13Z,133
The hydroxyl group of 18 was removed by dehydration with POCl3 in pyridine
followed by subsequent hydrogenation of the alkene intermediate, to give
compound 21. The amide function of 21 was reduced successfully, using LiAIH4 as
described above. Debenzylation of 22 by catalytic transfer hydrogenation was
unsuccessful. Hydrogenation with Pd(OHb as catalyst, under 35 atm Hz, resulted in
a clean formation of pyrrolidine analogue 23.
*The reported formation by Winter et al.lOG of a l,2-diprotected-4-carboxaldehyde imidazole
derivative from a 1,2-diprotected-5-lithio imidazole by quenching with DMF, seems to be
based on a wrong structure assignment. If indeed the 4-carboxaldehyde derivative was
isolated, a rearrangement must have taken place, perhaps during work-up.
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Table 1. H3 activity of the described analogues of thioperamide, as determined on
guinea pig jejunum.
Schild
No. Compound Structure R pAz value -slope Ni
2 VUF4735 rP'R H 6.2 0.8 4
HN~N
1 thioper- J-ND 8.9 1.0 4amide
H
9 VUF4736 p'R H 5.4 0.9 4
HN~N
S
10a VUF4737
,)lN/CH3 5.4 0.7 3
H
lOb VUF4738 J-ND 6.3 0.9 5
H
lOc VUF4739 s~ 5.6 0.9 4
,)lN
H
a Number of different animals used.
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The H3 activity of the compounds was determined on an in vitro test system, on the
basis of the concentration dependent inhibitory effect of histamine H3 agonists on
the electrically evoked contractile response of isolated guinea pig jejunum segments
(see Chapter 3).15
Results and Discussion
All the compounds have been tested for H3agonism and H3 antagonism.
The analogues of thioperamide (1) all displayed full reversible antagonism on the
histamine H3receptor, as determined on guinea pig jejunum (see table I).
Further redu:ction of the conformational flexibility of VUF 4735 (2) by the introduc-
tion of a double bond, is clearly not favourable. The piperidine derivative YUF 4735
(2) is almost ten times more potent as an H3 antagonist than its more rigid 1,2,3,6-
tetrahydropyridine analogue VUF 4736 (9).
The extraordinary increase of antagonistic activity when the amino group of YUF
4735 (2) is replaced by a N-cyclohexyl thiourea moiety, leading to thioperamide (1),
is not observed with the tetrahydropyridine analogues. This must be the result of the
reduced conformational flexibility as well; apparently the thiourea function can not
assume the same orientation, relatively to the imidazole ring as in thioperamide.
Nevertheless, although not as extreme as going from VUF 4735 (2) to thioperamide,
an increase of affinity is observed going from VUF 4736 to the N-cyclohexyl
thiourea derivative YUF 4738 (lOb). This compound is almost ten times more potent
than its precursor. Furthermore, YUF 4738 (lOb) is more potent than its methyl- or
phenyl analogue. This favourable behaviour of the cyclohexyl group was observed
for thioperamide (1) as well (see Chapter 2). Apparently this part of the ligand binds
to a hydrophobic site of the receptor; a 1t-1t interaction is not likely.
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Table 2. H3 activity of the described analogues of immepip, as determined on
guinea pig jejunum.
No. Compound Structure H3 activity
3a immepip ~H pD2 = 8.0 ±0.1 8
HNvN
3b YUF 4858b r=rQ pA2 = 6.5 ±0.2c 2
HNvN H
3e YUF 4888b r==N pA2< 5.0c 2
HNvN H
OH
20 YUF 4863b pD2 = 5.5 ±0.2 (ex = 0.6 ±0.2) 2FffiH
HN~N
23 YUF4864b ~NHHNvN Li
pD2 =7.3 ± 0.1 (ex =0.8 ± 0.1) 2
a Number of different animals used.
b Unresolved mixture of enantiomers.
c No agonistic activity was observed.
The H3 activities of the analogues of immepip (3a) were determined on the guinea
pig jejunum and are represented in table 2.
Replacement of the 4-piperidine ring of immepip by a 3-piperidine ring is c1early
disastrous for H3activity, since YUF 4858 (3b) does not display any agonistic activi-
ty and is a weak H3 antagonist. This suggests that the amino group of YUF 4858
(3b) can not be positioned as optimal as the amino group of immepip (3a), relatively
to the imidazole ring, verifying the strict structural requirements for an H3 agonist.
This information can be very useful for further SAR and molecular modelling studies,
since certain low energy conformations of several potent H3 agonist (e.g. histamine
derivatives and immepip) matching those ofVUF 4858, can be exc1uded now.
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The 2-piperidine derivative of immepip, VUF 4888 (3e), which can be regarded as a
rigid analogue of histamine, has a negligible affinity for the H3 receptor. This is less
surprising, because substitution of the amino group of histamine is only allowed
with small alkyl groups, e.g. Na-propylhistamine has also been described to be
inactive (see chapter 2; table 6). This verifies the difference between immepip and
e.g, histamine as an H3 agonist and indicates that immepip can not be regarded as an
analogue of histamine.
The replacement of the 4-piperidine ring of immepip (3a) by a 3-pyrrolidine ring
however is allowed and YUF 4864 (23) proved to be a rather good H3 agonist with
a pDz value of 7.3 and an intrinsic activity of about 0.8. This compound has also
been reported in a patent application,31 to displace [3H] Na-methylhistamine on
guinea pig brain tissue, with a pKi value of 7.0 (see Chapter 2; table 11). YUF 4864
can be fitted on the potent H3 agonist immepip (3a), as weIl as on the weak H3
antagonist YUF 4858 (3b). Apparently YUF 4864 (23) can obtain a comparabie
conformation as immepip (3a) and activate the H3 receptor. For this reason, also YUF
4864 (23) is very useful as a tooI for SAR and molecular modelling studies, but has
to be resolved first.
Experimental Section
lH NMR and BC NMR spectra were recorded on a Bruker AC-200 (200 MHz)
spectrometer with tetramethylsilane or sodium 3-(trimethylsilyl)-propionate as an
internal standard. Mass spectra were recorded on a Finnigan MAT-90. Melting
points were measured on a Mettler FP-5 + FP-52 apparatus and are uncorrected.
THF was distilled from LiAl14. n-Butyllithium was purchased from Janssen Chimica
as a 15% solution in hexane.
1-(N,N-Dimethylsulfamoyl)imidazole 5 was synthesized by the method described by
Chadwick and Ngochindo.?'' with the exception that toluene was used as a solvent
instead of benzene.
The synthesis of immepip (3a) is described in Chapter 6.
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l-Benzyl-ë-]1-(N,N-dimethylsuljamoyl)imidazol-5-yl]-4-hydroxypiperidine (7)
10.0 g (57 mmol) l-(N,N-Dimethylsulfamoyl)imidazole (5) was dissolved in 200 mi
dry THF under an atmosphere of dry nitrogen and cooled to -70°C. n-Butyllithium
in hexane ( 35 mi, 57 mmol) was added dropwise (temperature should not exceed
-65°C). After 15 min, a solution of trimethylsilyl chloride (6.2 g, 57 mmol) in 50 mi
dry THF was added and the solution was stirred at room temperature for 1 h. The
mixture was cooled to -70°C again and n-butyllithium in hexane (35 mi, 57 mmol)
was added dropwise (temperature should not exceed -65°C). After 1 h, a solution of
N-benzyl-4-piperidone (10.8 g, 5.7 mmol) in dry THF was added gradually and the
mixture was allowed to (slowly) warm to room temperature overnight. The reaction
mixture was poured into 500 mi water and the THF was removed under reduced
pressure. The product was extracted with dichloromethane (3 x 250 mi), dried on
Na2S04 and concentrated in vacuo. The residue (25.0 g) was purified by column
chromatography with a mixture of ethyl acetate and petroleum ether (60/80) (ratio =
111)as eluent. 18.0g (87%) Light-yellow crystals (Rj = 0.1) where isolated.
rnNMR (CDCI3) : Ö2.72-3.51 (m, 8H, Pip-H), 2.97(s, 6H, NCH3), 4.37 (s, 1H, OH),
4.42 (s, 2H, CHÛ; 7.28 (s, 1H, Im-4H), 7.38-7.60 (m, 5H, Phen-H), 8.68 (s, 1H, Im-2H)
ppm.
4-[1-(N,N-Dimethylsuljamoyl)imidazol-5-yl]-4-hydroxypiperidine (8)
1.0 g (2.7 mmol) 7 was dissolved in 25 mi methanol. 0.1 gram 10% Pd/C and 1.0 g
(15.9 mmol) ammoniumformate was added. The mixture was refluxed for 1 h. After
filtration over a short celite column, the solution was concentrated in vacua and 0.7
g (93%) of a white solid was isolated.
lH NMR (CDCI3) : Ö1.80-1.98 (m, 2H, Pip-3,5-Hax), 2.03-2.19 (m, 2H, Pip-3,5-Heq),
2.81-2.88 (m, 2H, Pip-2,6-Hax), 2.97 (s, 6H, NCH3), 2.94-3.16 (m, 3H, Pip-2,6-Heq +
OH), 6.92 (s, 1H, Im-4H), 7.70 (s, 1H, Im-2H) ppm.
4-(Iriûdazol-4(5)-yl)-1,2,3,6-tetrahydropyridine dihydrobromide (VUF 4736) (9)
2.5 g (9 mmol) 8 was dissolved in 30% HBr (50 mi) and refluxed for 16 h. The HBr-
solution was removed under pressure and the residue was refluxed for 2 h in 50 mi
absolute ethanol. A white precipitate was collected by centrifugation and dried. The
supernatant was concentrated in vacua and the residue was washed with acetone
(3 x 50 mi). The remaining light beige solid and the white precipitate were combined
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and recrystallized from methanol/ethanol. 2.1 g (74%; 60% overall) White crystals
where collected. Melting point: 271-275 oe.
lH NMR (D20) : Ö2.77 (m, 2H, THP-3H), 3.52 (t, 2H, J 6.7 Hz, THP-2H), 3.90 (s, 2H,
THP-6H), 6.36 (m, 1H,THP-5H), 7.52 (s, 1H, Im-4(5)H),8.74 (s, 1H, Im-2H) ppm.
l3C NMR (D20) : Ö23.5, 41.8, 43.2, 116.9, 119.8, 124.6, 133.2, 135.7 ppm.
MS (EI) : mie 149 (M+, 100%), 148 (M+-H, 68%),120 (M+-CH3N, 24%),119 (M+-
CI:4N, 43%), 94 ([CSH6N2]+, 22%),80 ([CsH6N]+, 48%),67 ([C3H3N2]+, 10%).
N -Methyl-N' -{4-(imidazol-4(5)-yl)-1,2,3,6-tetrahydropyridyllthiourea oxalate
(VUF 4737) (10a)
0.7 g (2.2 mmol) YUF 4736 (9), was added to 2 equivalent sodium ethanolate in 50
mI absolute ethanol. This solution was refluxed for 1 h and cooled to room tempera-
ture. The formed precipitate was removed by filtration and 1.0 g (13.7 mmol)
methylisothiocyanate was added to the filtrate. The ethanol was removed under
reduced pressure, after stirring overnight. The residue was purified by column-
chromatography by washing with a mixture of ethyl acetate and petroleum ether
(60/80) (ratio = 111) (isothiocyanate eluted Rf = 1.0). The product was subsequently
eluted with methanol as eluent. The methanol was removed under reduced pressure
and the free base was dissolved in ethyl acetate/iso-propanol. A saturated oxalic
acid solution in ethyl acetate was added dropwise to the free base solution, under
vigorous stirring, until pH<3. A white precipitate formed, which was collected by
centrifugation, washed with ethyl acetate (three times) and recrystallized from abso-
lute ethanol/ethyl acetate. Yield 0.7 g (83%). Melting point 148-151 oe.
lH NMR (D20) : Ö2.58 (m, 2H, THP-3H), 3.01 (s, 3H, CH3),4.00 (t, 2H, J 6.7 Hz, THP-
2H), 4.29 (s,.2H, THP-6H), 6.27 (s, 1H, THP-5H), 7.42 (s, 1H, Im-4(5)H), 8.61 (s, 1H,
Im-2H)ppm.
BC NMR (D20) : Ö 26.7, 33.7, 45.7, 48.2, 116.0, 123.4, 125.0, 134.1, 135.3, 181.0
ppm.
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N -Cyclohexyl-N' -{4-(imidazol-4(5)-yl)-1,2,3,6-tetrahydropyridyl}thiourea oxalate
(VUF 4738) (lOb)
The same procedure and amounts were used as described for the synthesis of YUF
4737 (lOa), but this time 1.0 g (7.0 mmol) cyclohexylisothiocyanate was added.
Yield 0.6 g (70%). Melting point 121-123.5°C.
lH NMR (D20) : 0 1.01-1.40 (m, 6H, cyclohexyl-3,4,5-H), 1.51-1.94 (m, 5H, cyclo-
hexyl-l,2,6-H), 2.51 (m, 2H, THP-3H), 4.03 (t, 2H, J 6.7 Hz, THP-2H), 4.37 (s, 2H,
THP-6H), 6.25 (s, lH, THP-5H),7.43 (s, lH, Im-4(5)H), 8.61 (s, lH, Im-2H) ppm.
N-Phenyl-N' -{4-(imidazol-4(5)-yl)-l,2,3,6-tetrahydropyridyl}thiourea oxalate
(VUF 4739) (lOc)
The same procedure and amounts were used as described for the synthesis of YUF
4737 (lOa), but this time 1.0 g (7.4 mmol) phenylisothiocyanate was added. Yield
0.7 g (83%). Melting point 115-118°C.
lH NMR (020) : 02.60 (m, 2H, THP-3H), 4.14 (t, 2H, J 6.7 Hz,THP-2H), 4.51 (s, 2H,
THP-6H), 6.32 (s, lH, THP-5H), 7.13-7.48 (m, 6H, Phen-H + Im-4(5)H), 8.66 (s, lH,
Im-2H)ppm.
4-(Imidazol-4(5)-yl)piperidine dihydrobromide (VUF 4735) (2)
1.0 g (3.2 mmol) YUF 4736 (9) was dissolved in 75 mI methanol. 0.1 g 10% Pd/C
was added and stirred for 16 hunder 20 atm hydrogen pressure in an autoclave. The
reaction mixture was filtrated over a short celite column, concentrated in vacuo and
washed with absolute ethanol. 1.0 g (100%; 60% overall) White crystals where
isolated. Melting point: 275-278 °C.
inNMR (D20 ) : 02,03 (m, 2H, Pip-3,5-Hax), 2.39 (dm, 2H, J 13 Hz, Pip-3,5-Heq),
3.29 (m, 3H, Pip-2,6-Hax + Pip-4Hax), 3.63 (dm, 2H, J 13 Hz, Pip-2,6-Heq), 7.48 (s,
lH, Im-4(5)H), 8.77 (s, lH, Im-2H)ppm.
BC NMR (020) : 028.8,31.3,45.0, 116.4, 135.0, 137.0 ppm.
MS (EI) : m/z 151 (M+, 20%), 123 (M+-CHzN, 9%), 95 (M+-CZH4NZ, 100%), 82
([CsHgN]+, 23%), 67 ([C3H3N2]+, 5%), 28 «(CHzN]+, 10%).
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N -Cyclohexyl-N' -[4-(imidazol-4(5)-ylï-piperidyljthiourea maleate (thioperamide)
(1)
The same procedure and amounts were used as described for the synthesis of YUF
4737 (10a), but this time 3 equiv cyclohexylisothiocyanate was added to YUF 4735
(2). Instead of oxalic acid, maleic acid in 2-propanol was added. Yield 60%. Melting
point 115.6 °C.
lH NMR (DMSO-c!<»: Ö1.01-2.00 (m, 14H, cyclohex-CHz + Pip-3,5-H), 2.88-3.13 (m,
3H, Pip-2,6-Hax + Pip-4Hax), 4.19 (bs, lH, cyclohex-CH), 4.73 (dm, 2H, J 13 Hz, Pip-
2,6-Heq), 6.06 (s, maleic acid), 7.28 (d, lH, J 7.7 Hz, NH), 7.42 (s, lH, Im-4(5)H), 8.38
(s, lH, Im-2H) ppm
3-[1-(N,N-Dimethylsulfamoyl)imidazol-5-ylhydroxymethyljpyridine (11b)
25.4 g (145 mmol) 1-(N,N-Dimethylsulfamoyl)imidazole (5) was dissolved in 400 mI
dry THF under an atmosphere of dry nitrogen and cooled to -70°C. n-Butyllithium
in hexane (100 mI, 0.16 mmol) was added dropwise (temperature should not exceed
-65°C). Trimethylsilyl chloride (20.3 mI, 0.16 mol) was added after 15 min and the
solution was subsequently stirred at room temperature for 1 h. The mixture was
cooled to -70°C again and n-butyllithium in hexane (95 mI, 0.15 mol) was added
dropwise (temperature should not exceed -65°C). After 1 h, 15.0 mI 3-pyridinecar-
boxaldehyde (0.16 mol) was added gradually and the mixture was allowed to
(slowly) warm to room temperature ovemight.
The solution was poured into 100 mI water and the THF was removed under
reduced pressure. 400 mllM HCl was added and the water layer was extracted with
ether (3 x 150 ml), After neutralization of the solution by addition of K2C03, the
product was extracted with ethyl acetate (5 x 100 mI). The ethyl acetate layers were
combined. dried on Na2S04and concentrated in vacuo. The residue (37.0 g) was
purified by recrystallization from ethyl acetate, resulting in 22.0 g (54%) white crys-
tals.
lH NMR (CDCI3) : Ö2.89 (s, 6H, NCH3),4.90 (br s, lH, OH), 6.10 (s, lH, CH), 6.53 (s,
lH, Im-4H), 7.25 (dd, lH, Pyr-5H), 7.76 (dt, lH, Pyr-4H), 7.86 (s, lH, Im-2H), 8.47 (dd,
lH, Pyr-6H); 8.53 (d, lH, Pyr-2H) ppm.
BC NMR (CDCh) : Ö 38.0, 64.5, 123.4, 130.6, 134.4, 134.5, 136.4, 139.1, 147.9,
149.0 ppm.
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3-[1-(N,N-Dimethylsulfamoyl)imidazol-5-ylacetoxymethyl]pyridine (Ub)
18.8 g (67 mmol) Of the alcohol llb was dissolved in a solution of 0.85 g (7 mmol)
4-dimethylaminopyridine (DMAP) and 20.0 ml (144 mmol) triethylamine in 400 ml
dichloromethane. After cooling the solution on an ice-bath, 9.5 ml (100 mmol) acetic
anhydride was added dropwise and the reaction mixture was stirred for 90 min at
room temperature. The mixture was subsequently washed with H20 (3 x 100 ml),
dried on NaiC03 and concentrated in vacuo, resulting in 21.6 g (100%) of a yellow
oil, which was used further without purification.
lH NMR (CDCI3) : Ö 2.06 (s, 3H, CH3CO), 2.87 (s, 6H, NCH3), 6.90 (s, lH, Im-4H),
7.05 ( s, lH, CH), 7.23 (dd, lH, Pyr-5H), 7.63 (dt, lH, Pyr-4H), 7.86 (s, lH, Im-2H),
8.54 (dd, lH, Pyr-6H), 8.60 (d, lH, Pyr-2H)ppm.
13C NMR (CDCI3): Ö20.7,37.9,66.8,123.3,130.1,131.1,133.0,135.0,139.0,148.8,
149.8, 169.3 ppm.
3-[1-(N,N-Dimethylsulfamoyl)imidazol-5-ylmethyl]pyridine (13b)
26.9 g Of the acetate 12b was dissolved in 100 ml ethanol and 10 ml triethylamine.
2.6 g 5% Pd/C Was added and this mixture was stirred under hydrogen pressure (50
atm) for 24 h in an autoclave. The catalyst was removed by filtration over a short
celite column and the solvents were removed under reduced pressure. The pale
brown residing oil was dissolved in 200 ml dichloromethane, washed with 100 ml
lM KZC03-solution, dried on NazS04 and concentrated in vacuo. The resulting light
brown oil (20.5 g, 94%) was purified by column chromatography using a mixture of
ethyl acetate and methanol (ratio 9/1) as eluent. Yield 16.82 g (76%) of a pale
yellow oil (Rf (MeOH) =0.55).
1H NMR (CDCl3) : ö.2.72 (s, 6H, NCH3), 4.04 (s, 2H, CHz), 6.57 (s, lH, Im-4H), 7.20
(dd, lH, Pyr-5H), 7.48 (dt, lH, Pyr-4H), 7.85 (s, lH, Im-2H), 8.40-8.50 (m, 2H, Pyr-2,6-
H)ppm.
13C NMR (CDCI3) : Ö 28.0, 37.5, 123.2, 129.9, 130.0, 132.7, 136.1, 138.3, 147.9,
149.6 ppm.
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3-(Imidazol-5-ylmethyl)pyridine (14b)
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16.3 g (61 mmol) Of 13b was refluxed in 150 ml30% HBr for 24 h. After removal of
the solvent under reduced pressure, the residue was dissolved in 100 ml absolute
ethanol. This solution was refluxed for 3 h, concentrated in vacuo and the product
was recrystallized from ethanol. Yield 16.2 g (82%) of a grey solid.
lH NMR (DzO) : Ö4.43 (s, 2H, CHz), 7.34 (s, 1H, Im-4(5)H), 8.03 (dd, 1H, Pyr-5H),
8.51 (dt, 1H, Pyr-4H), 8.67 (s, 1H, Im-2H), 8.70-8.80 (m, 2H, Pyr-2,6-H) ppm.
13C NMR (DzO) : Ö28.5,118.9,129.0,130.9,135.6,138.9, 141.7, 142.4, 148.8 ppm.
3-(Imidazol-4(5)-ylmethyl)piperidine (VUF 4858) (3b)
1.0 g 10% Pd/C was added to a solution of 10.0 g (31 mmol) 14b in 50% ethanol and
this suspension was stirred for 48 hunder hydrogen-pressure (50 atm) in an auto-
clave. After filtration over a short celite column, the solution was concentrated in
vacuo. The crude product was recrystallized from methanol, resulting in 9.23 g
(90%) of a white solid.
in NMR (DzO): Ö 1.15-1.40 (m, 1H, Pip-5Hax), 1.50-2.00 (m, 3H, Pip-5Heq + Pip-
4H), 2.00-2.25 (m ,lH, Pip-3H), 2.65-3.00 (m, 4H, Pip-2,6-Hax + Im-CHz), 3.30-3.55
(m, 2H, Pip-2,6-Heq), 7.28 (s, 1H, Im-4(5)H),8.57 (s, 1H, Im-2H) ppm.
13C NMR (DzO) : Ö23.1,28.9,29.2,34.6,45.6,49.3,118.1,131.6, 134.7 ppm.
2-[I-(N ,N -Dimethylsuljamoyl)imidazol-5-ylhydroxymethyl]pyridine (11c)
The same procedure was used as described for the synthesis of Ub, starting with
1.75 g (l0 mmol) l-(N,N-dimethylsulfamoyl)imidazole (5) and 0.95 ml (l0 mmol) 2~
pyridinecarboxaldehyde. The residue after hydrolysis was purified by recrystalliza-
tion from ethyl acetate. Yield 1.3 g (46%) of white crystals.
in NMR (CDC13) : Ö3.00 (s, 6H, NCH3), 5.15 (d, 1H, OH), 6.10 (s, 1H, CH), 6.45 (s,
1H, Im-4H), 7.20-7.40 (m, 2H, Pyr-3H + Pyr-5H), 7.72 (dt, 1H, Pyr-4H), 7.90 (s, 1H,
Im-2H), 8.60 (m, 1H, Pyr-6H) ppm.
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2-[i-(N,N-Dimethylsulfamoyl)imidazol-5-ylacetoxymethyljpyridine (12e)
The same procedure was used as describedfor the synthesis of 12b. Yield 100% of a
yellow oil, which was used further withoutpurification.
inNMR (CDCI3) : 02.15 (s, 3H, CH3CO), 295 (s, 6H, NCH3), 6.80 (s, 1H, Im-4H),
7.10 (s, 1H, CH), 7.20-7.40 (m, 2H, Pyr-3H + Pyr-5H), 7.72 (dt, 1H, Pyr-4H),7.95 (s,
1H,Im-2H), 8.60(m, 1H,Pyr-6H) ppm.
2-[i-(N,N-Dimethylsulfamoyl)imidazol-5-ylmethyljpyridine (13e)
The same procedure was used as described for the synthesis of 13b. Yield 68%.
lH NMR(CPC!J) : 02.82 (s, 6H, NCH3), 4.30 (s, 2H, CHz), 6.68 (s, 1H,Im-4H),7.05-
7.30(m, 2H,Pyr-3H+Pyr-5H), 7.60(dt, 1H,Pyr-4H), 7.95(s, 1H,Im-2H), 8.55(m, 1H,
Pyr-6H)ppm.
2-(Imidazol-5-ylmethyl)pyridine (14e)
The same procedurewas used as described for the synthesis of 14b. Yield 50%.
inNMR(OzO): 04.51 (s, 2H, CHz), 7.45(s, 1H,Im-4(5)H), 7.85-8.00 (m, 2H,Pyr-3H
+ Pyr-5H), 8.55(dt, 1H,Pyr-4H), 8.67(s, 1H,Im-2H), 8.71 (m, 1H,Pyr-6H) ppm.
2-(Imidazol-4(5)-ylmethyl)piperidine (VUF 4888) (3e)
The same procedure was used as describedfor the synthesis of 3b. Yield 75%.
lH NMR (DzO) : 0 1.40-2.05 (dm, 6H, Pip-3H + Pip-4H+ Pip 5H), 2.90-3.20(m ,3H,
CHz+ Pip-6Hax), 3.30-3.55(m, 2H, Pip-2H+ Pip-6Heq+ Im-CHz), 7.40 (s, 1H, Im-
4(5)H), 8.65(s, 1H,Im-2H) ppm.
13C NMR (DzO): 022.8,23.1,29.3,29.8,46.6,57.0,119.4,128.5,135.5 ppm.
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Ethyl [I-(N ,N-dimethylsulfamoyl)imidazol-4-yl]carboxylate (16)
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27.0 g (0.15 mol) l-(N,N-Dimethylsulfamoyl)imidazole 5 was dissolved in 250 ml dry
THF under an atmosphere of dry nitrogen and cooled to -70°C. n-Butyllithium in
hexane (100 ml, 0.16 mol) was added dropwise (temperature should not exceed
-65°C). After 15 min, a solution of trimethylsilyl chloride (17.1 g, 0.16 mol) in 20 ml
dry THF was added and the solution was stirred at room temperature for 2 h. The
mixture was cooled to -70°C again and n-butyllithium in hexane (100 ml, 0.16 mol)
was added dropwise (temperature should not exceed -65°C). After 1 h, 16.3 g ethyl
chloroformate (0.15 mol) was added and the mixture was allowed to (slowly) warm
to room temperature. The reaction mixture was poured into 250 ml water and the
THF was removed under reduced pressure. The product was extracted with
dichloromethane (3 x 150 ml), dried on Na2S04 and concentrated in vacuo. The
residue was dissolved in 200 ml ether and stirred for 1 h with 200 ml 0.5 M HCI. The
ether layer was separated, dried on Na2S04 and concentrated in vacuo. 34.5 g
(91%) Of a light oil remained.
lH NMR (CDCI3) : Ö1.29 (t, 3H, J 6.7 Hz, CH3),2.79 (s, 6H, NCH3),4.29 (q, 2H, J 6.7
Hz, CH2),7.79 (s, 1H, Im-5H), 7.81 (s, 1H, Im-2H)ppm.
13C NMR (CDCh): Ö14.1, 37.9, 60.9,122.6,134.7,136.7,161.5 ppm.
MS (EI): 247 (M+, 17%),202 (M+-OCH2CH3, 28%), 175 (M+-C02CH2CH3, 44%),
139 (M+-S02NMe2, 4%),108 ([S02NMe2]+, 100%),66 ([Im]+, 1%),44 ([N(CH3h]+,
11%).
Ethyl [I-(N ,N-dimethylsulfamoyl)imidazol-5-yl]carboxylate (15)
15 was prepared employing the same procedure and amounts as for the synthesis of
16. However the workup procedure was different. This time the reaction mixture
was poured into 250 ml 5% NaHC03 solution and this was stirred overnight. The
organic layer was separated and the water layer was additionally extracted with
ether (3 x 75 ml). The combined organic layers were dried on Na2S04 and coneen-
trated in vacuo. The product was purified by column chromatography, using a
mixture of ethyl acetate and petroleum ether (60/80) (ratio 1:1) (Rf =0.2). Yield 30.0
g (78%).
inNMR (CDC13) : Ö1.32 (t, 3H, J 7.3 Hz, CH3),3.00 (s, 6H, NCH3),4.28 (q, 2H, J 6.7
Hz, CH2),7.69 (s, 1H, Im-5H), 8.09 (s, 1H,Im-2H) ppm.
13C NMR (CDCI3) : Ö 13.9,38.3,60.9,123.3,139.0, 143.8, 157.8 ppm.
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MS (EI): 247 (M+, 14%),202 (M+-OCHzCH3, 24%),175 (M+-COzCHzCH3, 40%),
139 (M+-SOzNMez, 4%),108 ([SOzNMez]+, 100%),66 (jlm]", 3%), 44 ([N(CH3)z]+,
12%).
[ i-(N,N-Dimethylsuljamoyl)imidazol-4-yl]carboxaldehyde (17)
16.0 g (65 mmol) 16 Was dissolved in 250 ml dry THF (l50 ml) under an atmosphere
of dry nitrogen and cooled to -60°C. 64.0 ml (78 mmol) diisobutylaluminum hydride
in toluene (DIBAL-H) was added dropwise. The solution was poured in 200 mll M
HCI-solution, after 2 h stirring at -60°C. The solution was treated with KZC03 to pH
- 11 after 0.5 h. The organic layer was separated, dried on NazS04 and concentrated
in vacuo. Recrystallization from iso-propanol resulted in 10.1 g (77%) white crys-
tals. Melting point 105.4-107.0 °C.
lH NMR (CDCI3) : Ö2.86 (s, 6H, NCH3),7.84 (s, lH, hn-5H), 7.91 (s, lH, hn-2H), 9.88
(s, lH, CH) ppm.
BcNMR (CDCl3): Ö38.02,122.24,137.38,141.99,185.43 ppm.
MS (EI): 203 (M+, 23%),108 ([SOzNMez]+, 100%),66 (jlm]", 3%), 44 ([N(CH3)z]+,
23%).
l-Benzyl-B»[i-(N,N-dimethylsuljamoyl)imidazol-4-ylhydroxymethylJ-2-pyrrolidi-
none (18)
1-Benzyl-2-pyrrolidinone (l3.9 g, 87 mmol) was dissolved in dry THF (400 ml)
under an atmosphere of dry nitrogen, and cooled to -65°C. n-Buty1lithium (87
mmol)was added dropwise (temperature should not exceed -60°C). The solution
was stirred at -60°C for 1 hand 11.8 g (58 mmol) (l-(N,N-dimethylsul-
famoyl)imidazol-4-yl)carboxaldehyde (17) in THF (60 ml) was added dropwise.
After 1 h the cooling bath was removed and the reaction mixture was allowed to
warm to 'room temperature. 200 ml 1 M HCI was added and the mixture was stirred
for 1 h. The solution was treated with KZC03 to pH - 11 and the organic layer was
separated. The water layer was extracted with dichloromethane (3 x 80 ml). The
organic layers were combined, dried on NaZS04 and concentrated in vacuo. The
residue was purified by column-chromatography using ethyl acetate (removal of 1-
benzyl-2-pyrrolidinone; Rf =0.2), followed by methanol as eluent. The methanol
was removed under reduced pressure resulting in 16.9 g (77%) of a white solid.
Me1ting point 145.2-148.0 °C.
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lH NMR (CDCIÛ : Ö 1.70-2.08 (m, 2H, Pyrr-4H), 2.73 (s, 6H, NCH3), 3.02-3.17 (m,
3H, Pyrr-3H + Pyrr-5H), 4.35 (dd, 2H, J 10.0 Hz, CHz), 4.80 (d, lH, J 7.3 Hz, CH),
5.26 (d, lH, J 4.7 Hz, OH), 7.06-7.29 (m, 6H, Phen-H + Im-5H), 7.78 (s, lH, Im-2H)
ppm.
13C NMR (CDCh) : Ö 17.97, 37.98, 45.08, 46.46, 47.22, 66.87, 114.51, 127.31-
128.59,135.85,145.57,174.92 ppm.
l-Benzyl-3-(imidazol-4(5)-ylhydroxymethyl)pyrrolidine (19)
LiAIH4 (0.20 g, 5.3 mmol) was added in small portions to a solution of 18 (0.5 g, 1.3
mmol) in THF (60 ml) at O°C under a dry nitrogen atmosphere. The mixture was
refluxed for 48 h and was subsequently cooled to O°Cagain. 0.2 ml HzO and 0.2 ml
4 M NaOH were added. The white/grey precipitate was removed by filtration and
the filtrate was dried and concentrated in vacuo. Yield 0.3 g (88%).
inNMR (CDCh) : Ö1.42-1.93 (m, 2H, Pyrr-4H),2.11-2.88 (m, lH, Pyrr-3H), 2.11-2.88
(m, 4H, Pyrr-2H + Pyrr-5H), 3.56 (s, 2H, CHz),4.68 (d, lH, J 2.7 Hz, CH), 6.72 (s, lH,
Im-5H), 7.01-7.61 (m,5H,Phen-H)7.01-7.61 (m, lH,Im-2H)ppm.
3-(Imidazol-4(5)-ylhydroxymethyl)pyrrolidine dioxalate (VUF 4863) (20)
0.1 g 10% PdlC and 0.7 g (11.1 mmol) ammonium formate were added to a solution
of 0.4 g (l.4 mmol) 19 in 20 ml methanol. The mixture was refluxed for 1 hand
subsequently filtrated through a short celite column. The methanol was removed
under reduced pressure and the residue (0.2 g, 100%) was dissolved in iso-propanol.
This solution was added dropwise to a saturated oxalic acid solution in iso-
propanol. The precipitate was collected by centrifugation and recrystallized from
methanol/ethyl acetate. Melting point 173.1-176.9 °C.
inNMR (OzO) : Ö1.92-2.29 (dm, 2H, Pyrr-4H), 2.82-3.02 (m, lH, Pyrr-3H), 3.02-3.61
(m, 4H, Pyrr-2H + Pyrr-5H), 4.86-5.06 (m, lH, CH), 7.46 (s, lH, Im-5H), 8.69 (s, lH,
Im-2H)ppm.
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i-Benzyl-3-[i-eN,N-dimethylsuljamoyl)imidazol-4-ylmethyl}-2-pyrrolidinone (21)
0.7 ml (7.3 mmol) POCl3 was added slowly to a cooled (O°C) solution of 2.8 g (7.3
mmol) 18 in 60 ml dry pyridine. After stirring at room temperature overnight, the
mixture was additionally refluxed for 4h. 60 ml H20 was added and the product was
extracted with ether (5x50 ml), The organic layers were dried on Na2S04 and
concentrated in vacuo. 1.2 g (46%) Of a light yellow oil was obtained.
lH NMR (CDCI3) : Ö2.82 (s, 6H, NCH3), 3.01-3.14 (m, 2H, Pyrr-4H), 3.32 (t, 2H, J 6.0
Hz, Pyrr-5H), 4.55 (s, 2H, CH2), 7.03-7.33 (m, 7H, Phen-H + =CH + Im-5H), 7.83 (s,
lH, hu-2H) ppm.
l3C NMR (CDCh) : Ö 24.24, 38.05,44.04,47.15,60.23, 117.93, 119.75, 127.49,
128.09, 128.55, 132.24, 136.80, 140.35, 168.66 ppm.
0.41 g (1.1 mmol) of this light oil was dissolved in 30 ml absolute ethanol and 0.3 g
5% Pd/C was added. This was stirred for 72 hunder hydrogen pressure (I5 atm) in
an autoclave. The mixture was filtrated over a short celite column and the ethanol
was removed under reduced pressure. Yield 0.26 g (63%).
lH NMR (CDCI3) : Ö 1.62-2.25 (dm, 2H, Pyrr-4H), 2.82 (s, 6H, NCH3), 2.94-3.23 (m,
2H, Im-CH2), 2.94-3.23 (m, 3H, Pyrr-3H + Pyrr-5H), 4.40 (q, 2H, J 14.7 Hz, CHû,
7.05-7.35 (m,IH, hu-5H), 7.05-7.35 (m, 5H, Phen-H),7.81 (s,IH, Im-2H) ppm.
l-Benzyl-B-(imidazol-4(5)-ylmethyl)pyrrolidine (22)
21 Was reduced and hydrolysed, employing the same method as described for the
synthesis of 19. Yield 52%.
lH (CDCI3) : Ö1.52-2.06 (dm, 2H, Pyrr-4H), 2.06-2.08 (m, lH, Pyrr-3H), 2.55-2.95 (m,
6H, Pyrr-2H + Pyrr-5H + Im-CH2), 3.79 (s, 2H, CH2), 6.63 (s, lH, Im-5H), 7.17-7.32
(m, 5H, Phen-H), 7.67 (s, lH, hu-2H) ppm.
l3C (CDCI3) : Ö 29.49, 30.62, 30.63, 52.57, 57.92, 58.87, 116.98, 128.21, 128.53,
129.56, 132.18, 134.05, 134.06 ppm.
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3-(Imidazol-4(5)-ylmethyl)pyrrolidine (VUF 4864) (23)
165
0.3 g (0.12 mmol) 22 was dissolved in 50 ml methanol and 0.1 g 20% Pd(OHh-C
was added carefully. The mixture was stirred for 48 hunder hydrogen pressure (35
atm) in an autoclave, filtrated and concentrated in vacuo. The residue (0.16 g, 89%)
was dissolved in iso-propanol and added dropwise to a saturated oxalic acid solu-
tion in iso-propanol. The precipitate was collected by centrifugation and recrys-
tallized from methanol/ethyl acetate. Melting point 176.5-178.9 "C.
1HNMR (D20): Ö1.61-2.29 (dm, 2H, Pyrr-4H), 2.59-2.79 (m, 1H, Pyrr-3H), 2.79-3.58
(m, 6H, Pyrr-2H + Pyrr-5H + CH2),7.27 (s, 1H, Im-4(5)H), 8.58 (s, 1H, Im-2H) ppm.
13C NMR (D20): Ö27.89,30.79,38.37,46.67,50.78,117.55,132.57,134.74,168.10
ppm.
Pharmacology
The histamine H3 activity of the compounds was determined with an in vitro assay,
based on the inhibitory effect of histamine H3 agonists on electricaUy evoked
twitches (induced by endogenous acetylcholine release) of guinea pig jejunum
preparations (see Chapter 3).15 The addition of cumulative concentrations of an H3
agonist, results in a concentration-dependent inhibition of these evoked twitehes,
from which a concentration-response curve can be constructed. The compounds
were tested for H3 agonism and antagonism. H3 antagonism was determined against
(Rj-u-methylhistamine. The potency of the antagonists was expressed by its pA2
value, calculated from the Schild regression analysis, and at least three different
concentrations were used. Statistical analysis was carried out with the Students' t-
test and p < 0.05 was considered statistically significant.
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Introduetion
For the development of new selective histamine H3 ligands, it may be useful to
construct an activation model for the H3 receptor, using molecular modelling tech-
niques. Such a three-dimensional model could contribute to a better understanding
of the structural requirements of an H3 agonist and possibly also of an H3 antago-
nist. Such an approach might guide us in the optimisation of known H3 ligands, but
might also lead us to the discovery of new lead structures.
Unfortunately, the histamine H3 receptor has not been cloned yet and not much is
known about the receptor topography. Therefore another approach for the identifi-
cation of the pharmacophore geometry of H3 ligands has to be used, known as
receptor mapping. This method is based on the assumption that the environment of
the 'active site' of the receptor is complementary to the structure of the agonists
(loek and key principle). Low energy conformations of several potent H3 agonists
can be fitted onto each other and the composite volume of the compounds repre-
sents a region in the H3 receptor, available for the binding of agonists (steric
mapping). The addition of inactive compounds or antagonists in this model using
the same pharmacophoric groups as fitting points, can indicate regions that can not
be accommodated by agonists.
Such a ligand-fit model can also be constructed for H3 antagonists, but this is more
complicated, since antagonists may interact at different sites within the receptor.
From the preceding chapters it is clear there is a difference in binding behaviour
between different classes of antagonists; compare e.g., the elongated imetit- (Table
16, Chapter 2) and histamine series (Chapter 7) with the burimamide series (Chapter
8). Therefore it appears that there are more binding models for antagonists possible.
A problem for the development of an agonistic model for the histamine H3 receptor
is that potent H3 agonists, like (Rj-u-methylhistamine and imetit can assume a
variety of conformations as a result of free rotations about single bonds. Even
immepip, with two single bonds and a piperidyl ring, still has a relatively large
conformational flexibility. Because most likely only one conformer of an agonist is
optimally suited to bind and activate the receptor, there is a need for a small and
rigid H3 agonist to serve as a template for an activation model of the H3receptor.
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An obvious candidate is cyclopropylhistamine (1) (4(5)-(2-aminocyclopropyl)-IH-
imidazole), which has been reported in a patent application by Arrang et al., to be an
agonist with a pD2 value of 8.0 on rat cortex (see also Chapter 2, table 5).18
.r-:
HN-...?N
1, cyclopropylhistamine
Since cyclopropylhistamine (1) has two chiral eentres and the histamine H3 receptor
is known to be highly stereoselective (see Chapter 2), it seems likely that only one
of the four possible stereoisomers is most potent. Unfortunately it was not reported,
which of the four possible stereoisomers of cyclopropylhistamine (1) is most active.
In the patent application by Arrang et al., describing the agonistic activity of cyclo-
propylhistamine (1),18 it was mentioned that cyclopropylhistamine had been
synthesized according to a method, described by Burger et al.33 This method
describes the synthesis of cyclopropylhistamine (1), via the cyclopropanation of sec-
butyl l-trityl-(trans)-urocanate with dimethyloxosulfonium methylide (Corey's
reagent),135 followed by a Curtius rearrangement of the carboxylate group.
However, nothing is mentioned about the stereoselectivity of the cyclopropanation
reaction, nor about the stereochemistry of the products. Nevertheless, since the
dimethyloxosulfonium methylide reacts with the a,p-unsaturated urocanate via a
conjugate addition reaction and not by concerted stereospecific addition, the
formation ofa mixture of isomers is very likely.
Because cyclopropylhistamine (1) can serve as a good template for an H3 receptor
activation model, we performed some prelirninary calculations in order to predict
which stereoisomer might be the most active one. This was done by fitting several
potent H3 agonists onto all four possible stereoisomers of cyclopropylhistamine (1)
and compare the quality of the fits (best overlap) and the intramolecular energies of
the fitted conformations.
From these preliminary calculations, it became clear that there are two distinct
possibilities for a mode1. The first model assumes that histamine (and analogues) is
active in the extended conformation ('extended' model). In this model, one of the
trans isomers of 1 is the most active agonist. The second model assumes a folded
active conformer to be the most potent agonist ('folded' model).
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For this reason we subsequently decided to develop a route for the synthesis of
trans-cyclopropylhistamine (trans-I) and cis-cyclopropylhistamine (cis-I).
Results and Discussion
Preliminary Modelling
It was assumed that in solution at physiological pH; cyclopropylhistamine (1) is
predominantly present in its monocationic fonn, just as calculated for histamine, 136
(Rj-u-methylhistaminelê" and (R)a.,(S)I3-dimethylhistamine.138 Therefore, the lowest
energy confonnations for the four stereoisomers of the monocationic species of
cyclopropylhistamine (1), were determined with the confonnational analysis tools in
MACRüMüDEL, using the Amber force field139 (see Figure 1).
'Folded' 'Extended'
(R)a.,(S)I3-cyclopropylhistamine (R,S-I) (R)a.,(R)I3-cyclopropylhistamine (R,R-1)
(S)a.,(R)I3-cyclopropylhistamine (S,R-1) (S)a.,(S)13-cyclopropylhistamine (S,S-I)
Figure 1 Lowest energy confonnations of the four stereoisomers of cyclopropyl-
histamine (1) as calculated with MACRüMüDEL using the Amber force
field.
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The four stereoisomers were further optimized with the semi-empirical MNDO-calcu-
lation method140 (MOPAC, version 6.0). Comparable torsion angles were observed
for the lowest energy conformations.
Table 1. Torsion angles of the four optimized stereoisomers of I, as calculated with
molecular mechanics (AMBER) and semi-empirical methods (MNDO).
AMBER MNDO
Compound E (Kcal/mol) 'ta 'ta
cis-l R,S-l 95 -177 -171
" S,R-l 95 177 180
trans-l R,R-l 104 -142 -150
" S,S,-l 104 142 135
a The torsional angle is defined by : C5-C4-C~-Ca.
From the results it was obvious that there are two distinct possibilities:
1) In the monocationic form, (R)a,(S)13-cyclopropylhistamine (R,S-I) and (S)a,(R)13-
cyclopropylhistamine (S,R-l) (both cis-enantiomers) forms an internal hydrogen-
bridge between the cationic primary amine and the N1t of the imidazole ring,
which will be favourable in solution. If one of these two enantiomers is the most
potent H3 agonist of the four possible isomers, a 'folded' model is a strong
possibility, where internal hydrogen bridge formation is important for activity.
2) If one of the two trans-enantiomers bas the highest H3 activity, of the four
possible stereoisomers, an 'extended' model is favourable and no internal hydro-
gen bridge is required for H3 agonism.
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The global energy minima of the four stereoisomers, in a monocationic form were
used as a template for further ligand-fit procedures. Conformational analyses were
performed on a few potent H3 agonists, like (Rj-u-methylhistamine, (R)a,(S)p-
dimethylhistamine and immepip. The lowest energy conformations of these agonists
were fitted on the most stabie conformations of 1, using CHEMX90. Within the
fitting procedures, a restraint constant of 50 Kcal/mollA2 was used for the nitrogen
atoms and the C-2 atoms in the imidazole rings to be matched. The nitrogen atoms of
the side chains were fitted with a restrain constant of 100 Kcal/mollA2 in a following
flexible fitting procedure.
Two main criteria were used to determine which of the four templates shows the
'best fit' and is therefore likely to be the most active histamine H3 agonist.
The energy difference between the conformation of the fitted agonist and its global
energy conformation had to be low «5 Kcal/mol), since it is unlikely that the agonist
will assume a high energy conformation. Furthermore it was assumed that there
should be a large steric overlap of the different agonists. Therefore the excluded Van
der Waal' s volume, * with respect to the template, was calculated. The smaller the
excluded volume, the better the fit.
Table 2. Intramolecular energy differences (~ E) and excluded volumes (~ V) for
the conformations of a few H3agonists, fitted onto the different isomers
ofl.
MNDO Amber
(R)a,(S)\3-dïMeHa a (R)-a-MeHa a immepip
~E ~E ~E
Comp. (Kcal/mol) ~V(A) (Kcal/mol) ~V(A) (Kcal/mol) ~V(A)
R,S-1 0.9 32.4 1.3 31.4 8.6 41.4
S,R-1 1.0 38.3 0.7 38.9
R,R-1 13.2 56.1 18.8 47.7 17.9 44.4
S,S-1 8.8 39.6 14.6 40.0
a MeHa =methylhistamine.
*Commonvolumeof template and fittedcompound, minusthe volumeof the templatealone.
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The results suggest that the H3 agonists fitted best on (R)a,(S)I3-cyclopropylhis-
tamine (R,S-I) (best volume overlap and small energy differences between ground
state and fitted states). These findings indicate that (R)a,(S)I3-cyclopropylhistamine
(R,S-I) is an active H3 agonist and that an intemal hydrogen bridge might be impor-
tant for H3 agonism.
This suggestion is in agreement with recent calculations on histamine and (R)a,(S)I3-
dimethylhistamine, in aqueous solution, by Nagy et al.138 Calculations from this
group predicted the gauche conformer of histamine and (R)a,(S)I3-dimethylhistamine
to be the predominant species in solution, indicating that hydrogen bonding is
commonly observed for H3 agonists. Also other reports underline the importance of
an intramolecular hydrogen bond for H3 agonists.137
This could also be an explanation for the finding that immepip and imetit are potent
H3 agonists as weIl, because the intemal hydrogen bridge positions the side chain
nitrogen atoms of immepip and imetit in a comparabie position relative to the imida-
zole ring, as with the histamine analogues. Immepip fits the 'folded' model in a
'boat' conformation.
Figure 2 Immepip in a 'folded' conformation.
From our preliminary modelling results, it appears that a 'folded' model is most likely,
but this conclusion is still highly speculative. Therefore the synthesis of the trans-
and the cis-diastereoisomers of cyclopropylhistamine becomes very important for
the development of an H3 agonistic receptor model.
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Synthesis
trans-cyclopropylhistamine
The key step in the synthesis route of trans-l is the cyclopropanationl'[! of the
methyl l-protected-urocanate 4 by the stereospecific addition of diazomethane,
using palladium(II)acetateas a catalyst. This method has been described as highly
stereoselective for the cyclopropanation of a,13-unsaturated carboxylic acids,
derivatized with camphc;>rsultam142,143 as achiral auxiliary.144,145
HNà
/.S~0'/ 0
camphor sultam (boman-lO,2-sultam)
This approach was applied successfully in the quantitative cyclopropanation of e.g.,
methyl (trans)-3-[2-(trifluoromethyl)phenyl]acrylate.145
VCF3
0
- OMe
o ~F3 ,~OMeo
For the synthesis of trans-cylcopropylhistamine, the readily available (trans),
urocanic acid (2) was used as starting material.
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0 0/OH
a
/OMe
bHN~N )Ir HN~N • HCI )Ir
2 3
0
0 pA/oMe
c
_ ' OMe
RN~N dRN~N )Ir )Ir
4a,b 5a,b
0pA p"NH'_ ' OH
e-i
RN~N )Ir HN~N • 2HCI
6b trans-1
a; R =p-CHsCeH5S02-,
b; R =(CHS)2NS02-
Scheme 2 Reagents used : (a) HCI-gas, MeOH, reflux; (b) R-CI, Et3N, DCM; (c)
CHzNz, cat. Pd(OAc)z, DCM; (d) 1M KOH, MeOH, THF; (e) EtCOCI,
Et3N, acetone; (f) NaN3, H20; (g) toluene, reflux; (h) tert-butanol, reflux;
(i) 1M HCI, reflux.
The carboxy.lic acid function of urocanic acid (2) was protected by esterification in
methanol, with HCl-gas, leading to 3.
Initially we used the p-tosyl group for the proteetion of the imidazole and cyclo-
propanation of 4a, with diazomethane and palladium(II)acetate as a catalyst, proved
possible. It must be noted however, that higher temperatures and larger amounts of
catalyst were required than described for e.g. the cyc1opropanation shown in
scheme 1.
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Unfortunately, hydrolysis of ester Sa under various basic conditions, to obtain the
carboxylic acid derivative 6, resulted in the hydrolysis of the p-tosyl group as well.
Hydrolysis of ester Sa under acidic conditions was also not successful, since only
deprotection of the imidazole ring was observed and no ester hydrolysis.
Dealkylation of the ester (Sa) with a chlorotrimethylsilane-sodium iodide complexl46
did not lead to 6a either.
Because the p-tosyl group was obviously not 'perfect' for our reaction sequence,
another protecting group for the NH function of the imidazole ring was selected.
The N,N-dimethylsulfamoyl group proved to be more suitable, since cyclopropana-
tion of 4b was successful and hydrolysis of Sb to 6b proceeded readily.
The carboxylic acid derivative 6b was subsequently converted in trans-cyclopro-
pylhistamine (trans-l) via a Curtius rearrangement. The resultant isocyanate deriva-
tive was treated with t-butanol to give the carbamate, which was subsequently
hydrolysed under acidic conditions, causing the removal of the N,N-dimethylsul-
famoyl group as well, The overall yield of this synthesis route, starting from urocanic
acid (2) was 30%.
cis-cyclopropylhistamine
For the synthesis of the cis-diastereoisomer of cyclopropylhistamine (cis-l), we tried
to use a comparable approach as for the synthesis of trans-l. Therefore the methyl 1-
protected-(cis)-urocanate (12) had to be prepared. For the synthesis of this
compound, we developed a route, based on the coupling of trimethylsilylacetylene
to a l-protected-4-iodoimidazole (8).
It was reported in literature that acetylenic hydrogen atoms can be readily substi-
tuted by aryl halides in the presence of the copper(I)iodidelbis[triphenylphosphine]-
palladium dichloride-complex as a catalyst in amines as solvent.147 For the synthesis
of terminal acetylenic compounds, the reaction was performed with trimethylsilyl-
acetylene and it was reported that trimethylsilyl group was removed quantitatively
by basic hydrolysis.148
a
...
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p(y0CH3
RN~N °
12b
Rr=AOCH~ ..
~ °
14b
a; R :::; p-CH3CeHsS02- ,
b; R =(CH3hNS02-
AOCH'
RN N ° --------..~
13b
rANH2HN~N. 2HCI
cis-1
Scheme 3 Reagents used: (a) R-CI. Et3N. toluene or DCM; (b) trimethylsilylacety-
lene, cat. [(C6HShPhPdCh. cat. eer, Et3N. SO°C; (c) 2M KOH. MeOH.
THF; (d) EtMgBr. (CH3)zCO; (e) Hz-gas. cat. Lindlar, cat. quinoline,
acetone; (f) CHzNz.cat. Pd(OAch. DCM.
We prepared 4-iodoimidazole (7) and protected the imidazole initially with a p-tosyl
group (8a). The iodo atom of compound (Sa), was readily substituted by the
trimethylsilylacetylene group, leading to 9a. Unfortunately, attempts to hydrolyse
the trimethylsilyl group of 9a under various basic conditions, were not satisfactory,
because the p-tosyl group was hydrolysed as weIl. Also treatment with tetrabutyl-
ammonium fluoride was unsuccessful. Again the use of the N,N-dimethylsulfamoyl
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group as an imidazole protecting group proved to be more satisfying. After the
palladium catalysed coupling reaction of Sb with trimethylsilylacetylene, 9b was
easily hydrolysed to lOb.
The conversion of the terminal acetylenic derivative lOb in alkynester llb was
initially tried by oxidative carbonylation in methanol, with carbon monoxide in the
presence of palladium(II)chloride and copper(II)chloride.149 No reaction was
observed, but the treatment of lOb with ethylmagnesium bromide and dimethylcar-
bonate was successful and resulted in Hb.
The alkynester llb was reduced to the cis-alkene Ub, by hydrogenation under
atmospheric pressure in the presence of Lindlar catalyst (palladium on calcium
carbonate, poisoned with lead).
The cyclopropanation of l2b to compound l3b proved to be more troubles ome. All
attempts to perform this reaction under the same, or even more drastic, conditions as
for the trans-alkene ester 4b, were unsuccessful, although the alkene moiety seems
sterically rather accessible. Apparently the cis-alkene l2b is seriously deactivated
towards attack by diazomethane. Deactivation of the catalyst (Pd(OAch by chela-
tion might be another explanation for these findings.
Pharmacology
The H3 activity of trans-cyclopropylhistamine (trans-1), was determined on an in
vitro test system, based on the concentration-dependent inhibitory effect of
histamine H3 agonists on the electrically evoked contractile response of isolated
guinea pig jejunum segments (see Chapter 3).15
This compound proved to be only a weak partial H3 agonist on this test system.
pD2 = 6.5 ±0.1; intrinsic activity =0.3
pA2 = 6.2 ±0.1; Schild-slope =0.8 ±0.1
Data expressed as mean ± SD Three different animals used. Slope of Schild plot not
significantly different from unity.
The H3 agonistic activity could not be verified by the determination of the pA2
value of a selective H3 antagonist (e.g. thioperamide), using trans-A as agonist,
because of its very low intrinsic activity.
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This observation is clearly different from the high pD2 value of 8.0 on rat cortex,
reported by Arrang et al.18 and could be an indieation that the material as tested by
this group does not consist of the pure trans-isomer, but likely a mixture of cis and
trans-cyclopropylhistamine. Therefore, one of the enantiomers of cis-cyclopropyl-
histamine (cis-1) could be responsible for the high agonistic properties of the unre-
solved mixture as reported by the authors.
Conclusions
Obviously, cyclopropylhistamine (1) can be a valuable tool for the development of
an agonistic H3 receptor model, but the stereoselective synthesis and the determina-
tion of the most active stereoisomer of 1 is required.
trans-Cyclopropylhistamine proved to be only very weakly active. Assuming that
the reported potent agonistic activity in the patent literature,18 is reliable, it is likely
that one of the cis-enantiomers of I is active and preparation of cis-l is required.
However, in case the actual activity of the isomerie mixture as published in the
patent application is actively much lower than reported, such an observation might
be used in the reversed sense: certain conformations can be excluded for activity.
Unfortunately the cyclopropanation of the cis-a1k:ene 12b with diazomethane in the
presence of a palladium catalyst, as successfully applied in the synthesis of trans-L,
has failed thusfar. It might be useful to try a different cyclopropanation reaction
with 12b. Another option might be the exchange of the N,N-dimethylsulfamoyl
group with another imidazole protecting group.
If (R)a,(S)13-cyclopropylhistamine (R,S-I) (best calculated fit) is indeed the most
active stereoisomer of 1 it seems likely that an intemal hydrogen bond is essential for
the H3 agonistic effect of histamine analogues.
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Experimental Section
IH NMR and 13C NMR spectra were recorded on JEOL JNM-EX270. GLC-
Analysis was performed on a Shimadzu GC-14A equipped with an FID detector and
an HP1 column (50 m x 0.32 mm). Melting points were determined in open glass
capillaries on a Thomas-Hoover apparatus and are uncorrected. Elemental analyses
was performed by Micro Kemi AB, Uppsala, Sweden.
THF was distilled from LiAIH4 and dimethylcarbonate was dried overnight on
molecular sieves (4Á).
4(5)-Iodoimidazole (7) was prepared by the reduction of 4,5-di-iodoimidazole with 3
eq Na2S03 as described by Pauly et al.150,151 4,5-Di-iodoimidazole was prepared by
the addition of a solution of iodine in 20% potassium iodide to a stirred solution of
imidazole in 2M sodium hydroxide. This was reported by Iddon and Lim106 for the
synthesis of 2,4,5-trl-iodoimidazole, but in our hands this reaction results only in 4,5-
di-iodoimidazole, all was noted by Turner and Lindel1101 as weIl.
Methyl (trans)-3-(imidazol-4(5)-yl)acrylate hydrochloride (3)
25.0 g (0.18, mol) Urocanic acid (2) was added to 150 mI refluxing methanol. HCI-
gas was bubbled through the mixture, according to literature procedures.Pê After 5
h of refluxing, the clear solution was cooled down to 5 °C and white needle-like
crystals appeared. Yield : 32.20 g (94.4%). Melting point 233.5 - 234.5 °C.
Methyl (trans)-3-{1-(p-toluenesulfonyl)imidazol-4-yl]acrylate (4a)
10.0 g (53 mmol) 3 Was dissolved in a solution of 400 mI dichloromethane and 50 mI
trlethylamine. 11.0 g (58 mmol) p-Tosylchloride was added and the reaction mixture
stirred at room temperature for 16 h. The solution was washed with 150 mI H20 and
150 mI Brine. After evaporation of the dichloromethane, 16.72 g of a white solid
remained. After recrystallization from methanol, 15.05 g of white cotton-like crystals
where collected (92.6%). Melting point 161.0 - 162.5 oe.
IH NMR (CDCI3): Ö2.45 (s, 3H, Tol-CH3),3.77 (s, 3H, OCH3),6.62 (d, 1H, J 15.6 Hz,
=CH), 7.38 (d, 2H, J 8.5 Hz, 2 x phenyl-H), 7.39 (s, 1H, Im-5H), 7.44 (d, 1H, J 15.6 Hz,
=CH), 7.84 (d, 1H, J 8.3 Hz, 2 x phenyl-H), 7.99 (s, 1H, Im-2H) ppm.
13C NMR (CDCI3): Ö21.8,51.7,118.1,119.4,127.5,130.6,134.2,134.4,137.4,140.2,
146.8, 167.2 ppm.
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Anal. (Cl4fIl<tN204S) : 54.9 %C, 4.5 %H, 9.1 %N;
Calcd. : 54.9 %C, 4.6 %H, 9.1 %N.
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Methyl (trans)-2-[1-(p-toluenesulfonyl)imidazol-4-yl]cyclopropanecarboxylate
(5a)
A solution of 52.5 g (245 mmol) N-methyl-N-nitroso-p-toluenesulfonamide
(Diazogen) dissolved in 500 ml ether was added dropwise to a heated mixture of
41.0 g (730 mmol) KOH in 150 ml H20 and 150 ml 2-(2-ethoxyethoxy)ethanol.
Special 'soft' glassware was used. The hence generated etheric diazomethane solu-
tion was distilled dropwise in a solution of 5.0 g (16 mmol) 4a in 1 L
dichloromethane, together with 150 mg Pd(OAch at room temperature. The light
yellow solution became dark yellow and N2-evolution was observed. The reaction
mixture stirred overnight. After the addition of a few drops acetic acid, the reaction
mixture was washed with 250 ml 5% NaHC03-solution. The organic layer was dried
on Na2S04, filtrated over a short silica column and concentrated in vacuo. The
remaining light yellow oil consisted of 74 % product and 26 % starting material
according to GC and lH NMR. The residue was extracted with methanol (starting
material dissolves only slightly in methanol), concentrated in vacuo and recrystal-
lized from nO-hexane. A white solid (4.30 g) was isolated, which still contained 10%
4a.
lH NMR (CDCI3) : 0 1.37-1.52 (m, 2H, CH2), 1.98-2.04 (m, 1H, CH), 2.33-2.40 (m, 1H,
CH), 244 (s, 3H, Tol-CH3), 3.68 (s, 3H, OCH3), 7.08 (s, 1H, hu-5H), 7.36 (d, 2H, J 8.1
Hz, 2 x phenyl-H), 7.81 (d, 1H, J 8.4 Hz, 2 x phenyl-H), 7.85 (s, 1H, hu-2H) ppm.
Methyl (trans)-3-[I-(N,N-dimethylsulfamoyl)imidazol-4-ylJacrylate (4b)
32.20 g (0.17 mol) 3 Was dissolved in a solution of 600 ml dichloromethane and 75
ml triethylamine. After the addition of 20.0 ml (0.19 mol) N,N-dimethylsulfamoyl-
chloride, the reaction mixture was refluxed for 48 h. The solution was washed with
150 ml H20 and 150 ml Brine. After evaporation of the dichloromethane, 43.37 g of
a white solid remained. Recrystallization from iso-propanol resulted in 37.55 g
(84.8%) white crystals. Melting point 137.0-138.0 °C.
lH NMR (CDC13) : 02.89 (s, 6H, NCH3), 3.80 (s, 3H, OCH3), 6.67 (d, 1H, J 15.6 Hz,
=CH), 7.38 (s, 1H, hu-5H), 7.52 (d, 1H, J 15.6 Hz, =CH), 7.90 hu-2H) ppm.
13c NMR (CDCh): 038.2,51.7,118.7,119.1,134.4,137.5,139.3,167.3 ppm.
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Anal. (C9H13N304S) : 41.7 %C, 5.2 %H, 16.6 %N;
Calcd. : 41.7 %C, 5.1 %H, 16.2 %N.
(trans)-2-[l-(N,N-Dimethylsulfamoyl)imidazol-4-yl]cyclopropanecarboxylic acid
(6b)
A solution of 40.0 g (0.19 mol) N-methyl-N-nitroso-p-toluenesulfonamide
(Diazogen) dissolved in 200 ml ether was added dropwise to a heated mixture of
31.0 g (0.55 mol) KOH in 200 ml H20 and 200 ml 2-(2-ethoxyethoxy)ethanol.
Special 'soft' glassware was used. The hence generated etheric diazomethane solu-
tion was distilled dropwise in a solution of 5.0 g (19.3 mmol) 4b in 1 L
dichloromethane, together with 200 mg Pd(OAch at room temperature. The light
yellow solution became dark brown and N2-evolution was observed. The reaction
mixture stirred overnight. After the addition of a few drops acetic acid, the reaction
mixture was washed with 250 ml 5% NaHC03-solution. The organic layer was dried
on Na2S04, filtrated over a short silica column and concentrated in vacuo. The
remaining light yellow oil consisted of 49 % product and 51 % starting material
according to GC and lH NMR.
lH NMR (CDC13) (Sb): Ö 1.42-1.57 (m, 2H, CHÛ, 2.03-2.13 (m, 1H, CH), 2.30-2.48
(m, 1H, CH), 284 (s, 6H, NCH3),3.70 (s, 3H, OCH3), 7.08 (s, 1H, Im-5H), 7.77 (s, 1H,
Im-2H)ppm.
The residue was dissolved in 1 L dichloromethane and the procedure was repeated,
employing the same amounts of reagents. This time the residing oil consisted of 82
% product and was dissolved in a mixture of 100 ml methanol and 100 ml tetrahy-
drofuran. 100 ml 1M KOH-solution was added and after 0.5 h stirring at room
temperature, the mixture was washed with dichloromethane (3 x 200 ml). The water-
layer was treated with 1M HCl-solution until the solution had a pH of 2. The
product was extracted with dichloromethane (3 x 200 ml) and after drying and
evaporation of the dichloromethane, 3.91 g of a light brown solidified oil remained.
After several triturations with dry acetone, 2.92 g (58.4%) of a white powder was
collected. Melting point 166.0 "C,
in NMR (DMSO-d6) (6b): Ö 1.28-1.37 (m, 2H, CH2), 1.78-1.88 (m, 1H, CH), 2.28-
2.38 (m, 1H, CH), 2.78 (s, 6H, CH3), 7.50 (s, lH, Im-5H),8.00 (s, 1H, Im-2H), 12.28 (bs,
1H, C02H) ppm.
13C NMR (DMSO-d6) (6b): Ö14.8, 18.7,22.0,37.7,114.1,136.7,141.5,173.8 ppm.
Anal. (CgH13N304S) : 41.5 %C, 4.9 %H, 16.2 %N;
Calcd. : 41.7 %C, 5.1 %H, 16.2 %N.
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2.22 g (8.6 mmol) 6b was dissolved in 65 mI dry acetone and 1.6 mI (11.5 mmol)
triethylamine under Nz atmosphere. The reaction mixture was cooled on a 0 °C bath
and 1.6 mI (16.7 mmol) ethylchoroformate was added dropwise (a white precipitate
formed). After 2 h, a solution of 0.85 g (13.1 mmol) sodiumazide in 15 mI H20 was
added slowly. The mixture was stirred for an additional hour. After addition of 65 mI
H20, the solution was concentrated in vacua until the water-layer remained. The
water-layer 'was extracted with toluene (3 x 65 ml) and the toluene-layers were
combined, dried on Na2S04 and refluxed for 2 h (Nj-evclution was observed). The
residue after evaporation of toluene was refluxed in 50 mI tert-butanol for 12 h (no
isocyanate-peak in IR-spectrum). After evaporation of the alcohol a dark residue
remained. This residue was dissolved in ethyl acetate and filtrated over a short silica
column. 2.10 g of a white solid remained after evaporation of the ethyl acetate. This
was refluxed for 12 h in 100 mIIM HCI. After concentration in vacuo, the residue
was refluxed in abs. ethanol for 0.5 hand subsequently washed with acetone. 1.06
g (63%; 30% overall, starting from urocanie acid (2)) Of a light beige solid remained,
which was recrystallized from iso-propanol/ether. Melting point 187.0-187.5 oe.
IH NMR (D20): 0 1.42 (ddd, lH, J 6.7,6.9 and 8.2 Hz), 1.55 (ddd, lH, J 4.7,7.2 and
10.2 Hz), 2.51 (ddd, lH, J 3.4, 6.5 and 10.1 Hz), 3.03 (ddd, lH, J 3.6,4.5 and 8.2 Hz),
7.25 (s, lH, Im-4(5)H), 8.57 (s, lH, Im-2H) ppm.
BC NMR (D20) : 0 12.4, 12.5, 30.7, 117.4, 132.4, 134.9 ppm.
Anal, (C()IIgN382HCI) : 36.8 %C, 5.5%H, 21.5 %N;
Calcd. : 36.8 %C, 5.7 %H, 21.4 %N.
l-(p-Toluenesulfonyl)-4-iodoimidazole (8a)
10.0 g (52 mmol) p-Tosylchloride was added to a stirred solution of 10.0 g (52 mmol)
4(5)-Iodoimidazole (7) in 500 mI toluene and 100 mI triethylamine. After 16 h, the
reaction mixture was filtrated and concentrated in vacuo. The white residue (19.20
g) was recrystallized from methanol and 13.00 g (72%) of white crystals where
collected. Melting point 156 oe.
IH NMR (CDCh) : 02.46 (s, 3H, Tol-CH3), 7.36 (s, lH, Im-5H), 7.38 (d, 2H, J 9.0 Hz,
phenyl-H), 7.82 (d, 2H, 1O.0Hz), phenyl-H), 7.87 (s, lH, Im-2H) ppm.
BC NMR (CDCI3): 021.8,85.2,122.4,127.6,130.6,134.2,137.7,146.9 ppm.
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Anal. (ClQH9NzOzSlo2HC1) : 34.6 %C, 2.4 %H, 8.0 %N;
Calcd. : 34.5 %C, 2.6 %H, 8.0 %N.
I-(p-Toluenesulfonyl)-4-[(I-trimethylsilyl)ethyn-2-yl]imidazole (9a)
6.0 g (17 mmol) Sa was stirred in 200 ml triethylamine under Nz-atmosphere. To this
mixture 120 mg (1%) bis(triphenylphosphine)palladium(II)chloride, 35 mg Cul (1%)
and 5.0 ml trimethylsilylacetylene (2 eq) was added. This was stirred for 12 h on a 50
°C oil bath. The brown mixture was filtrated and the filtrate was concentrated in
vacuo. The brown solid was washed several times with n-hexane and a white solid
was collected.
lH NMR (CDC13) : 00.21 (s, 9H, SiCH3), 2.45 (s, 3H, Tol-CH3), 7.36 (d, 2H, phenyl-
H), 7.41 (s, lH, Im-5H), 7.81 (d, 2H, phenyl-H),7.91 (s, lH, Im-2H) ppm.
I-(N ,N, -Dimethylsulfamoyl)-4-iodoimidazole (Sb)
12.0 ml (0.11 mol) N,N-Dimethylsulfamoylchoride was added to a solution of 20.0 g
(0.10 mol) 4-iodoimidazole (7) in 600 ml dichloromethane and 40 ml triethylamine.
The reaction mixture was refluxed for 60 h and subsequently washed with 250 ml
HzO and 250 ml NazSz03-solution (5%). 30.22 g Of a light brown solid remained
after evaporation of the solvents. Recrystallization from hot iso-propanol resulted in
18.65 g (60 %) white crystals. Melting point 131.5 °C.
lH NMR (CDCh) : 02.89 (s, 6H, CH3),7.34 (s, lH, Im-5H), 7.78 (s, lH, Im-2H) ppm.
l3c NMR (CDC13) : 038.2,84.4,122.7,137.8 ppm.
Anal. (CsHsN30ZSI) : 19.8 %C, 2.5 %H, 14.0 %N;
Calcd. : 19.9 %C, 2.7 %H, 14.0 %N.
I-(N;N-Dimethylsulfamoyl)-4-[3-(ethyl 2-propynoate)]imidazole (l1b)
20.0 g (67 mmol) Sb was stirred in 250 ml triethylamine under Nz-atmosphere. To
this mixture 05 g bis(triphenylphosphine)palladium(II)chloride (1 mol%), 130 mg
Cul (1 mol%) and 20.0 ml trimethylsilylacetylene (141 mmol) was added. This was
stirred for 60 h on a 50°C oil bath. After filtration of the reaction mixture, the solu-
tion was concentrated in vacuo.
lH NMR (CDC13) (9b): 00.25 (s, 9H, SiCH3), 2.87 (s, 6H, NCH3),7.40 (s, lH, Im-5H),
7.81 (s, lH, Im-2H) ppm.
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The residue (9b) was dissolved in 150 ml methanol and 150 ml tetrahydrofuran. 150
ml 2M potassium hydroxide was added and the mixture was poured in 150 ml of a
saturated N14C1-solution. After extraction of the product with dichloromethane (l x
300 ml; 2 x 100 ml), drying on Na2S04 and evaporation of the dichloromethane,
12.30 g of a brown oilremained. The oil was purified on a silicagel column with
ethyl acetate as eluent(Rf = 0.7). 7.82 g (59%) of a light beige solid was isolated.
lH NMR (CDCI3) (lOb) : s2.88 (s, 6H, NCH3), 3.13 (s, 1H, CH), 7.42 (s, 1H, ho-5H),
7.83 (s, 1H, ho-2H) ppm.
5.0 g (25 mmol) of this beige solid (lOb) was dissolved in 50 ml dichloromethane
and added dropwise to a Grignard mixture, prepared with 0.8 g (33 mmol) magne-
sium and 2.5 ml (33 mmol) ethyl bromide in 5 ml tetrahydrofuran. After 1 h the
mixture was poured in 100 ml dimethylcarbonate and stirred ovemight. The solution
was poured in 250 ml H20 and extracted with dichloromethane (3 x 200 ml). After
evaporation of the solvents, 5.53 g of a brow oil remained, which was purified on a
silicagel column with ethyl acetate as eluent. (Rr = 0.8). After two Recrystallization
from iso-propanol, 2.98 g (46%) white crystals where collected. Melting point
126.0-127.0°C.
lH NMR (CDCI3)(Ub) : s2.91 (s, 6H, NCH3),3.84 (s, 3H, OCH3),7.63 (s, 1H, ho-5H),
7.88 (s, 1H, ho-2H) ppm.
13CNMR (CDCI3) (Ub): s38.2, 52.9, 78.6, 82.1,123.2,124.6,137.1,154.0 ppm.
Anal. (C9HUN304S) : 41.7 %C,4.1 %H, 16.3 %N;
Calcd. : 42.0 %C, 4.3 %H, 16.3 %N.
Methyl (cis)-3-[1-(N,N-dimethylsulfamoyl)imidazol-4-yl]acrylate (12b)
2.6 g (10.1 mmol) llb was dissolved in 75 ml acetone. 120 mg Lindlar catalyst and
300 mg quinoline were added and the reaction mixture was stirred under hydrogen-
atmosphere (1 atm). After hydrogen consumption had ceased, additional Lindlar
catalyst was added (repeated twice; a total of 280 mg catalyst extra was added).
After 8 hand 300 ml of hydrogen gas consumption, the reaction mixture was
filtrated and concentrated in vacuo. The residue consisted of 92% product and 8%
of the trans isomer, according to GC. This was purified on a silicagel column with
ethyl acetate as eluent (Rf = 0.5) and recrystallization from n-hexane. 1.8 g (69%)
white crystals where isolated. Melting point 74.0 °C.
lH NMR (CDCI3) : ö 2.92 (s, 6H, NCH3), 3.76 (s, 3H, OCH3), 5.95 (d, 1H, J 12.7Hz,
=CH), 6.96 (d, 1H, J 12.2Hz, =CH), 7.88 (s, 1H, ho-5H), 8.64 (s, 1H, ho-2H) ppm.
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Anal. (C9H13N304S) : 41.6 %C, 5.0 %H, 16.4 %N;
Calcd. : 41.7 %C, 5.0 %H, 16.2 %N.
Pharmacology
The histamine H3 activity of the compounds was determined on an in vitro assay,
based on the inhibitory effect of histamine H3 agonists on electrically evoked
twitches (induced by endogenous acetylcholine release) of guinea pig jejunum
preparations (see Chapter 3).15 The addition of cumulative concentrations of an H3
agonist, results in a concentration-dependent inhibition of these evoked twitches,
from which a concentration-response curve can be constructed. The compounds
were tested for H3 agonism and antagonism. H3 antagonism was determined against
(R)-a-methylhistamine. The potency of the antagonists was expressed by its pAz
value, calculated from the Schild regression analysis, and at least three different
concentrations were used. Statistical analysis was carried out with the Student' t-
test and p < 0.05 was considered statistically significant.
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With the development of a new route for the synthesis of a variety of 4(5)-
substituted imidazoles, it was possible to obtain several new ligands of the histamine
H3receptor.
Especially remarkable are the structurally new potent and selective H3 agonist
immepip (Chapter 6), and the H3 antagonist impentamine (Chapter 7). Both
compounds can be useful as pharmacological tools and perhaps in the future as
therapeutical agents. The histamine H3 receptor currently attracts interest from
industries, for the development of therapies for e.g. epilepsy, Alzheimer's disease
and sleeping-disorders. For these applications H3 receptor antagonists might be
useful.
For the design of an agonistic model for the histamine H3 receptor, the small and
rigid cyclopropylhistamine (Chapter 10) might serve as a template, but isolation and
determination of the activity of the pure stereoisomers is required. Immepip (and its
pyrrolidine derivative YUF 4864) (Chapter 9) can also be very useful in the
development of an H3 receptor activation model, because of its rigid structure,
different from histamine and its derivatives.
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The research described in this thesis was mainly focused on the synthesis and
development of new ligands for the histamine H3 receptor, as tools for molecular
pharmacology- and structure activity relationship studies. This was mainly accom-
plished by structural modifications of some weIl known histamine H3 ligands.
An overview of all the reported compounds that are active on the histamine H3
receptor, either as agonists or as antagonists, is presented in chapter 2.
The H3 activity of novel synthesized compounds, described in this thesis, was
determined on a specifically developed in vitro assay for the rapid screening of
histamine H3 ligands. This simple test system is based on the concentration depen-
dent inhibitory effect of histamine H3 agonists on the electrically evoked contractile
response of isolated guinea pig jejunum segments as presented in chapter 3 together
with an overview of other possible H3 in vitro assays.
From chapter 2 it appears that an imidazole ring, substituted by an alkyl group on
the 4(5)-position, is essential for both agonistic and antagonistic activity on the H3
receptor. Therefore a suitable route was developed for the rapid synthesis of various
4(5)-substituted imidazole derivatives, on a preparative scale. An overview of some
potential synthesis routes to these compounds is given in chapter 4.
A new route for the synthesis of 4(5)-(ro-aminoalkyl)-lH-imidazoles through C5-
lithiation of a suitable 1,2-diprotected imidazole, is described in chapter 5. When the
resulting 1,2-diprotected 5-lithio-imidazole is treated with a l-chloro-m-iodoalkane,
selective substitution of the iodo group takes place and the chloro group of the
resultant product was converted into an amino group. These derivatives can be
regarded as homologues of histamine and can be used as precursors for a large range
of other histaminergic compounds.
In chapter 6, the synthesis and identification of the new, potent and selective
histamine ~3 agonist immepip, with a pD2 value of 8.0 (guinea pig jejunum), is
described. Key step in the synthesis of this compound was the addition of 4-
pyridinecarboxaldehyde to a suitable 1,2-diprotected 5-lithioimidazole. Immepip can
be useful as a pharmacological tooI and perhaps as a therapeutical agent, but also,
because of its distinctive structure, for SAR- and Molecular Modelling studies.
The influence of alkyl chain length variation on the histamine H3 receptor activity of
a series of histamine homologues was investigated in chapter 7, with an alkyl chain
length varying from one methylene group to 10 methylene groups. The ethylene
chain of histamine was clearly optimal for H3 agonistic activity with this series of
compounds, since the other compounds were all antagonists (no agonistic activity
observed on guinea pig intestine). However, the affinity of the compounds for the
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H3 receptor, increased with increasing chain length, with the pentylene derivative
(impentamine) as the most potent and selective H3 antagonist, with a pA2 value of
8.4 (guinea pig jejunum). Apparently there is a specific antagonistic binding site for
this compound.
The synthesis and activities of a large series of analogues of burimarnide are
discussed in chapter 8. Within this series the chain length of the alkyl spaeer and the
N-substituents were varied. All analogues were competitive H3 antagonists.
Decrease of the chain length of the alkyl spaeer of burimarnide led to a decrease in
activity, but elongation of the alkyl spaeer resulted in more potent and selective H3
antagonists. The pentylene and hexylene homologues of burimarnide are about ten
times more potent than burimarnide itself. Replacement of the methyl group of
burimarnide with a variety of substituents, did not have much influence on the affini-
ty for the H3 receptor. The results indicate a binding behaviour of these derivatives
in a non-lipophilic environment, different from other H3 antagonists, likethio-
perarnide and clobenpropit.
Some rigid H3 ligands, which can be regarded as analogues of immepip and thio-
perarnide are presented in chapter 9. The analogues of the H3 antagonist thio-
perarnide, in which the piperidine ring was replaced by the more rigid 1,2,3,6-tetra-
hydropyridine ring led to a drastic decrease of H3 antagonistic activity. The
replacement of the 4-piperidine ring of the potent H3 agonist immepip by a 3-
piperidine ring results in a weak H3 antagonist. This information can be very useful
for further SAR and molecular modelling studies, since certain conformations of
several known potent H3 agonists (e.g. histamine derivatives and immepip) may be
excluded. The 2-piperidine derivative of immepip, which can be regarded as a rigid
analogue of histamine, has a negligible affmity for the H3 receptor. The replacement
of the 4-piperidine ring of immepip (3a) by a 3-pyrrolidine ring however is allowed
and Vl,JF 4864 proved to be a rather good H3 agonist with a pD2 value of 7.3,
although an intrinsic activity of about 0.8 was observed. Consequently, YUF 4864
(23) can also be very useful as a tool for SAR and molecular modelling studies.
For the development of an activation model of the histamine H3 receptor, cyclo-
propylhistamine (4(5)-(2-arninocyclopropyl)-IH-irnidazole) can become a valuable
tool, because of its small and rigid structure. It has been reported as a potent H3
agonist in a patent application. The possible use of cyclopropylhistamine as a tem-
plate for an H3 receptoractivation model is discussed in chapter 10, together with
the synthesis of trans-cyclopropylhistamine and the attempts of the preparation of
its cis-isomer. trans-Cyclopropylhistamine proved to be only very weakly active on
the histamine H3 receptor.
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Doordat veel mensen met overgevoeligheidsreacties (zoals huiduitslag, hooikoorts
en astma), antihistaminica slikken, wordt histamine vaak in verband gebracht met
allergieën. Histamine wordt door het lichaam zelf aangemaakt via decarboxylatie
van het aminozuur L-histidine met behulp van het enzym L-histidine decarboxylase.
In het lichaam blijken diverse soorten eiwitten (receptoren) aanwezig te zijn, waar
histamine een specifieke interactie mee aan kan gaan. Binding van histamine aan
deze receptoren heeft een activerende werking en een cascade van specifieke
reacties is het gevolg. Tot nu toe zijn er drie typen histamine receptoren geïdenti-
ficeerd, nl.:
• de histamine Hl receptor, die een rol speelt in allergische reacties en waarvan de
werking geblokkeerd kan worden door de bovengenoemde antihistaminica (Hl
antagonisten);
• de histamine H2 receptor die een rol speelt bij de maagzuursecretie en waarvoor
diverse maagzuurremmende medicijnen zijn ontwikkeld (H2 antagonisten) en
• recentelijk is daar de histamine H3receptor bijgekomen.
De rol van de histamine H3 receptor in het lichaam wordt op het ogenblik nog
onderzocht. Duidelijk is al wel dat deze receptor een regulerende (remmende) rol
speelt in de "aanmaaken afgifte van histamine, voorkomend als neurotransmitter in
zenuwuiteinden van histaminerge neuronen. De histamine H3 receptoren zijn voor-
namelijk gelokaliseerd in de hersenen en blijken tevens een regulerende functie te
hebben in de afgifte van andere neurotransmitters. Daardoor lijkt een therapeutische
toepassing voor verbindingen die selectief op de H3 receptor binden en al dan niet
de receptor activeren, mogelijk. Op het ogenblik word hierbij voornamelijk gedacht
aan medicijnen tegen epilepsie, slaapstoornissen en de ziekte van Alzheimer. Dit
moet echter nog grondig onderzocht worden. Hiervoor is bet nodig om potente en
selectieve verbindingen te ontwikkelen die de histamine H3 receptor activeren (H3
agonisten) dan wel blokkeren (H3 antagonisten).
Het in dit proefschrift beschreven onderzoek heeft zich voornamelijk gericht op het
synthetiseren van nieuwe selectieve histamine H3 actieve verbindingen (H3 ligan-
den), door middel van structuurmodificaties van bekende H3 liganden. Omdat alle
potente H3 liganden die tot nu toe beschreven zijn in de literatuur een imidazool
ring bevatten met op de 4(5)-positie een alkyl zijketen, hebben we een nieuwe
syntheseroute ontwikkeld om verschillende van deze imidazoolderivaten op een
snelle manier in handen te krijgen.
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Met behulp van deze nieuwe route was het mogelijk om diverse histamine H3 ligan-
den te ontwikkelen. De H3 activiteit van de nieuwe verbindingen werd bepaald met
behulp van een speciaal voor dit doel ontwikkeld biologisch testsysteem (in vitro).
Met behulp van de verkregen informatie was het mogelijk om enige relaties op te
stellen tussen de structuur van de verbindingen en de H3 activiteit. Enkele van de
beschreven nieuwe potente en selectieve H3 liganden kunnen mogelijk een belang-
rijke rol gaan spelen in de farmacologie en eventuele therapeutische toepassingen
zijn denkbaar.
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